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The alarming rise in HIV-1 associated neurocognitive disorder (HAND) is, at least in 
part, associated with HIV-1 viral proteins shed from infected macrophages, including 
transactivator of transcription (Tat) despite the success of anti-retroviral therapies. The 
dopamine (DA) system is greatly involved in the progression of HAND and is influenced by 
psychostimulants like cocaine. The DA transporter (DAT), a key regulator of neurocognitive 
functions, is a major molecular target for both Tat and cocaine. Our lab previously reported 
that exposure to Tat decreases DA uptake through allosteric regulation and alters cocaine 
binding sites in DAT. 
In this research project the hypothesis ‘HIV-1 Tat protein via allosteric modulation of 
DAT induces inhibition of DA transport, leading to dysfunction of the DA system’ was 
tested. Initially, it was shown that Tat protein directly interacts with DAT to impair DA 
translocation. Based on the predictions of computational modeling and simulations, Y470, 
Y88 and K92 residues of the human DAT (hDAT) are essential to stabilize the compact 
structure of DAT and potentially recognize Tat. Mutating these residues in hDAT – Y470H, 
Y88F, and K92M attenuated Tat-induced inhibition of DA uptake. Additional substitutions 
Y470A and Y470F at 470 displayed attenuated or no effect on Tat-induced inhibition of DA 
uptake respectively, indicating the significant role of aromatic ring of Y470 in DAT and Tat 
interaction. Pharmacological characterization showed that compared to wild type hDAT, 
Y470H and K92M but not Y88F reduce Vmax with no change in the Km values for DA 
uptake. Moreover, Y470H, K92M, and Y88F mutants exhibited no alterations in IC50 values  
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 of DA to inhibit [3H]DA uptake  but increased [3H]DA uptake potency or [3H]WIN35,428 
binding potency for cocaine and GBR12909, suggesting that these three Tat-recognition 
residues do not overlap with substrate DA binding but influence binding of small molecule 
inhibitors. Besides, all five mutants reversed zinc-induced increase of [3H]WIN35,428 
binding and differentially altered basal DA efflux properties of the DAT, indicating that Tat 
protein through interaction at these recognition residues disrupts intermolecular interactions 
that are critical for maintenance of the outward-facing conformation of DAT.  
Another study was conducted to determine the effects of Tat on DAT 
phosphorylation, trafficking and its influence on sequestration of [3H]DA by vesicular 
monoamine transporter 2 (VMAT2). We found that protein kinase C (PKC) inhibitor, 
bisindolylmaleimide-I eliminates Tat effects on DA uptake and Tat increases intracellular 
DAT immunoreactivity. Moreover, Tat also produced inhibitory effects on VMAT2 
function. Collectively, these findings revealed that Tat inhibits DAT function through PKC 
and trafficking- dependent mechanisms; besides, both DAT and VMAT2 proteins may 
involve in Tat-induced dysregulation of the DA system.  
In conclusion, Tat inhibits DA translocation process principally by altering the 
conformational states of the DAT through interaction at specific recognition residues. 
Furthermore, regulatory pathways that control the functional attributes of DAT may play a 
vital role in Tat-mediated impairment of the DA system. Future studies will be necessary to 
identify and characterize other recognition residues for Tat binding and these molecular 
insights will be helpful to develop adjunctive therapies to restore the impaired DA system in 
HIV-1 positive individuals.  
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1.1 HIV-ASSOCIATED NEUROCOGNITIVE DISORDER (HAND) 
The devastating effects of Human Immunodeficiency Virus-1 (HIV-1) infection were 
substantially reduced in HIV-infected individuals with the introduction of antiretroviral 
therapies (ARTs) in 1996 (Carpenter et al., 1996; Deeks et al., 2013). This resulted in 
reclassification of HIV-1 from life threatening disease to a manageable chronic illness 
(Clifford and Ances, 2013). However, HIV-1 has the propensity to have broad effects on 
central nervous system (CNS) and impairs CNS functions which results in serious 
consequences that lead to HIV-associated neurocognitive disorder (HAND). Approximately 
70% of HIV-1 positive adults and children exhibit a neurological disease at one point during 
the course of their infection (Grovit-Ferbas and Harris-White, 2010; Simioni et al., 2010; 
Bilgrami and O'Keefe, 2014). The spectrum of neurological complications in HAND ranges 
from asymptomatic neurocognitive impairment, to mild neurocognitive disorder, to the more 
severe form HIV-associated dementia (Antinori et al., 2007). The clinical impairments in 
HAND include attention, memory, learning, motor functioning and behavioral changes. 
ARTs improve the survival rate of infected people but cannot eliminate the virus from their 
brain (Antiretroviral Therapy Cohort, 2008; Heaton et al., 2010) meaning that these therapies 
do not offer complete cure. In addition, the incidences and progression of HAND are further 
compounded by the consumption of recreational drugs like cocaine and methamphetamine 
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(Buch et al., 2011; Nair and Samikkannu, 2012). If HAND can be prevented at early 
infection stage, quality of patient’s life will be improved and economic burden will be 
lessened on the health care system.  
During the course of HAND, HIV-1 infected monocytes infiltrates the brain by 
crossing the blood-brain barrier at the early infection stage approximately 2-3 weeks after 
primary infection (Davis et al., 1992; Nath and Clements, 2011; Williams et al., 2013). 
Subsequently, virus spreads to perivascular macrophages and microglia and establishes a 
reservoir within the brain. These infected cells release large number of viral particles daily 
which ultimately increase the viral load in the CNS. Moreover, these cells secrete neurotoxic 
HIV-1 viral proteins that include structural protein gp120 and nonstructural protein Tat 
(trans-activator of transcription) as well as proinflammatory cytokines and chemokines 
(Mattson et al., 2005). Several studies observed that HIV-1 cannot directly infect 
dopaminergic neurons but extracellularly discharged viral proteins through direct interaction 
progressively destruct the neurons and cause subsequent neurodegeneration (Nath et al., 
2000b; Ferris et al., 2008). Among these proteins, Tat has been highly linked to progressive 
neuronal dysegulation leading to the development of HAND. Lastly, dopamine (DA) 
dysregulation has been associated with cognitive deficits in HIV-1 positive people (Purohit 
et al., 2011; Jacobs et al., 2013). Long-term viral proteins exposure can accelerate the 
damage in the DA system (Del Valle et al., 2000; Ferris et al., 2008; Hudson et al., 2010; 
Nath, 2010). Considering the oxidative stress-induced damage to the dopaminergic neurons, 
long lasting exposure to viral proteins and elevated DA eventually lead to DA deficits which 
enhance the severity and acceleration of the HAND (Purohit et al., 2011). For the purpose of 
this dissertation, the following literature review broadly discusses HIV-1 viral proteins, DA 
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transporter (DAT) structure, function and regulation, and general effects of Tat protein on 
dopaminergic neurons through impairment of DAT function.  
1.1.1 HIV-1 VIRAL PROTEINS 
The proviral DNA of HIV-1 is composed of at least nine genes flanked by a repeated 
sequence called the long terminal repeats (LTRs). These genes encode proteins that can 
principally be divided into three categories: (1) major structural proteins – Gag, Pol and Env, 
(2) regulatory proteins – Tat and Rev, (3) accessory proteins – Vpu, Vpr, Vif and Nef (Gallo 
et al., 1988). These proteins are required at various stages of virus life cycle.  
Structural proteins  
The Gag (group-specific antigen) codes for Gag precursor protein (p55) which is 
associated with cell membrane after post-translational modifications. Viral protease 
processes this p55 to generate the following proteins: matrix protein (p17) – facilitates 
nuclear transport of viral genome, capsid (p24) protein – forms conical core of the viral 
particle, nucleocapsid (p9) – recognizes packaging signal and helps in reverse transcription, 
and p6 protein – aids in interaction of p55 and vpr, and release of viral particles from 
infected cells (Göttlinger et al., 1989; King, 1994; Lee et al., 2012). The pol gene expresses 
four essential enzymes that include, reverse transcriptase – transcribes DNA from RNA 
template, RNase H – facilitates complementary DNA strand synthesis by cleaving original 
RNA template, integrase – required for integration of proviral DNA into the host genome, 
protease – necessary to p55 protein (Lee et al., 2012). Furthermore, Env (for ‘envelope’) 
codes for gp160 protein and this protein is glycosylated in the endoplasmic reticulum before 
being processed by a cellular protease to produce gp41 and gp120 proteins. While gp41 acts 
as an anchor in the viral envelope, gp120 mediates HIV-1 infection by interacting with CD4 
receptor that is present on the lymphocytes (King, 1994; Merk and Subramaniam, 2013). 
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Regulatory proteins  
Tat, an RNA-binding protein is absolutely required for the HIV-1 replication. Tat acts 
as the transcriptional activator by interacting with transactivation response element (TAR) at 
the 5’ terminus of HIV-1 RNA template (Ruben et al., 1989; Feinberg et al., 1991). Rev 
(regulator of expression of virion proteins) is an RNA-binding protein that binds at Rev 
response element (RRE) within the second intron of the HIV-1 genome. Rev is essential to 
activate late genes and thus for synthesis of viral proteins to produce virions (Zapp and 
Green, 1989; Vercruysse and Daelemans, 2014). 
Accessory proteins 
 The other four viral genes such as Nef, Vpu, Vif and Vpr encode accessory proteins. 
These proteins perform multiple functions at different stages of viral infection (Trono, 1995; 
Strebel, 2013). It appears that they mostly work toward evasion of innate and adaptive 
immune systems. Specifically, Nef and Vpu proteins manipulate the localization and 
functional aspects of host cell membrane proteins. These alterations greatly influence viral 
replication and also help the virus to escape the immunity shield. Vif and Vpr proteins 
protect the virus by inhibiting cytoplasmic host defense molecules and by modifying host 
cell intracellular environment. 
1.1.2 HIV-1 TAT PROTEIN 
Tat is a key early regulatory protein for viral gene expression and replication. It is a 
small polypeptide encoded from two separate exons, length varies from 86 to 101 amino 
acids depending on the viral strain (Ratner et al., 1985; Jeang et al., 1999). Tat protein has 
been divided into five different protein domains.  The first exon encodes the first four well 
conserved domains that include acidic domain (residues 1-21), cysteine rich domain 
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(residues 22-37), hydrophobic core (residues 38-48) and basic domain (residues 49-72), 
whereas sixth domain (residues 73-101) is encoded by second exon (Li et al., 2012). Clinical 
isolates from HIV-infected patients’ display the presence of Tat1-101 or its truncated form, 
Tat1-86 in different target organs (Jeang et al., 1999; Barré-Sinoussi et al., 2004; Strazza et al., 
2011). Besides its canonical function as a transcriptional activator, Tat is actively secreted 
from infected cells and can be detected in cell culture supernatants, in serum and in 
cerebrospinal fluid of HIV-1 infected individuals (Ensoli et al., 1990; Westendorp et al., 
1995; New et al., 1997; Bachani et al., 2013; Midde et al., 2013). Westendorp et al. (1995) 
reported ~1 to 3 ng/mL and ~16 ng/mL of Tat levels in the plasma and the cerebrospinal 
fluid (CSF) of HIV-1 infected patients respectively. Furthermore, another study using 80 
anonymous HIV-1 positive patients’ sera found that soluble Tat levels range from 2 ng/ml to 
40 ng/ml (Xiao et al., 2000). However, authors argued that these estimations may be lower 
than the actual concentration present in the system (Westendorp et al., 1995; Xiao et al., 
2000). Although the precise Tat concentration in the brain is not yet known, one could 
expect that this level to be markedly elevated in CSF than plasma because of close proximity 
of HIV-1-infected cells in the brain (Hayashi et al., 2006). This secreted Tat can act as 
neurotoxin by effecting bystander cells including neurons (Del Valle et al., 2000) . The 
precise mechanism by which Tat damages neurons is not clear. However, it has been 
suggested that Tat can interact with specific cell surface proteins or can be taken up by 
neurons to manipulate intracellular signaling and trafficking events (Ensoli et al., 1990; Nath 





1.1.3 EFFECT OF HIV-1 TAT PROTEIN ON DOPAMINERGIC NEURONS 
DA, a key catecholamine neurotransmitter is involved in a variety of functions 
including cognition, locomotion, reward and neuroendocrine secretion (Lyon et al., 2011; 
Money and Stanwood, 2013). A plethora of investigations suggest that HIV-1 infection 
damages DA-rich regions in the brain that include substantia nigra, caudate nucleus, basal 
ganglia and globus pallidus. Interestingly, studies using animal models and human subjects 
revealed that HIV-mediated damage to the DA neurons occurs at the early infection stage of 
the disease (Lopez et al., 1999; Koutsilieri et al., 2002). Moreover, in vitro studies showed 
that increased levels of DA enhances the replication of the virus in the infected lymphocytes 
and macrophages (Scheller et al., 2000; Gaskill et al., 2009) and promotes oxidative stress 
which subsequently causes neuronal death. In this backdrop, DAT, a crucial player to 
maintain DA homeostasis in the brain, is central focus for this dissertation for the following 
reasons (1) DAT is the primary regulator for the termination of the DA neurotransmission at 
the synapse; (2) it has been reported that DAT density is strikingly reduced in HIV-1 
infected patients and Tat protein inhibits DAT function (Wang et al., 2004; Chang et al., 
2008; Ferris et al., 2009a; Zhu et al., 2009); and (3) DAT is a major target for  highly 
addictive psychostimulants like cocaine and methamphetamines. Studies demonstrated that 
HIV-1 viral protiens in concert with these abused drugs have additive or synergistic effects 
to elevate the extracellular synaptic DA levels. This escalation of DA concentration leads to 
increased viral load and DA metabolism which ultimately  cause neuronal death (Nath et al., 
2000b; Gaskill et al., 2009; Gannon et al., 2011). While some investigators worked broadly 
on connections of HIV-1 infection, dysregulation of the DA system and drugs of abuse, 
limited studies have focused on the influence of Tat protein on DAT. This project is focused  
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to understand the effects of Tat protein on structure and functional regulation of DAT. 
Neurotoxic effects of Tat protein were first described in a study using neurblastoma 
cells (Sabatier et al., 1991). Although these cells are not dopaminergic, they provided basic 
idea of Tat protein interaction with the neurons and associated neurotoxicity. Application of 
synthetic Tat to the striatal regions of rat brain in vivo causes deleterious effects on the 
neurons (Hayman et al., 1993). Studies using Tat exposed cultured human fetal neurons  and 
microinjection of Tat into striatal neurons showed that Tat protein promotes neurotoxicity by 
triggering inflammatory cascades that eventually induce neuronal death by apoptosis (New et 
al., 1997; Jones et al., 1998; Zauli et al., 2000; Aksenov et al., 2001), suggesting that the 
dopaminergic neurons are predominantly susceptible to Tat protein. Moreover, Tat protein 
direct interaction with dopaminergic neurons increases intracellular calcium levels which in 
turn activate the caspases and generation of reactive oxygen species leading to neuronal 
injury (Kruman et al., 1998; Bonavia et al., 2001; Haughey and Mattson, 2002; Mattson et 
al., 2005). Elevated levels of Tat mRNA have been detected in the brain tissue extracts of 
HIV-1 infected patients (Wiley et al., 1996; Hudson et al., 2000) and these brain derived Tat 
sequences showed mutations at second exon region (Bratanich et al., 1998; Cowley et al., 
2011), indicating that the Tat protein exhibits significant molecular diversity and this 
heterogeneity may render the neuronal cells vulnerable to this protein. Extracellular Tat uses 
neuronal transport to reach different anatomical pathways that are distant from viral 
replication site (Bruce-Keller et al., 2003) and its passage to the spinal cord through 
cerebrospinal fluid (Pocernich et al., 2005) clearly implicate secreted Tat as a major 
contributor to HIV-1 associated dementia. Along these lines, an in vivo microdialysis study 
showed compromised DA levels in the striatum of the Tat-treated animals (Ferris et al., 
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2009b). Specifically, Tat protein contributed to the alterations in the dopaminergic markers 
expression levels that include tyrosine hydroxylase and dopamine receptor like-1 (Zauli et 
al., 2000; Silvers et al., 2006; Silvers et al., 2007). Thus, the above findings suggest that Tat 
protein directly or indirectly causes injury to dopaminergic pathways which are highly 
correlated with the dementia and motor deficits observed in HIV-1 positive individuals (Fig. 
1.1). 
1.1.4 ANIMAL MODELS OF HIV-INFECTED BRAINS 
Animal models for HAND are critical to understand the disease onset and 
progression, and to develop and test adjunctive therapies along with retroviral drugs. Non-
human primates such as chimpanzees are logical models to mimic HIV-1 infection and 
disease progression due to their genetic similarities to humans (van Maanen and Sutton, 
2003). However, financial considerations, maintenance, difficulty to obtain sufficient 
numbers to achieve statistically significant outcomes and public apprehensions limit their use 
in HAND research. Rodent models in contrast are extensively used to study HIV-1 and 
associated neurological dysfunctions despite the need of quite challenging efforts to generate 
disease in rodents because of species-specific nature of HIV-1 infection. These models offer 
several advantages that include low cost, easy maintenance during housing and subsequent 
experimental stage and well characterized genome that can be exploited to alter a particular 
cell or region of interest (Gorantla et al., 2012). These models may be created by employing 
several approaches that include stereotactic injection of viral proteins directly into the brain, 
expressing viral transgenes in animals, and transplantation of infected human cells into 
immunodeficient rodents (Van Duyne et al., 2009; Barreto et al., 2014).  
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In vivo mouse model was initially developed by introducing human neurofilament 
promoter controlled the whole HIV-1 proviral DNA into a mouse genetic background 
(Thomas et al., 1994). The transgene was expressed in anterior thalamic and spinal motor 
neurons, and animals exhibited neurological complications both in central and peripheral 
nervous systems. Another proviral mouse model that expresses gap-pol deleted mutant of the 
HIV-1 full length genome demonstrated that viral proteins and accessory genes may be 
sufficient to produce neurotoxicity and motor abnormalities observed in HIV-1 positive 
patients (Santoro et al., 1994). Further studies showed that individual viral components that 
include gp120/gp160, gp140, Tat, Nef, Vpr and Rev are capable of eliciting neurotoxicity in 
the brain (Nath, 2002; Li et al., 2005). Efforts were made to determine the role of Tat and 
gp120 in producing neurotoxic effects by direct injection of these proteins into the rodent 
brains (Jones et al., 1998; Bansal et al., 2000). 
 In advanced approaches, transgenic models were generated by inserting gp120 or Tat 
coding genes into the animal genome. Transgenic expression of HIV-1 env gene that encodes 
for gp120 revealed that extracellularly released gp120 is neurotoxic and produces alterations 
in neuronal and glial cells. These modifications are similar to the changes in HIV-1 infected 
human brains (Toggas et al., 1994). These transgenic animals also showed impairment in 
open filed activity and spatial reference memory in an age-dependent manner suggesting the 
role of gp120 in cognitive and motor decline observed in HIV-1 positive patients (D'Hooge 
et al., 1999). Another study created a transgenic mouse model that expresses Tat protein 
under the control of both GFAP promoter and doxycycline (Dox) inducible promoter (Kim et 
al., 2003). Interestingly, findings from these studies suggest that presence of Tat expression 
is adequate to attain neuronal damage in the brain and this neurotoxicity is severe than that 
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observed in gp120 transgenic animals (Toggas et al., 1994; Kim et al., 2003). Thus, these 
transgenic animal models are quite useful to study the HIV-associated neuropathogenesis. 
However, there are certain limitations to fully utilize these models to understand the HIV-1 
mediated neurocognitive dysfunctions. For example, these models can replicate certain 
features of the disease but do not represent the whole spectrum of neuropathology associated 
with HIV-1 (Nath, 2010; Jaeger and Nath, 2012). 
For the purpose of our project-2, to study whether HIV-1 viral proteins and nicotine 
together produce molecular changes in mesolimbic structures that mediate psychomotor 
behavior, we used HIV-1 transgenic (HIV-1 Tg) rat as small animal model that was 
developed by reid et al. (2001). HIV-1 Tg rats are derived from Fisher344/ BHsd strain 
and carry proviral DNA that is devoid of Gag and Pol genes. Expressing only seven of 
nine HIV- 1 genes makes this model as noninfectious, and displays immune, motor and 
behavioral abnormalities (Reid et al., 2001). Deficits in learning and cognition that are 
associated with asymptomatic HIV-1 infection have been reported in these animals 
(Vigorito et al., 2007; Lashomb et al., 2009). Observed dopaminergic alteration, 
neuroinflammation and deficits in several synaptic proteins (Persidsky and Fox, 2007; 
Webb et al., 2010; Rao et al., 2011) make HIV-1 Tg rat  as a suitable animal model to 
study the effects of HIV-1 viral proteins on nicotine induced behavioral sensitization and 
associated signaling protein changes. Furthermore, HIV-1 Tg rats have also been 
successfully employed to study the concerted effects of HIV-1 viral proteins and drugs of 
abuse (Liu et al., 2009; Kass et al., 2010; Moran et al., 2012).   
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1.2 DOPAMINE TRANSPORTER (DAT) 
1.2.1 STRUCTURE AND FUNCTION 
The DAT, a member of the Solute Carrier 6 family (SLCA3), comprises of 620 
amino acids with 12 putative transmembrane domains with both amino and carboxy termini 
located in the cytoplasmic side of the cells (Kristensen et al., 2011). The DAT, clears 
extracellular DA via rapid reuptake, is a primary determinant for the regulation of DA 
neurotransmission and maintaining DA homeostasis in the brain (Fig. 1.2). In addition to DA 
transport, DAT can move endogenous trace amines tyramine and β-phenethylamine; 
neurotoxin 1-methyl-4-phenylpyridinium (MPP+) and amphetamines (Sulzer, 2011) into 
presynaptic terminal. Great insights into structure and function relations of DAT come from 
the mutagenesis analysis, engineering of zinc binding sites, substituted-cysteine accessibility 
method and homology modeling to bacterial leucine transporter LeuT, a prokaryotic 
homolog of DAT (Kitayama et al., 1992; Javitch, 1998; Chen and Reith, 2000; Loland et al., 
2003; Loland et al., 2004; Lin and Uhl, 2005; Yamashita et al., 2005). DAT uses Na+ and Cl- 
dependent process to translocate DA back into dopaminergic neurons against its 
concentration gradient. Active substrate translocation by DAT follows the alternating access 
model (Jardetzky, 1966; Yamashita et al., 2005). This model suggests that the transporter 
cycles through at least three conformational states: outward, occluded and inward, in order to 
re-accumulate DA into cell interiors. Correspondingly, recent studies suggest that substrate 
translocation is a dynamic process and it requires multiple interaction sites within DAT 
(Schmitt and Reith, 2011; Shan et al., 2011).  
Different chemical classes of ligands induce specific conformations in DAT to 
achieve a particular physiological or behavioral effect. For example, cocaine-like inhibitors 
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have inclination to outward facing conformation (Beuming et al., 2008; Reith et al., 2012) 
whereas benztropine and related analogs preferentially interact with inward facing 
conformation of the transporter (Loland et al., 2008; Schmitt and Reith, 2011). It is worth 
noting that benztropine was established as an anticholinergic agent in the management of 
Parkinson’s disease (Katzenschlager et al., 2003) and, it may also be used to treat 
extrapyramidal reactions caused by use of antipshycotics (Teoh et al., 2002; González-Lugo 
et al., 2010). Consistent with these findings, a recently solved X-ray crystal structure of DAT 
shows that tricyclic antidepressant nortriptyline occupies the substrate binding site and 
stabilizes the Drosophila melanogaster transporter in outward conformation and thus 
preventing substrate translocation (Penmatsa et al., 2013). Substrate efflux or reversal of 
transport is mechanistically distinct from the translocation process. Recent studies implied 
that synthetic compounds like N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-
20041) and point mutations at specific residues in DAT cause subtle alterations in the 
transporter conformation which in turn have differential effects on inward transport and 
efflux properties (Guptaroy et al., 2009; Rothman et al., 2009; Guptaroy et al., 2011). Thus, 
conformational transitions in the transporter protein and associated structural changes 
provide a basic framework for ligand binding and have a great impact on transport kinetics 
and functionality of the DAT.  
1.2.2 REGULATION 
DAT regulation is a complex and vital process for the spatial and temporal 
management of DA concentration in the brain. DAT mediated behavioral and physiological 
functions are dynamically controlled by multitude of exogenous factors, macromolecules and 
signaling cascades. Many of these check points work interactively while exerting their 
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actions. Although there is a lack of complete understanding of regulation of DAT, available 
information suggest that the diverse set of DAT-affecting molecules achieve their function 
through ligand-transporter interactions, trafficking, post-translational modifications and 
protein-protein interactions (Fig. 1.3). In recent years, several reviews comprehensively 
presented extensive details about DAT regulation (Chen et al., 2010; Eriksen et al., 2010; 
Schmitt and Reith, 2011; Vaughan and Foster, 2013) and for the purpose of this dissertation, 
I briefly discuss some of these DAT regulatory processes that are relevant to HIV-1 Tat 
protein and DAT interaction.  
1.2.2.1 ALLOSTERIC MECHANISM DEPENDENT REGULATION 
 Initial evidence for the existence of allosteric binding site for DA, a modulatory 
binding site on the transporter that is topographically distinct from the primary binding site 
comes from molecular dynamics and simulation studies (Shi et al., 2008; Shan et al., 2011). 
These studies suggest that direct interaction of substrates and ions at allosteric sites elicit 
progressive rearrangements in the transporter structure that help to shift the conformational 
state in order to transport substrate DA (Fig. 1.4). Furthermore, different structural classes of 
DAT ligands that include tricyclic antidepressants and selective reuptake inhibitors have 
been shown to influence this allosteric binding site (Zhou et al., 2007; Zhou et al., 2009). 
Likewise, investigations conducted by schmitt and reith (2010) further supported the 
presence of allosteric binding by using bivalent phenethylamines (two substrate like 
molecules connected with aliphatic spacer) that act as potent inhibitor rather than substrate 
molecule. In addition to the secondary binding site for DA, the existence of allosteric binding 
sites for synthetic DAT ligands were reported (Pariser et al., 2008). According to this study, 
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenyl ethyl)-2-
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phenyl-4-quinazolinamine (SoRI-20040), and SoRI-20041 compounds inhibit the binding of 
[125I]3beta-(4'-iodophenyl) tropan-2beta-carboxylic acid methyl ester ([125I]RTI-55) by 
following allosteric inhibitory patterns, meaning that these compounds do not follow 
classical dose dependent competitive inhibition paradigm irrespective of the concentration of 
[125I]RTI-55. These modulators also slowed down the dissociation rate of prebound 
[125I]RTI-55 and presented a decrease in Bmax and increase in Kd values for [125I]RTI-55 
binding, further confirming the allosteric binding of these 4-quinazolinamine derivatives 
with the DAT. Taken together, these investigations strongly imply that various ligands 
allosterically regulate local rearrangements in the structural elements of the DAT that finally 
contribute to the formation of functionally unique conformation of the transporter to achieve 
targeted function.  
1.2.2.2 TRAFFICKING AND POST-TRANSLATIONAL DEPENDENT REGULATION 
Post-translational modifications, in particular phosphorylation of the transporter or its 
binding partners are the key strategy for controlling the function and distribution of the 
transporter. Numerous studies have showed that DAT trafficking to and away from plasma 
membrane is precisely regulated by various protein kinases that include protein kinase C 
(PKC), Ca2+/calmodulin kinase, phosphoinositide 3-kinase, protein tyrosine kinase and 
members of mitogen-activated protein kinase (MAPK) family (Foster et al., 2006; 
Ramamoorthy et al., 2011). Of these, PKC-mediated processes are most well characterized. 
Activation of PKC causes decrease in Vmax without effecting Km value by directing active 
transporter population to intracellular regions (Melikian, 2004). This mode of internalization 
controls short and long-term availability of the transporter on the surface. While acute 
endocytic regulation targets DAT to early and recycling endosomes, long-term endocytosis 
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triggers lysosomal degradation of the protein (Chen et al., 2010; Rao et al., 2011; Hong and 
Amara, 2013; Sorkina et al., 2013). Interestingly, it has also been reported that PKC-
stimulated direct phosphorylation of DAT does not require for internalization (Granas et al., 
2003; Pramod et al., 2013) indicating the involvement of accessory proteins for the 
regulation of DAT endocytosis. Correspondingly, protein-protein interactions have been 
implicated as the crucial regulators that dictate DAT function (Eriksen et al., 2010; Sager and 
Torres, 2011). For example membrane raft protein Flotillin-1/Reggie-1 (Flot-1) has been 
shown to be required for the PKC-mediated internalization of DAT (Cremona et al., 2011). 
Besides eliciting DAT endocytosis, PKC also induces DAT down regulation in the presence 
of endocytotic blockers (Foster et al., 2008; Foster and Vaughan, 2011), indicating 
phosphorylation led intrinsic kinetic alterations in the transporter.  On the other hand, MAPK 
family kinases enhance the functionality of the DAT by potentially phosphorylating serine 
and threonine residues in the transporter (Schmitt and Reith, 2010; Vaughan and Foster, 
2013). Overall, these studies reveal that a plethora of convergent and divergent pathways 
regulate DAT activities: substrate translocation, substrate efflux and ion conductance 
through alterations in conformational states and endocytosis of the transporter.    
1.2.3 DAT AND HIV-1 TAT PROTEIN 
The apparent indirect evidence for dysregulation of the DAT in HIV-1 positive 
patients comes from reduced DA levels observed in infected brains. Decreased DA and its 
major metabolite homovanillic acid (HVA) were observed in post mortem brain samples and 
CSF (Larsson et al., 1991; Berger et al., 1994; Sardar et al., 1996; Kumar et al., 2009). These 
DA deficits differ from region to region in the brain, however, greater neuronal loss is 
associated with dopaminergic neurons especially at the subcortical area. These claims were 
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further substantiated by imaging studies and neuropsychological performance tests (Aylward 
et al., 1993; Kieburtz et al., 1996; Kumar et al., 2011).  Although the above studies do not 
explain the underlying mechanism of HIV-infection and impairment of DA system, the 
possible explanation would be dysregulation of DAT that results from HIV-1 viral proteins. 
Because HIV-1 viral proteins load is usually peak in the dopaminergic rich areas, where the 
highest density of DAT protein is situated, it is reasonable to hypothesize that Tat protein 
impairs DAT function to promote neuronal injury. However, we cannot exclude the 
possibility of involvement of other HIV-1 neurotoxic proteins like coat glyco protein gp120, 
HIV-induced host chemokines and free radicals for the loss of dopaminergic neurons 
(Purohit et al., 2011). Indeed, significantly reduced DAT levels were reported in HIV-1 
associated dementia patients’ using positron emission tomography (Wang et al., 2004; 
Sporer et al., 2005; Chang et al., 2008). In contrary to these imaging studies, a recent 
biochemical characterization on human brain specimen collected from HIV-1 encephalitis 
subjects demonstrated elevated levels of DAT protein (Gelman et al., 2006). Furthermore, a 
single photon emission tomography imaging on treatment naïve HIV-1 patients showed 
enhanced DA levels with no change in the DAT density (Scheller et al., 2010). These 
contradictory outcomes for DAT levels suggest that the stage of the disease, treatment 
condition of the patient and host as well as viral factors may play a defining role in 
dopaminergic neuronal degeneration. Taken together, these findings indicate the altered 
regulation of DAT function in HIV-1 infected individuals. Although these studies clearly 
show the pivotal role of DAT in Tat-induced DA system impairment, mechanisms 




1.3 OBJECTIVES OF THE RESEARCH 
The overall objective of this research is to understand how Tat protein interacts with 
DAT at specific recognition sites and thereby modulating transporter structure-function 
coordination in DA translocation process. This study provides valuable information of Tat 
binding residues and mechanistic understanding of Tat action on DAT at the molecular level, 
which is important to study Tat induced DA deficits in the animal models. This project seeks 
to delineate structural and molecular basis of how Tat protein interacts with DAT through 
conceptual and technical innovations. First, this work aims to address the novel concept of 
allosteric influence of Tat on DAT via interaction at specific binding sites. Second, our study 
is technically innovative because combining computational modeling and neuro-
pharmacology represent a novel approach that allowed us to define potential Tat interacting 
residues on DAT. While previous studies broadly established Tat mediated dysfunction of 
the DAT, they have fallen short in precisely locating the molecular determinants of Tat 
recognition sites on DAT. This is the first time that this state-of-art-technique, integrated 
with conventional approaches was used to determine Tat and DAT protein interaction. We 
also employed molecular biological and cell surface biotinylation techniques to answer the 
fundamental question how Tat protein controls dynamic surface expression and trafficking of 
the DAT. Findings of this work lay a platform to study the relationship between Tat 
interaction and associated changes in DAT structure-function, and open the door to rational 
drug development to treat cognitive and motor deficits associated with neuroAIDS. 
1.4 SPECIFIC AIMS 
Our lab previously reported that Tat inhibits DAT function and that inhibition is due 
to a protein-protein interaction (Zhu et al., 2009). Recently, we have also demonstrated that 
Tat protein allosterically inhibits DAT function and influences cocaine binding sites on DAT 
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(Zhu et al., 2011). Moreover, our preliminary three dimensional computational modeling 
predicts that amino acid Tyr470 of human DAT is an important residue for favorable 
intermolecular interaction between DAT and HIV-1 Tat. Our initial pharmacological data for 
Tyr470His (Y470H) mutant DAT revealed significant attenuation of Tat-induced effects on 
DA uptake without changes in the binding affinity of DA to the DAT.  This is consistent 
with the observed attenuated effects of Cys22Gly mutant Tat on DA transport (Zhu et al., 
2009). Collectively, these observations ascertain the critical role of recognition sites for Tat-
mediated influence on DAT structure and function.  
Therefore, we hypothesized that HIV-1 Tat protein via allosteric modulation of 
DAT induces inhibition of DA transport, leading to dysfunction of the DA system. This 
central hypothesis was tested with the specific aims outlined below.  
Aim 1: To create and validate computational modeling predicted HIV-1 Tat recognition sites 
(Y88, K92 and Y470) on human DAT. (Chapter 2 and 3) 
Aim 2: To determine whether Tat has any influence on the trafficking and phosphorylation 
dependent regulation of DAT. (Chapter 4) 
In addition to the above stated aims, the findings from my second project, combined 
effects of HIV-1 viral proteins and nicotine on nicotine-induced behavioral sensitization and 
associated changes in the expression of intracellular signaling proteins were described in 
Chapter 5. Finally, Chapter 6 provides overall summary and conclusions for the dissertation 




Figure 1.1 Overview of HIV-1 Tat and cocaine synergistic or additive effects on dopamine 
neurotransmission in HIV-1 infected individuals. HIV-1 penetrates the brain at the early 
infection stage and infects macrophages and microglial cells. These cells exude viral proteins 
that including Tat and other neurotoxic factors. Cocaine, a major psycho stimulant blocks 
DAT to inhibit DA translocation. Both Tat and cocaine elevate synaptic DA levels by 
inhibiting DA reuptake into presynaptic terminal. This increased DA induces further 
replication of virus in infected cells. Persistent exposure to the viral proteins, oxidative stress 
induced by increased DA levels and other chemokines aggravate the severity of the 




Figure 1.2 DAT is localized to the presynaptic terminal of the dopaminergic neurons. It 
regulates the DA availability at the synapse by rapid reuptake into the terminal. In addition to 
the DA, amphetamine and MPP+ (1-methyl-4-phenylpyridinium) act as substrates for DAT. 
Selective pharmacological inhibitors for DAT such as cocaine, GBR12909, WIN 35,428 and 






Figure 1.3 Illustration of potential regulatory pathways that control the function and 
availability of the DAT. (A) The surface localization of DAT is maintained by trafficking 
and endocytosis to and from the surface of the membrane. (B and C) Direct interaction of 
small molecules such as substrates and inhibitors may modulate the function of the DAT 
through conformational alterations. (D) Phosphorylation of DAT or its accessory proteins 
controls the catalytic activity of the transporter by influencing protein kinase signaling 
cascades. (E) Activation of G-protien coupled receptors and (F) direct interaction with D2-
like autoreceptors modulate the DAT function. (G) Post-translational modification such as 
ubiquitination of the DAT also dictates the number of active transporter molecules on the 




Figure 1.4 Model of substrate translocation cycle for DAT. Binding of the ions primes 
substrate-free (apo) DAT to fully stabilized outward-facing conformation with an open 
extracellular gate to bind to the substrate DA. Substrate binding at the S1 binding site 
promotes the formation of an occluded state and closure of the extracellular gate. Binding of 
a second substrate molecule at the S2 site induces the opening of an intracellular gating 
network leading to release of the S1-bound substrate from the inward-facing state of the 




MUTATION OF TYROSINE 470 OF HUMAN DOPAMINE TRANSPORTER IS CRITICAL 
FOR HIV-1 TAT-INDUCED INHIBITION OF DOPAMINE TRANSPORT AND 
TRANSPORTER CONFORMATIONAL TRANSITIONS1 
 
ABSTRACT: HIV-1 Tat protein plays a crucial role in perturbations of the dopamine (DA) 
system. Our previous studies have demonstrated that Tat decreases DA uptake, and 
allosterically modulates DA transporter (DAT) function. In the present study, we have 
found that Tat interacts directly with DAT, leading to inhibition of DAT function. 
Through computational modeling and simulations, potential recognition binding site of 
human DAT (hDAT) for Tat was predicted. Mutation of tyrosine470 (Y470H) attenuated 
Tat-induced inhibition of DA transport, implicating the functional relevance of this 
residue for Tat binding to hDAT. Y470H reduced the maximal velocity of [3H]DA uptake 
without changes in the Km and IC50 values for DA inhibition of DA uptake but increased 
DA uptake potency for cocaine and GBR12909, suggesting that this residue does not 
overlap with the binding sites in hDAT for substrate but critical for these inhibitors. 
Furthermore, Y470H also led to transporter conformational transitions by affecting zinc 
modulation of DA uptake and WIN35,428 binding as well as enhancing basal DA efflux. 
                                                            
1 Midde NM, Huang X, Gomez AM, Booze RM, Zhan CG, Zhu J (2013) Mutation of tyrosine 
470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine 
transport and transporter conformational transitions. Journal of neuroimmune pharmacology : the 





Collectively, these findings demonstrated Tyr470 as a functional recognition residue in 
hDAT for Tat-induced inhibition of DA transport and transporter conformational 
transitions. The consequence of mutation at this residue is to block the functional binding 
of Tat to hDAT without affecting physiological DA transport. 
2.1 INTRODUCTION  
The estimated prevalence of HIV-1-associated neurocognitive disorders (HAND) 
is about 70% of HIV-1 positive individuals with antiretroviral therapy (Robertson et al., 
2007; Tozzi et al., 2007; Ernst et al., 2009). Cocaine has been shown to increase the 
incidence and exacerbate the severity of HAND by enhancing viral replication (Nath et 
al., 2001; Ferris et al., 2008). Antiretroviral agents cannot prevent the production of HIV-
1 viral proteins, such as Tat protein, in HIV-1 infected brains in the early stage of HIV-1 
infection (McArthur et al., 2010; Nath and Clements, 2011). Tat has been detected in the 
brains (Del Valle et al., 2000; Hudson et al., 2000; Lamers et al., 2010) and the sera 
(Westendorp et al., 1995; Xiao et al., 2000) of HIV-1 infected patients. Furthermore, Tat 
interacting with cocaine exacerbates the progression of the neurocognitive impairment 
(Buch et al., 2011; Gannon et al., 2011). 
Accumulating clinical evidence supported by imaging (Chang et al., 2008; Meade 
et al., 2011a), neurocognitive (Kumar et al., 2011; Meade et al., 2011b), and postmortem 
examinations (Kumar et al., 2009; Gelman et al., 2012), reveals that abnormal 
neurocognitive function observed in HAND is associated with dysfunctions in dopamine 
(DA) neurotransmission (Berger and Arendt, 2000; Purohit et al., 2011). The DA 
transporter (DAT) terminates DA signaling and thus is central to control synaptic 
dopaminergic tone (Torres and Amara, 2007). DAT activity is strikingly reduced in HIV-
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1-infected patients with a history of cocaine use (Wang et al., 2004; Chang et al., 2008). 
We have demonstrated that Tat allosterically modulates DAT function and reduces DAT 
cell surface expression in rat striatal synaptosomes (Zhu et al., 2009; Zhu et al., 2011; 
Midde et al., 2012).  
Viral replication within HIV-1 infected brain regions results in Tat release, which 
elevates DA levels via inhibiting DAT function (Gaskill et al., 2009). Exposure of HIV-1 
infected patients to cocaine further impairs DAT function and increases synaptic DA 
levels (Ferris et al., 2010). Importantly, the elevated DA induced by Tat and cocaine 
stimulates viral replication and Tat release (Gaskill et al., 2009), which has been 
implicated in the neuropathogenesis of HAND (Li et al., 2009). Considering oxidative 
stress-induced damage to dopaminergic neurons, long lasting exposure to viral proteins 
and elevated DA eventually lead to a DAT deficit that potentiates severity and accelerates 
the progression of HAND (Purohit et al., 2011). To the best of our knowledge, the 
mechanisms of Tat and cocaine interaction with hDAT have been virtually unexplored. In 
order to explore the molecular mechanism(s) underlying the interplay of Tat with cocaine 
in disrupting DAT-mediated DA neurotransmission, we performed computational 
modeling and simulations to predict potential recognition binding sites of human DAT 
(hDAT) for Tat. Identifying the functional recognition residues in hDAT for Tat may 
provide therapeutic insights into HAND in concurrent cocaine abusers. Upon prediction 
and validation of the functional relevance of tyrosine 470 (Tyr470) in hDAT, we 
determined the mechanisms that underlie mutation of Tyr470 in Tat-induced inhibition of 




2.2 MATERIALS AND METHODS  
2.2.1 CONSTRUCTION OF PLASMIDS  
Plasmid pcDNA3.1+/Tat1-72 that encodes Tat1-72 protein was provided by Dr. 
Avindra Nath (NINDS/NIH). Plasmid GFP-tagged Tat1-86 was a gift from by Dr. Mauro 
Giacca (Molecular Medicine Laboratory, ICGEB, Italy). Plasmids pcDNA3.1+/Tat1-101 
that encodes Tat1-101 protein was provided by NIH AIDS Reagent Program. Mutation in 
hDAT (tyrosine to histidine, Y470H-hDAT) was generated based on WT hDAT sequence 
(NCBI, cDNA clone MGC:164608 IMAGE:40146999) by site-directed mutagenesis. 
Synthetic cDNA encoding hDAT subcloned into pcDNA3.1+ (provided by Dr. Haley E 
Melikian, University of Massachusetts) was used as a template to generate Y470H-hDAT 
using QuikChange™ site-directed mutagenesis Kit (Agilent Tech, Santa Clara CA). The 
sequence of the mutant construct was confirmed by restriction enzyme mapping and 
DNA sequencing. 
2.2.2 CELL CULTURE AND DNA TRANSFECTION 
CHO cells (ATCC #CCL-61) were maintained in F12 medium supplemented with 
10% fetal bovine serum (FBS) and antibiotics (100 U/ml penicillin and 100 µg/mL 
streptomycin) at 37°C in a 5% CO2 incubator. For hDAT transfection, cells were seeded 
into 24 well plates at a density of 1×105 cells/cm2. After 24h, cells were transfected with 
WT or mutant DAT plasmids using Lipofactamine 2000 (Life Tech, Carlsbad, CA). Cells 
were used for the experiments after 24 h of transfection.  
2.2.3 CO-IMMUNOPRECIPITATION (CO-IP) OF DAT AND TAT 
To determine whether Tat directly binds to DAT, Co-IP of Tat and DAT assays 
were performed in rat synaptosomes after exposure to recombinant Tat1-86 as described 
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previously (Li et al., 2008). In brief, rat anti-DAT antibody (6 µg, MAB369, Millipore, 
Temecula, CA) was incubated with 20 μl protein A/G agarose beads (SC2003, Santa 
Cruz Biotechnology Inc., Santa Cruz, CA) for 5-6 h at 4°C with constant rotating and 
were centrifuged at 8,000 g for 5 min.  The agarose-anti DAT antibody complex was 
washed five times with immunoprecipitation buffer (1% Triton X-100, 150 mM NaCl, 10 
mM Tris, 1 mM EDTA, 1 mM EGTA, 0.2 mM sodium ortho-vanadate, 0.2 mM PMSF, 
0.5% NP-40) to remove the unbound antibody. Rat synaptosomes from striatum and 
cerebellum, and spleen homogenates were prepared as described previously (Zhu et al., 
2009) and adjusted to equal protein concentration (1.5 mg/ml) using the Bradford protein 
assay (Bradford, 1976). Then, aliquots (500 µg) of synaptosomes or homogenates were 
incubated in Krebs-Ringer-HEPES (KRH) buffer (final concentration in mM: 125 NaCl, 
5 KCl, 1.5 MgSO4, 1.25 CaCl2, 1.5 KH2PO4, 10 D-glucose, 25 HEPES, 0.1 EDTA, 0.1 
pargyline, and 0.1 L-ascorbic acid; pH 7.4) containing recombinant Tat1-86 (350 nM, final 
concentration, Clade B, # REP0002a, DIATHEVIA, Fano, Italy) for 1 h at room 
temperature and were then centrifuged at 8,000 g for 5 min. The resulting pellets were 
washed 5 times with KRH buffer. The pellets were resuspended and added to the 
agarose-antibody complex and incubated with agitation at 4°C overnight. These samples 
(agarose-antibody-protein complex) were centrifuged at 8,000 g for 1 min and the 
resulting pellets were washed with immunoprecipitation buffer for 5 times. These 
samples were then mixed with 2 × Laemmli sample buffer and boiled for 5 min. To 
detect immunoreactivity of DAT or Tat protein, the samples were then subjected to 
Western blotting with either goat polyclonal DAT antibody (1:200, Cat # SC-1433, Santa 
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Cruz Biotechnology Inc., Santa Cruz, CA) or mouse anti HIV-1 Tat (1:1000, Cat # 
ab24778, Abcam, Cambridge, MA ) using our published method (Zhu et al., 2009).  
2.2.4 GST-PULL-DOWN ASSAY 
To confirm whether Tat interacts with DAT through a protein-protein interaction, 
GST-Tat fusion protein was used as bait for pull-down DAT to show their interaction as 
described previously (Li et al., 2008).  In brief, BL21 E. coli expressing pGEX-Tat1-86 
(obtained from Dr. Virginie W Gautier, University College Dublin, Ireland) and GST 
only (as negative control) were grown in liquid culture media and induced GST protein 
expression by 100 mM IPTG. These GST proteins were added to glutathione sepharose 
beads (17-0756-01, GE Healthcare) and then incubated with the cell lysates from CHO 
cells transfected with hDAT. The beads were washed with the immunoprecipitation 
buffer described above and mixed with protein sample buffer. The eluted proteins were 
subjected to immunoblotting with anti-DAT antibody (Cat # sc-1433, Santa Cruz 
Biotechnology Inc., Santa Cruz, CA). 
2.2.5 PREDICTING THE SITE FOR HDAT BINDING WITH TAT 
The binding structure of hDAT with HIV-1 clade B type Tat was modeled and 
simulated based on the nuclear magnetic resonance (NMR) structures of Tat (Peloponese 
et al., 2000) and the constructed structure of DAT(DA), as reported previously (Huang 
and Zhan, 2007; Huang et al., 2009). Briefly, Brownian dynamics (BD) simulations were 
performed to obtain the initial binding structure of the hDAT-Tat complex.  Starting from 
the available 11 NMR structures of Tat, the BD simulations were launched from a 
spherical surface around the extracellular side of hDAT, and the electrostatic interaction 
energy was calculated for each BD trajectory by multiplying the electrostatic potential of 
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hDAT with the atomic charges of Tat.  The initial complex for hDAT binding with Tat 
was identified from the BD trajectories, with the lowest interaction energy and the best 
geometric matching quality. The identified initial hDAT-Tat complex structures were 
energy-minimized in the same way as described in our previous studies on hDAT binding 
with DA and cocaine (Huang and Zhan, 2007; Huang et al., 2009). Molecular dynamics 
(MD) simulations were performed to further relax and equilibrate the energy-minimized 
structure of the hDAT-Tat binding complex. Finally, the MD-simulated hDAT-Tat 
binding structure was energy-minimized and analyzed.    
2.2.6 PREPARATION OF RELEASED TAT FROM TAT-EXPRESSING CELLS 
To generate released Tat from Tat-expressing cells, CHO cells were seeded into 
60 mm plates at a density of 1 × 106/cm2.  After 24 h, cells were transfected with different 
amounts (5 and 10 µg) of plasmid DNAs for Tat1-72, GFP-tagged Tat1-86 and Tat1-101 using 
Lipofactamine 2000. Cells transfected with pcDNA3.1+ were used as a negative control. 
After transfection, culture media from Tat- transfected cells were collected at 24, 48 and 
72 h. 
2.2.7 [3H]DA UPTAKE ASSAY 
Twenty four hours after transfection, [3H]DA uptake in CHO cells transfected 
with wild type hDAT (WT hDAT) and Y470H-hDAT was performed in KRH buffer 
using a modified procedure as reported previously (Zhu et al., 2009). To determine 
whether mutated hDAT alters the maximal velocity (Vmax) or Michaelis-Menten constant 
(Km) of [3H]DA uptake, kinetic analyses were conducted in WT hDAT versus Y470H-
hDAT in the presence or absence of recombinant Tat1-86. To generate saturation 
isotherms, [3H]DA uptake was conducted in duplicate wells containing one of six 
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concentrations of unlabeled DA (final DA concentrations, 1.0 nM–5 µM) and a fixed 
concentration of [3H]DA (500,000 dpm/well, specific activity, 31 Ci/mmol; PerkinElmer 
Life and Analytical Sciences, Boston, MA). In parallel, nonspecific uptake of each 
concentration of [3H]DA (in the presence of 10 µM nomifensine, final concentration) was 
subtracted from total uptake to calculate DAT-mediated uptake. To determine the effect 
of Tat on DA uptake, cells transfected with WT or Y470H-hDAT were preincubated with 
each concentration of [3H]DA in the presence or absence of the concentrations of 
released Tat or Tat1-86 (350 nM). The reaction was terminated by washing twice with ice 
cold uptake buffer. Cells were solubilized in 1% SDS and radioactivity was measured 
using a liquid scintillation counter (model Tri-Carb 2900TR; PerkinElmer Life and 
Analytical Sciences, Waltham, MA). Kinetic parameters (Vmax and Km) were determined 
using Prism 5.0 (GraphPad Software Inc., San Diego, CA).  
For the competitive inhibition experiment, assays were performed in duplicate in 
a final volume of 500 µl. Cells in each well were incubated in 450 µl buffer containing 50 
µl one of final concentrations of unlabeled DA (1 nM-1 mM), GBR12909 (1 nM-10 µM), 
cocaine (1 nM-1 mM), and ZnCI2 (10 µM) at 37°C for 10 min and [3H]DA uptake was 
determined by addition of 50 µl of [3H]DA (0.1 µM, final concentration) for an additional 
5 min.   
2.2.8 IMMUNODEPLETION 
Released Tat was prepared as described above. Seventy-two hours after 
transfection with Tat1-72 plasmid, aliquots (500 μl) of the conditioned media were 
incubated with mouse anti-Tat antibody (1:200, # ab6539, Abcam, Cambridge, MA) at 
4°C for 2 h on a shaking platform, followed by incubation with 20 μl of Protein A/G – 
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PLUS Agarose beads (# SC2003, Santa Cruz Biotechnology Inc., Santa Cruz, CA) at 4°C 
for 2 h.  After incubation, the agarose-antibody-Tat complex was pelleted at 12,000g for 
2 min at 4°C and supernatants were collected. For the immunodepletion assay, CHO cells 
transfected with hDAT were incubated with either Tat-conditioned media or supernatant 
at 37°C for 2 h, followed by [3H]DA uptake assay, as described above.  Anti-Tat 
antibody specificity for the Tat protein was determined by using mouse IgG1 kappa 
monoclonal antibody (1:200, # ab18447, Abcam, Cambridge, MA) as an isotype control.  
2.2.9 CELL SURFACE BIOTINYLATION 
To determine whether decreased DA uptake in Y470H-hDAT is due to a 
reduction of cell surface DAT, biotinylation assays were performed, as described 
previously (Zhu et al., 2005). CHO cells expressing hDAT and Y470H-hDAT were 
plated on 6 well plates at a density of 105 cells/well. Cells were incubated with 1 ml of 
1.5 mg/ml sulfo-NHS-SS biotin (Pierce, Rockford, IL) in PBS/Ca/Mg buffer (In mM: 
138 NaCl, 2.7 KCl, 1.5 KH2PO4, 9.6 Na2HPO4, 1 MgCl2, 0.1 CaCl2, pH 7.3). After 
incubation, cells were washed 3 times with 1 ml of ice-cold 100 mM glycine in 
PBS/Ca/Mg buffer and incubated for 30 min at 4°C in 100 mM glycine in PBS/Ca/Mg 
buffer. Cells were then washed 3 times with 1 ml of ice-cold PBS/Ca/Mg buffer and then 
lysed by addition of 500 ml of Triton X-100, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µM 
pepstatin, 250 µM phenylmethysulfonyl fluoride), followed by incubation and continual 
shaking for 20 min at 4 °C. Cells were transferred to 1.5 ml tubes and centrifuged at 
20,000g for 20 min. The resulting pellets were discarded, and 100 µl of the supernatants 
was stored at -20 °C for determination of immunoreactive total DAT. Remaining 
supernatants were incubated with continuous shaking in the presence of monomeric 
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avidin beads in Triton X-100 buffer (100 µl/tube) for 1 h at room temperature.  Samples 
were centrifuged subsequently at 17,000g for 4 min at 4°C, and supernatants (containing 
the nonbiotinylated, intracellular protein fraction) were stored at -20°C. Resulting pellets 
containing the avidin-absorbed biotinylated proteins (cell-surface fraction) were 
resuspended in 1 ml of 1.0% Triton X-100 buffer and centrifuged at 17,000g for 4 min at 
4°C, and pellets were resuspended and centrifuged twice. Final pellets consisted of the 
biotinylated proteins adsorbed to monomeric avidin beads. Biotinylated proteins were 
eluted by incubating with 50 µl of Laemmli sample buffer for 20 min at room 
temperature. If further assay was not immediately conducted, samples were stored at -20 
°C. 
2.2.10 [3H]WIN 35,428 BINDING ASSAY 
For the competitive inhibition experiment, cells transfected hDAT and Y470H-
hDAT were incubated in KRH buffer containing 50 µl of [3H]WIN 35,428 (5 nM, final 
concentration, specific activity, 85 Ci/mmol) and ZnCI2 (10 µM) using our published 
method (Zhu et al., 2009). The reaction was terminated by washing twice with ice cold 
KRH buffer. Nonspecific binding at each concentration of [3H]WIN 35,428 was 
determined in the presence of 30 µM cocaine (final concentration).  Cells were 
solubilized in 1% SDS and radioactivity was measured using a liquid scintillation 
counter.  
2.2.11 DA EFFLUX ASSAY 
Basal efflux from CHO cell transfected with hDAT or mutated hDAT was 
measured, as described previously (Guptaroy et al., 2009). Cells were incubated in 24 
well plates at a density of 105 cells/well for 24 h before assays were washed 3 times with 
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KRH buffer and preloaded with [3H]DA (0.05 µM, final concentration) for 20 min at 
room temperature. After loading, cells were washed 3 times with KRH buffer. To obtain 
an estimate of the total amount of [3H]DA in the cells at the zero time point, cells from a 
set of wells (four wells/sample) were lysed rapidly in 1% SDS after preloading with 
[3H]DA. Buffer (500 µl) was added into separate set of cell wells and transferred to 
scintillation vials after 1 min as fractional efflux at 1 min, and another 500 µl buffer was 
added to the same wells (where the buffer was just removed for 1 min point) and 
collected to vials after 10 min. Additional fractional efflux at 20, 30, 40 and 50 min, 
respectively, was repeated under the same procedure. After 40 or 50 min, cells were lysed 
and counted as total amount of [3H]DA remaining in the cells from each well. To 
determine whether exposure to Tat alters basal DA efflux, CHO cells transfected with 
hDAT were incubated with Tat- conditioned media from Tat-transfected cells collected at 
72 h after transfection at 37°C for 2 h, followed by DA efflux assay.   
2.2.12 DATA ANALYSIS  
Descriptive statistics and graphical analyses were used as appropriate. Results are 
presented as mean ± SEM, and n represents the number of independent experiments for 
each experiment group. IC50 values for DA, cocaine and GBR12909 inhibiting specific 
[3H]DA uptake were determined from inhibition curves by nonlinear regression analysis 
using a one-site model with variable slope. Kinetic parameters (Vmax or Km) of [3H]DA 
uptake were determined from saturation curves by nonlinear regression analysis using a 
one-site model with variable slope. For experiments involving comparisons between 
unpaired samples, unpaired Student’s t test was used to assess any difference in the 
kinetic parameters (IC50, Vmax or Km) between WT and mutant; log-transformed values of 
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IC50 or Km were used for the statistical comparisons. Significant differences between 
samples were analyzed with separate ANOVAs followed by post-hoc tests, as indicated 
in the results Section of each experiment. All statistical analyses were performed using 
IBM SPSS Statistics version 20, and differences were considered significant at p, < 0.05. 
2.3 RESULTS 
2.3.1 TAT PROTEIN DIRECTLY BINDS TO hDAT 
Exposure of rat striatal synaptosomes to Tat protein inhibits DA uptake (Zhu et 
al., 2009). To determine whether Tat protein directly binds to DAT, we performed Co-IP 
of hDAT and Tat assays. As depicted in Fig. 2.1A, recombinant Tat1-86 bound to Tat 
antibody was able to immunoprecipitate hDAT in rat striatal synaptosomes but not in 
spleen and cerebellum where the density of DAT was low.  To confirm this finding, we 
also used GST-Tat fusion protein (as bait) to pull down hDAT to show their interaction. 
Figure 2.1B shows that GST-Tat1-86 bound to hDAT protein. These data strongly suggest 
that the influence of Tat on DAT function involves a protein-protein interaction between 
Tat and DAT, which provides an experimental base for us to perform the following 
computational modeling analysis of the bindings between Tat and hDAT. 
2.3.2 BINDING STRUCTURE OF hDAT WITH HIV-1 TAT   
The energy-minimized binding structure of hDAT with Tat following the MD 
trajectory was shown in Fig. 2.1C and 1D.  Tat protein is located on the gate of the 
vestibule of hDAT(DA). A loop (formed from residues #19 to #22) of Tat is plunged into 
the vestibule of hDAT(DA), blocking the central pore of the substrate-entry tunnel of 
hDAT(DA). Tat and DAT molecules bind with each other through both electrostatic 
interactions and shape complementarity. Particularly, the side chain of Cys22 (C22) of 
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Tat is located inside the vestibule of hDAT(DA), contacting closely with the side chain of 
Tyr470 residue of hDAT and Lys19 (K19) side chain of Tat. The positively charged head 
group of Lys19 side chain of Tat is hydrogen-bonded with the hydroxyl oxygen on 
Tyr470 side chain of hDAT(DA). The positively charged side chain of Lys19 also 
interacts with the aromatic side chain of Tyr470 through the cation-π interaction; the 
modeled distance between the N atom of Lys19 side chain and the center of the aromatic 
ring of Tyr470 side chain of hDAT(DA) is 4.55 Å.  Based on the modeled hDAT-Tat 
complex structure, we predicted that residue Tyr470 is critical for the hDAT binding for 
Tat. 
2.3.3 EXTRACELLULARLY RELEASED TAT IS MORE POTENT THAN RECOMBINANT TAT IN 
INHIBITING hDAT FUNCTION 
Most previous studies of Tat-induced inhibition of DAT function have been 
performed using recombinant Tat. To mimic the nature of Tat released from HIV-1 
infected cells, we have established a technique to ensure that clade B type Tat can be 
released from Tat-expressing cells and the effects of released Tat on DA uptake were 
examined. CHO cells were transfected with different amount of plasmid Tat1-72, GFP-
tagged Tat1-86, and Tat1-101 DNA, and subsequently the conditioned media from these 
transfected cells were collected as a source of released Tat. The estimated amount (~1 
ng/ml) of released Tat in culture media was measured by the density of immunoreactive 
bands and quantitated by comparison to a known amount of recombinant Tat1-86.  
 To determine the effects of released Tat on DA uptake, we first performed the 
concentration and time-dependent studies for released Tat. Different amounts of released 
Tat from conditioned media collected at 24, 48 and 72 h were tested in [3H]DA uptake in 
CHO expressing hDAT. A maximal effect of released Tat on DA uptake was observed 
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when 100 µl conditioned media collected at 72 h were used (data not shown). As shown 
in Fig. 2.2A, released Tat from cells transfected with Tat1-72, Tat1-86 or Tat1-101 produced a 
similar magnitude of change from control in [3H]DA uptake (F(3, 12) = 29.6; p < 0.01, one-
way ANOVA with Dunnett’s Multiple comparison test), suggesting that Tat1-72, Tat1-86 
and full length Tat1-101 exhibit an equal ability in Tat-induced inhibitory effect on DA 
transport. We next determined whether the inhibitory effect on DA uptake was specific 
for released Tat by immunodepletion assay (Fig. 2.2B). Exposure to released Tat (1 
ng/ml) produced a significant reduction (31 ± 2.7%) of specific [3H]DA uptake compared 
to the control (media collected from cells transfected with vector alone). The released 
Tat-induced decrease in DA uptake was diminished by immunodepletion with anti-Tat 
antibody but not with an isotype control antibody (F(3, 12) = 13.4; p<0.001, one-way 
ANOVA with Tukey’s multiple comparison test).  These data also confirmed that the 
inhibitory effect of incubation with conditioned media on DA uptake was specific for 
released Tat.  
2.3.4 MUTATION OF TYR470 ALTERS DA UPTAKE KINETICS AND POTENCY OF SUBSTRATE AND 
INHIBITORS  
To validate the feasibility of the computational model of the DAT(DA)-Tat 
complex, we determined whether a specific residue (Tyr470, which was predicted by the 
computational modeling as one of favorable inter-molecular interactions between Tat and 
hDAT) in hDAT is important for intermolecular interaction between Tat and DAT. A 
mutation in hDAT (tyrosine to histidine, Y470H-hDAT) was generated by site-directed 
mutagenesis. We first determined the pharmacological profiles of [3H]DA uptake in CHO 
cells transfected with equal amount of plasmid DNA for WT hDAT and mutated hDAT.  
As shown in Fig. 2.3A, the Y470H-hDAT displayed a decrease in the Vmax values (2.8 ± 
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0.8 pmol/min/105 cells) compared with WT hDAT [15.7 ± 0.9 pmol/min/105 cells; t(3) = 
15.6, p<0.001, unpaired Student’s t test]; no difference in the Km values was observed.   
We have reported that Tat protein influences selective binding sites on the DAT, 
with differential impact on binding to GBR12935, WIN35,428 and cocaine (Zhu et al., 
2009; Zhu et al., 2011). To explore the potential relationship between the binding sites of 
Tat in DAT and the binding sites of DAT substrate and inhibitors, we also tested the 
ability of DA, cocaine and GBR12909 to inhibit [3H]DA uptake in WT hDAT and 
Y470H-hDAT (Table 1). The apparent affinity (IC50) for DA was not significantly 
different between the WT hDAT (895 ± 80 nM) and Y470H-hDAT (737 ± 72 nM). 
However, the potencies of cocaine and GBR12909 for inhibition of [3H]DA uptake were 
~3.5-fold greater in Y470H-hDAT as compared with WT hDAT (unpaired Student’s t 
test).   
To assess whether the decreased Vmax in this mutant was caused by decreased 
surface DAT expression, we determined DAT surface expression in CHO cells 
transfected with WT or Y470H-hDAT using cell surface biotinylation. As shown in Fig. 
2.3B, despite no difference in the ratio of surface DAT to total DAT between WT and 
Y470-hDAT (biotinylated/total: WT, 0.70 ± 0.06; and Y479H, 0.68 ± 0.1; p >0.05, one-
way ANOVA), the absolute surface DAT in the mutant hDAT was indeed decreased 
compared to WT hDAT (unpaired Student’s t test). Thus, the reduction of available DAT 
on the cell surface could contribute to the decreased DA uptake actually measured in 





2.3.5 MUTATION OF TYR470 ATTENUATES TAT-INDUCED INHIBITORY EFFECTS ON DA 
TRANSPORT 
To determine whether the mutation of Tyr470 alters inhibitory effects of Tat on 
DA uptake, we examined the specific [3H]DA uptake in WT hDAT and Y470H-hDAT in 
the presence or absence of released Tat1-72 (1 ng/ml) or recombinant Tat1-86 (350 nM). As 
shown in Figure 2.4A, two-way ANOVA on the specific [3H]DA uptake in WT and 
Y470H-hDAT revealed a significant main effect of mutation (F(1, 24) = 6.5; p < 0.05), Tat 
treatment (F(1, 24) = 7.5; p < 0.05) and a significant mutation × Tat interaction (F(1, 24) = 
8.9; p < 0.05). A subsequent simple effect analysis revealed a dramatic decrease (80%) in 
[3H]DA uptake in Y470H-hDAT (F(1, 12) = 25; p < 0.001) compared to WT hDAT in the 
absence of Tat. Exposure to Tat decreased [3H]DA uptake by 50% in hDAT (F(1, 12) = 
16.1; p < 0.01; Fig. 2.4A); however, no effect of Tat was observed in Y470H-hDAT (F(1, 
12) = 0.05; p > 0.05), suggesting that mutation of Tyr470 in hDAT attenuates Tat-induced 
reduction of hDAT function.  
With regard to the effect of recombinant Tat1-86 on DA uptake (Fig. 2.4B), a 
separate two-way ANOVA analysis revealed a significant main effect of mutation (F(1, 24) 
= 7.4; p < 0.05) and Tat treatment (F(1, 24) = 9.5; p < 0.05) as well as a significant 
mutation × Tat interaction (F(1, 24) = 12.9; p < 0.05). [3H]DA uptake in Y470H-hDAT was 
19% of that in WT hDAT in cells transfected with equal amount of plasmid DNA for WT 
and mutated DAT, which is consistent with the low DAT expression observed in Fig. 
2.3B. Exposure to Tat1-86 decreased [3H]DA uptake by 38% in WT hDAT (F(1, 12) = 12.8; 
p < 0.01); however, no effect of Tat on [3H]DA uptake was observed in Y470H-hDAT. 
Since DA uptake is linear with DAT expression, in order to rule out whether the lack of 
effect of Tat on DA uptake in this mutant hDAT is due to a low DAT expression level in 
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Y470H-hDAT relative to WT hDAT, we corrected Vmax value of Y470H-hDAT to 40% 
of that in WT hDAT using 3x amount of plasmid Y470H DNA in transfection (Fig. 
2.4C), as reported previously (Chen et al., 2004). A two-way ANOVA revealed a 
significant main effect of mutation (F(1, 24) = 6.4; p < 0.05) and Tat treatment (F(1, 24) = 
5.5; p < 0.05) as well as a significant mutation × Tat interaction (F(1, 24) = 11.2; p < 0.05). 
Similarly, exposure to recombinant Tat1-86 decreased Vmax by 35% and 6% in WT hDAT 
and Y470H-hDAT, respectively. Thus, this result supports the inference that Tyr470 in 
hDAT is critical for HIV-1 Tat-induced inhibition of dopamine transport.   
2.3.6 MUTATION OF TYR470 AFFECTS ZINC REGULATION OF DAT CONFORMATIONAL 
TRANSITIONS AND BASAL DA EFFLUX 
We hypothesize that Tat, via allosteric modulation sites, alters conformational 
states of DAT, thereby decreasing DA transport. To test this possibility, we determined 
whether mutation of Tyr470 affects zinc regulation of DAT conformational transitions 
and basal DA efflux. In general, the conformational changes in DA transport process 
involve conversions between outward- and inward-facing conformations (Zhao et al., 
2010). Occupancy of the endogenous Zn2+ binding site in WT hDAT (His193, His375, 
and Glu396) stabilizes the transporter in an outward-facing conformation, which allows 
DA to bind but inhibits its translocation, thereby increasing [3H]WIN 35,428 binding 
(Norregaard et al., 1998; Moritz et al., 2013), but decreasing DA uptake (Loland et al., 
2003). Addition of Zn2+ is able to partially reverse an inward-facing state to an outward-
facing state (Norregaard et al., 1998; Loland et al., 2003). On the basis of this principle, 
the addition of Zn2+ to WT hDAT would inhibit DA uptake, whereas in a functional 
mutation in DAT Zn2+ might diminish the preference for the inward-facing conformation 
and thus enhance DA uptake. To explore this possibility, we examined the effects of 
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Tyr470 mutation on Zn2+ modulation of [3H]DA uptake and [3H]WIN35,428 binding that 
are thought to reflect stabilization of outwardly facing transporter forms (Richfield, 1993; 
Norregaard et al., 1998).  For these experiments, CHO cells expressing WT and Y470H-
hDAT were treated with 10 µM ZnCI2 and assayed for both [3H]DA uptake and [3H]WIN 
35,428 (Fig. 2.5A and 5B). As shown in Fig. 2.5A, two-way ANOVA on the specific 
[3H]DA uptake in WT and Y470H-hDAT revealed a significant main effect of mutation 
(F(1, 24) = 11.5; p < 0.05), zinc (F(1, 24) = 9.1; p < 0.05) and a significant mutation × zinc 
interaction (F(1, 24) = 9.9; p < 0.05). The addition of Zn2+ decreased [3H]DA uptake in WT 
and Y470H-hDAT by 89% versus 32%, respectively (Fig. 2.5A, p< 0.001 relative to 
control, unpaired Student’s t test). A two-way ANOVA on the specific [3H]WIN35,428 
binding in WT and Y470H-hDAT revealed a significant main effect of mutation (F(1, 24) = 
6.5; p < 0.05), zinc (F(1, 24) = 4.3; p < 0.05) and a significant mutation × zinc interaction 
(F(1, 24) = 4.2; p < 0.05).  Zn2+ caused a 40% increase in [3H]WIN 35,428 binding in WT 
but had no effect on Y470H-hDAT (Fig. 2.5B, p< 0.001 relative to control, unpaired 
Student’s t test). The data suggest that Tyr 470 mutation disrupts an intermolecular 
interaction key for maintenance of the outward‐facing conformation. 
To further determine the role of Y470H-hDAT in the transition between outward-
facing and inward-facing states, we also examined basal DA efflux in WT hDAT and this 
mutant. As shown in Fig. 2.5C, after preloading with 0.05 µM [3H]DA for 20 min at 
room temperature, cells were washed and fractional DA efflux samples were collected at 
the indicated times.  A two-way ANOVA revealed significant main effects of mutation 
(F(1, 14) = 170; p<0.001) and time (F(4, 56) = 145; p<0.001). A significant mutation × time 
interaction (F(4, 56) = 78; p<0.001) was also found. Post-hoc analysis revealed robust 
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increases in DA efflux at 1, 10, 20, and 30 min compared to WT hDAT (p < 0.05, 
Bonferroni t-test). To determine whether exposure to Tat represents similar results, basal 
DA efflux in WT hDAT was determined in the presence or absence of released Tat1-72 
(Fig. 2.5D). The fractional basal DA efflux data in WT hDAT were expressed as a 
percentage change in the respective controls of total DA content in cells with or without 
Tat. Analysis of two-way ANOVA revealed that a significant main effect of treatment 
(F(1, 10) = 18.7; p < 0.01) and time (F(5, 50) = 291.9; p<0.001) as well as a significant 
treatment × time interaction (F(5, 50) = 9.9; p<0.001). Although a lower magnitude of DA 
efflux in response to Tat treatment was found in WT hDAT in comparison to DA efflux 
in Y470H-hDAT (Fig. 2.5D), post-hoc analysis revealed that exposure to released Tat1-72 
significantly increased basal DA efflux at 1, 10, 20 and 30 min compared to control (p < 
0.05, Bonferroni t-test). These data further support the possibility that Tyr 470 mutation 
causes a regional conformational change that affects hDAT associated with Tat.  
2.4 DISCUSSION 
In the current study, we used an integrated approach including computational 
modeling and simulations, protein mutagenesis and molecular pharmacological function 
assays to explore a key residue in the intermolecular interactions between HIV-1 Tat and 
hDAT. Our data provide additional evidence showing a direct interaction between Tat 
and hDAT as suggested in our previous report (Zhu et al., 2009). Through modeling and 
simulations, the site for Tat interaction with DAT has predicted that residue Tyr470 in 
hDAT is crucial for HIV-1 Tat-induced inhibition of DA transport. Tyr470 mutation did 
not alter the affinity for DA uptake but increased DA uptake potency for cocaine and 
GBR12909, suggesting that Tyr470 does not overlap with the substrate binding site but 
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disrupts the binding sites on DAT for these inhibitors. Importantly, mutation of Tyr470 
alters Zn2+ modulation of DAT and basal DA efflux, compared to WT hDAT, implying a 
mechanistic context for the transporter conformational transitions by this mutant. 
Collectively, our results provide a relatively comprehensive molecular insight into this 
important residue for DA translocation and the underlying allosteric mechanism in DAT 
for Tat binding.  
In response to the fundamental question how Tat interacts with hDAT through 
their recognition binding sites to interrupt DAT-mediated DA transmission, our 
computational model has predicted Tyr470 of hDAT and Cys22 as well as Lys19 in Tat 
as one of the favorable inter-molecular interactions between hDAT and Tat protein. Data 
from Co-IP and GST pull-down experiments demonstrate a direct interaction between Tat 
and DAT, which is consistent with the predictions from computational modeling and 
simulations. This study, based on the computational prediction, demonstrated that 
mutation of Tyr470 changes hDAT conformation and attenuates Tat-induced inhibition of 
DA transport.  Despite the importance of Tyr470, our computational modeling does not 
anticipate that a single residue in hDAT is sufficient to control the interaction of Tat with 
hDAT.  Therefore, once all recognition residues in hDAT are identified, an essential task 
in our future study will be to determine the influence of combined recognition residues on 
Tat-DAT interaction. The computational prediction of the binding mode was based on a 
series of computational modeling studies including homology modeling, Brownian 
dynamics simulations (Gabdoulline and Wade, 1998), and molecular dynamics 
simulations. Considering the fact that the Tat molecule has a large positive electrostatic 
potential, and hDAT(DA) bears negative charge, the long-range electrostatic attraction 
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can be viewed as the driving force for the association of Tat with hDAT. The binding 
mode of hDAT with Tat demonstrates that the Tat molecule is associated with DAT 
through inter-molecular electrostatic attractions and complementary hydrophobic 
interactions. In support of our proposed model, the current study and our previous report 
(Zhu et al., 2009) demonstrate that mutation of either Tyr470 in hDAT or Cys22 in Tat 
leads to attenuation of WT Tat-induced inhibitory effects on DA transport, implicating a 
structural and functional relationship between Tat and hDAT. Since Lys19 is also 
predicted as a critical residue for Tat interacting with the Tyr470 residue in DAT, we will 
also determine whether mutation of Lys19 produces a similar effect as mutation of Cys22 
in Tat on DAT function in our future investigation. These data also qualitatively support 
that our computationally simulated model of the hDAT(DA)-Tat complex is reliable to be 
used to predict the intermolecular interactions between Tat and DAT.  
Although both recombinant Tat and Tat released from cells expressing Tat 
produced a strong inhibitory effect on DA transport, released Tat was ~4000-fold more 
potent than recombinant Tat. This finding is consistent with a previous report showing 
this form of Tat was more neurotoxic than recombinant Tat protein (Li et al., 2008). We 
also found that Tat1-72, Tat1-86 and full length Tat1-101 exhibited an equivalent inhibitory 
effect on DAT function, which is consistent with the previous studies showing that equal 
ability of Tat protein in Tat-induced neurotoxicity (Li et al., 2008; Aksenov et al., 2009). 
The concentration of released Tat (1 ng/ml) used in this study is similar to native HIV-1 
Tat actually detected in the serum of patients with HIV infection (Westendorp et al., 
1995) and in the conditioned medium of HIV-infected cells (Albini et al., 1998). Thus, 
our data support that physiologically secreted Tat is more neurotoxic to neuronal targets, 
44 
 
such as DAT. The advantage of this approach is feasible for further determination of the 
recognition sites of Tat (WT versus mutated) that functionally interact with hDAT. 
The present results show that mutation of Tyr470 decreased the Vmax with no 
changes in Km value and IC50 value for DA inhibiting DA uptake compared to WT 
hDAT, demonstrating that the Tyr470 residue does not affect substrate transport 
characteristics. These data are consistent with the aforementioned computational 
prediction based on the modeled hDAT(DA)-Tat complex structure: Tat binding site in 
hDAT(DA) complex does not overlap with the binding site of substrate DA (Fig. 2.2). In 
contrast, the DA uptake potency of cocaine and GBR12909 was increased in Y470H-
hDAT compared to WT hDAT. While GBR12909 labels the classic DA uptake site in 
rodent brain, binding to the piperazine acceptor site (Andersen et al., 1987) was affected 
much less by mutation of hDAT than cocaine (Loland et al., 2002; Guptaroy et al., 2011), 
consistent with the fact that cocaine preferentially stabilizes the hDAT in the outward-
facing conformational state, resulting in a reduction of DA uptake (Reith et al., 2001; 
Loland et al., 2002). One interpretation of our finding is that Tat allosterically modulates 
DA transport rather than overlaps DA uptake sites on DAT as previously suggested (Zhu 
et al., 2011). However, the Tat binding site in hDAT may be close to the binding sites in 
hDAT for cocaine and GBR12909, increasing their DA uptake potency. Thus, the results 
may suggest synergistic influences of Tat and cocaine on DAT function: Tat, via 
allosteric modulation of the DAT, enhances the inhibitory effects of cocaine on DA 
transport. These findings also provide evidence to support our previous reports that Tat 
and cocaine synergistically inhibit DAT function in vivo and in vitro (Harrod et al., 2008; 
Ferris et al., 2010).  
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Our previous work provides evidence that Tat allosterically modulates DAT 
function (Zhu et al., 2009; Zhu et al., 2011). The allosteric modulation of DAT is 
responsible for conformational transitions via substrate- and ligand-binding sites on DAT 
(Zhao et al., 2010; Shan et al., 2011). In the present study, we found that mutation of 
Tyr470 diminished Zn2+-induced inhibition of [3H]DA uptake and attenuated increased 
[3H]WIN 35,428 binding compared to WT hDAT.  The endogenous Zn2+ binding sites in 
hDAT have been widely employed to investigate whether mutations of hDAT alter 
transporter conformational transitions in DA transport (Norregaard et al., 1998).  The 
Zn2+-mediated inhibition of DA transport and stimulation of WIN35,428 binding to DAT 
occur by stabilization of outwardly facing transporter conformations (Richfield, 1993; 
Norregaard et al., 1998; Moritz et al., 2013). Although analysis of Zn2+ regulation of 
DAT function only reflects one mechanistic aspect of DAT mutant-induced 
conformational change, our data provide strong evidence for the context of an allosteric 
mechanism responsible for conformational transitions in DAT. To explore the possible 
mechanism, we also examined the effects of mutant hDAT on basal DA efflux and 
observed extremely low accumulation of DA over time in Y470H-hDAT relative to WT 
hDAT. One possible explanation for the low accumulation of DA is that basal DA efflux 
can be elevated in this mutant, resulting in reduced accumulation of intracellular DA. 
One caveat is that DA efflux data may reflect not only DA moving out of the cell through 
the transporter, but also non-specific diffusion and reuptake. However, there is evidence 
(Guptaroy et al., 2009; Guptaroy et al., 2011) that this measurement largely reflects basal 
DA efflux through DAT because such basal DA efflux is consistent with amphetamine- 
or voltage-stimulated efflux of intracellular DA in cells expressing hDAT and its mutant. 
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Amphetamine, a substrate for DAT, competitively inhibits DA reuptake and elicits 
outward transport of DA by reversal of the transporter (Sulzer et al., 2005). Thus, it is 
possible that Y470H mutation shifts the conformation of DAT from physiologically 
favored substrate influx mode to an efflux one; a conformational switch promoted by Tat 
protein, and disturbs transition between inward- and outward-facing conformations. 
Taken together, these findings infer a potential mechanism that mutation of Tyr470 alters 
the transporter conformational transitions, which is consistent with our previous findings 
that Tat mediates allosteric modulation of DAT (Zhu et al., 2011). Additionally, the 
enhanced DA efflux was also observed in WT hDAT in the presence of Tat. Interestingly, 
the magnitude of DA efflux in WT hDAT was lower in response to Tat compared to that 
in Y470H-hDAT. One possible explanation for the discrepancy is that in addition to 
residue Y470, other recognition residues of the DAT may be involved in the effects of 
Tat on DA efflux. Therefore, to fully understand the mechanisms by which Tat inhibits 
DAT function, future studies based on the combined experimental and computational 
approaches will be necessary to further analyze the changes in the conformational 
transition attributed to the identified residues in DAT (i.e. an outward-facing form and an 
inward-facing form).   
In conclusion, we have begun to identify the specific intermolecular interactions 
between Tat and DAT and the molecular mechanism(s) that underlies how Tat, via the 
recognition binding sites in DAT, interrupts DA transport. Particularly, our results 
provide relatively a broad molecular validation of this important residue of DA 
translocation and the underlying allosteric mechanism in DAT for Tat.  We propose that 
multiple recognition residues in the DAT are involved in the dynamic and complex 
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interactions between Tat and DAT. Results obtained from Tyr470 only reflect the role of 
this residue in DAT-Tat interaction. The current findings have shed light on further 
mapping and validating the predicted sites for Tat interaction with DAT towards an 
ultimate goal to develop compounds that specifically block Tat binding site(s) in DAT 
without affecting physiological DA transport. Ideally, these compounds would be 




Table 2.1 Summary of inhibitory activities in [3H]DA uptake in WT and mutated hDAT 














737 ± 72 100 ± 30* 50 ± 10* 
 
Data are calculated as a percentage of DA uptake in the absence of substrate or inhibitor 
and analyzed by nonlinear regression. Data are presented as mean ± S.E.M. of IC50 values 
from three to four independent experiments performed in duplicate. * p < 0.05 compared 










Figure 2.1 A direct interaction between Tat and DAT and the energy-minimized 
hDAT(DA) binding complex following the MD simulation. Co-IP of DAT and Tat was 
performed by immunoprecipitation (IP) with anti-DAT antibody as bait and immunoblot 
(IB) with anti-Tat antibody. (A) Co-IP of DAT and Tat. Rat synaptosomes from spleen, 
cerebellum, striatum were preincubated with (+, lanes 1, 2 and 4, from left) or without (-, 
lane 3) 350 nM recombinant Tat1-86 (rTat1-86). Top panel: DAT immunoreactivity was 
detected in striatum but not in spleen and cerebellum. Bottom panel: rTat1-86 bound to 
agarose beads was able to immunoprecipitate DAT in rat striatum but not in spleen and 
cerebellum. rTat1-86 (10 ng) was loaded in lane 5 as the positive control for Tat 
immunoreactivity. (B) GST-Tat1-86 bound to WT hDAT protein. Top panel: The GST-
Tat1-86 fusion proteins were bound to glutathione-sepharose beads, and then incubated 
with cell lysates from CHO cells transfected with WT hDAT at room temperature for 1h 
following Western Blot using anti-DAT. GST-Tat fusion protein bound to glutathione-
sepharose was able to pull down DAT, but GST alone was not. Bottom panel: DAT 
immunoreactivity in CHO cells expressing hDAT was shown in all lanes. (C) Side view 
of the complex structure. Tat is shown as ribbon in cyan color and hDAT(DA) as ribbon 
in gold color. Atoms of residue C22 (Cys22) of Tat are shown as overlapped balls in cyan 
color. Atoms of substrate dopamine (DA) and the Cl- ion are shown as overlapped balls 
in green color. 2 Na+ ions are shown as balls in blue color. The vestibule (colored in 
purple) is represented as molecular surface calculated by using program HOLLOW (Ho 
and Gruswitz, 2008). (D)  Local view of the anchoring residues Lys 19 (K19) and Cys22 
(C22) of Tat inside the vestibule of hDAT(DA). Residues K19 and C22 of Tat are shown 
in ball-and-stick style, and colored by the atom types. Residue Tyr470 (Y470) of 
hDAT(DA) is also shown in ball-and-stick style and colored by the atom types. The 
hydrogen bonding between the K19 side chain of Tat and the hydroxyl oxygen atom on 
Y470 side chain of hDAT(DA) is indicated with the dashed line. The non-polar hydrogen 
atoms are not shown for clarity. The positions of trans membrane domain11 and 12 











































































































Figure 2.2 Inhibition of DA uptake by released Tat from Tat-expressing cells. (A) CHO 
cells transfected with WT hDAT were preincubated in KRH buffer including 100 µl 
conditioned media collected at 72 h from cells transfected with plasmid Tat1-72, Tat1-86, 
Tat1-101 DNAs and vector alone (Control) followed by addition of [3H]DA uptake. *p < 
0.05 different from control (Dunnett’s Multiple comparison test). (B) Specificity of 
released Tat in inhibition of [3H]DA uptake. Conditioned media collected at 72 h from 
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cells transfected with Tat1-72 were preincubated with anti-Tat antibody or isotype control 
IgG at 4°C for 3h, followed by incubation with protein A/G – Agarose beads 4°C for 2h. 
Media collected at same time from cells transfected with vector alone was used as 
control. Cells transfected with WT hDAT were preincubated in KRH buffer containing 
supernatants from the agarose-antibody-medium-beads complex, followed by [3H]DA 
uptake. Released Tat1-72 caused significant decrease in [3H]DA uptake, which was 
attenuated by immunodepletion with anti-Tat antibody but not isotype control antibody 
(one-way ANOVA followed by Tukey’s multiple comparison test). * p < 0.05 different 
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Figure 2.3 [3H]DA uptake and DAT surface expression in WT hDAT and mutant. (A) 
Kinetic analysis of [3H]DA uptake in WT hDAT and Y470H-hDAT. CHO cells 
transfected with WT hDAT or Y470H-hDAT were incubated with one of six mixed 
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concentrations of the [3H]DA as total rate of DA uptake. In parallel, nonspecific uptake 
of each concentration of [3H]DA (in the presence of 10 µM nomifensine, final 
concentration) was subtracted from total uptake to calculate DAT-mediated uptake. * p < 
0.05 compared to control value (unpaired Student’s t test) (n = 5). (B) Cell surface of WT 
hDAT (WT) or Y470H-hDAT (Y470H) was analyzed by biotinylation. Top panel: 
representative immunoblots in CHO cells expressing WT hDAT or Y470H-hDAT. 
Bottom panel: DAT immunoreactivity is expressed as mean ± S.E.M. densitometry units 
from three independent experiments (n = 3). * p < 0.05 compared to WT hDAT (unpaired 






















































































































Figure 2.4 Effects of Tat on kinetic analysis of [3H]DA uptake in WT hDAT and mutant. 
(A) CHO cells transfected with WT or Y470H-hDAT were preincubated with or without 
released Tat1-72 (1.0 ng/ml) at room temperature for 20 min followed by the addition of 
one of six mixed concentration of the [3H]DA.  In parallel, nonspecific uptake at each 
concentration of [3H]DA (in the presence of 10 µM nomifensine, final concentration) was 
subtracted from total uptake to calculate DAT-mediated uptake. (B) [3H]DA uptake in 
cells transfected with WT or Y470H-hDAT was determined in the presence or absence of 
recombinant Tat1-86 (rTat1-86, 350 nM, final concentration). (C) [3H]DA uptake in cells 
transfected with WT (0.8 µg plasmid cDNA) or Y470H-hDAT (2.4 µg plasmid cDNA) 
was determined in the presence or absence of rTat1-86 (350 nM). Data are expressed as 
means from three independent experiments ± S.E.M. * p < 0.05 compared with the 
respective control values. # p < 0.05 compared to WT hDAT. (n = 5) 
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Figure 2.5 Mutation of Tyr470 alters transporter conformational transitions.  Tyr470 
mutation of DAT affects zinc regulation of DA uptake (A) and [3H]WIN 35,428 binding 
(B). CHO cells transfected with WT or Y470H-hDAT were incubated with assay buffer 
alone (control) or ZnCl2 (10 µM, final concentration) followed by [3H]DA uptake or 
[3H]WIN 35,428 binding (n = 4). The histogram shows [3H]DA uptake and [3H]WIN 
35,428 binding expressed as mean ± S.E.M. of the respective controls set to 100% for the 








































































(C) Functional DA efflux properties of WT hDAT and mutant. CHO cells transfected 
WT or Y470H-hDAT were preincubated with [3H]DA (0.05 µM, final concentration) at 
room temperature for 20 min. After incubation, cells were washed and incubated with 
fresh buffer as indicated time points. Subsequently, the buffer was separated from cells, 
and radioactivity in the buffer and remaining in the cells was counted. Each fractional 
[3H]DA efflux in WT hDAT and Y470H-hDAT was expressed as percentage of total [3H] 
in the cells at the start of the experiment. Fractional [3H]DA efflux at 1, 10, 20, 30 and 40 
min are expressed as the percentage of total [3H]DA with preloading with 0.05 µM (WT 
hDAT: 15379 ± 1800 dpm and Y470H-hDAT: 2488 ± 150 dpm) present in the cells at 
the start of the experiment (n = 4).  × p < 0.05 and ×× p < 0.01, compared to WT hDAT 
(Bonferroni t-test). (D) Functional DA efflux properties of WT hDAT in the presence or 
absence of Tat1-72. CHO cells transfected with WT hDAT were preincubated with 
released Tat1-72 (1 ng/mg) followed by DA efflux assay. Fractional [3H]DA efflux at 1, 
10, 20, 30, 40 and 50 min are expressed as the percentage of total [3H]DA with 
preloading with 0.05 µM (control: 14200 ± 1448 dpm and released Tat: 10102 ± 1505 
dpm) present in the cells at the start of the experiment (n = 6). ^ p < 0.05 and ^^ p < 0.01, 











POINT MUTATIONS AT TYR 88, LYSINE 92 AND TYR 470 OF THE HUMAN 
DOPAMINE TRANSPORTER ATTENUATE TAT-INDUCED INHIBITION OF DOPAMINE 
TRANSPORTER FUNCTION 
 
ABSTRACT: HIV-1 transactivator of transcription (Tat) protein disrupts the dopamine (DA) 
neurotransmission by inhibiting DA transporter (DAT) function, leading to increased 
neurocognitive impairment in HIV-1 infected individuals. Through computational modeling 
and simulations, three functional residues in human DAT (hDAT) were predicted as 
potential recognition binding sites for Tat.  We previously showed that mutation of 
tyrosine470 (Y470H) of hDAT attenuates Tat-induced inhibition of DA uptake by changing 
the transporter conformational transitions. In the present study we examined the functional 
influences of other substitutions at tyrosine470 (Y470F and Y470A) and tyrosine88 (Y88F) 
and lysine92 (K92M), two other predicted residues for Tat binding to hDAT, in Tat-induced 
inhibitory effects on DA transport. Compared to wild type (WT) hDAT, K92M but not Y88F 
reduced Vmax without changes in Km.  Both Y88F and K92M did not alter IC50 values for DA 
inhibition of [3H]DA uptake but increased [3H]DA uptake or [3H]WIN35,428 binding 
potencies for cocaine and GBR12909, indicating that these residues do not overlap with the 
binding sites in hDAT for DA transport but are critical for these inhibitors. Besides, Y88F, 
K92M and Y470A attenuated Tat-induced inhibition of DA transport that is observed in WT 
hDAT. Y470F, Y470A, Y88F and K92M mutants reversed the zinc-induced increase of 
[3H]WIN35,428 binding but not the [3H]DA uptake. Moreover, Y470A and K92M mutants
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displayed enhanced DA basal efflux compared to WT hDAT. Taken together, these results 
demonstrate that Tyr88 and Lys92 along with Tyr470 as functional recognition residues in 
hDAT for Tat interaction-induced inhibition of DA transport and provide mechanistic 
insights into identifying target residues on the DAT for Tat binding.  
3.1 INTRODUCTION  
HIV-associated neurocognitive disorder (HAND) that encompasses neurological and 
psychiatric complications has been on the considerably rise in people living with HIV-1 and 
AIDS even in the era of highly active antiretroviral therapy (HAART)(Heaton et al., 2010; 
Simioni et al., 2010; Mothobi and Brew, 2012). The growing body of evidence indicates that 
the HAND progression and severity is exacerbated by comorbid factors like widely abused 
drugs, particularly cocaine (Buch et al., 2011; Nair and Samikkannu, 2012). Lower 
adherence to medication regimen by HIV-1 positive people is also strongly associated with 
the active cocaine use (Arnsten et al., 2002; Norman et al., 2009). HAND is highly correlated 
with neurotoxic effects of HIV-1 viral proteins that are exuded from infected microglial cells 
(Bansal et al., 2000; Kaul et al., 2001; Mattson et al., 2005; Kaul and Lipton, 2006). Tat, a 
non-structural viral protein required for productive infection of virus, is one of the major 
neurotoxins responsible for neurotoxicity and oxidative stress in the central nervous system 
(Pocernich et al., 2005; Wallace et al., 2006). Studies have demonstrated that Tat protein and 
cocaine interaction have deleterious effects in HIV-1 positive brains by altering viral 
replication, neuropathogenesis and behavioral effects (Gandhi et al., 2010; Paris et al., 2013).    
Dysregulation of dopamine (DA) neurotransmission in HIV-1 infected patients is 
greatly associated to HAND pathophysiology and has been reviewed extensively elsewhere 
(Koutsilieri et al., 2002; Ferris et al., 2008; Purohit et al., 2011). HIV-infection has been 
61 
 
shown to deplete intracellular DA levels in postmortem brains (Scheller et al., 2005; Kumar 
et al., 2009). Recently, enhanced DA levels were reported in cerebrospinal fluid of HIV-1 
positive individuals with no treatment compared to normal subjects (Scheller et al., 2010). 
An explanation for this elevated level of DA is possibly due to impairment of DA transporter 
(DAT) function (Purohit et al., 2011). DAT is a presynaptic membrane protein that rapidly 
clears extracellular DA via rapid reuptake and is a primary determinant for the regulation of 
DA homeostasis in the brain (Vaughan and Foster, 2013). Clinical results using positron 
emission tomography imaging have demonstrated that HIV-associated dementia patients 
show a dramatic loss of DAT protein in the putamen and ventral striatum regions (Wang et 
al., 2004; Chang et al., 2008). Likewise, previous animal and in vitro studies including 
published data from our own laboratory indicated that the Tat manipulates the function of 
DAT (Ferris et al., 2009b; Ferris et al., 2009a; Zhu et al., 2009; Perry et al., 2010). 
Furthermore, we showed that Tat down regulates DAT function through allosteric 
mechanism (Zhu et al., 2011); also it decreases DAT cell surface expression in rat striatal 
synaptosomes (Midde et al., 2012). Therefore, it is expected that DAT would be a promising 
clinical target for therapeutic interventions to curb the damage of DA system instigated by 
the Tat protein.  
It has been proposed that different ligands exert their actions on DAT by inducing 
specific conformational changes in the transporter that can influence DA uptake and efflux 
(Schmitt et al., 2013). DAT substrates and inhibitors initially recognize specific amino acids 
and are likely followed by a series of molecular changes to modulate DAT function (Tanda 
et al., 2009; Shan et al., 2011).  Previous studies suggest that allosteric modulators of DAT 
differentially regulate transporter uptake and efflux properties (Pariser et al., 2008; Rothman 
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et al., 2009). Along these lines, our published report showed that Tat decreases DAT activity 
via binding to allosteric sites and also alters cocaine binding sites (Zhu et al., 2011), 
indicating different mode of Tat interaction that does not directly  interfere with substrate 
translocation.  Likewise, computational and experimental studies have focused to identify the 
binding mode and pocket of dopamine as well as cocaine (Li et al., 2002; Beuming et al., 
2008; Huang et al., 2009; Shan et al., 2011). Having emerging evidence for additive and/or 
synergistic effects of Tat and cocaine (Gandhi et al., 2010; Paris et al., 2013), it is worth 
noting that molecular relationship between Tat binding site and the binding site of cocaine on 
the transporter remain unclear. Thus, in order to identify the binding pocket for Tat protein in 
DAT, it is necessary to identify the residues forming the crevice and understand the 
contribution of these recognition residues in substrate translocation, cocaine binding and 
conformational rearrangements in the transporter. 
In the process of understanding the combined effects of Tat and cocaine on down 
regulation of DA transport through alteration of DAT function, using biophysical (Zhu et al., 
2009) and biochemical  methods (Midde et al., 2013), we demonstrated that Tat directly 
interacts with DAT. Based on predictions of computational modeling and simulations, as a 
proof of principle study we showed evidence that mutating Y470 of human DAT (hDAT) 
attenuates Tat-mediated inhibition of DA uptake but increases the potency of DAT inhibitor 
cocaine (Midde et al., 2013). It has also been demonstrated that Tyr470His-hDAT (Y470H-
hDAT) mutant differentially modulates zinc-mediated regulation of DA uptake and 
WIN35,428 binding, and basal DA efflux properties, suggesting a role of Tyr470 in 
maintaining structural integrity of the transporter and mutating this amino acid resulted in a 
transporter that favors an inward facing conformation. As a follow up to this published data, 
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in the current study we investigated the role of additional substitutions at Tyr470 and other 
predicted potential Tat binding residues, Tyr88 and Lys92 of hDAT in Tat-induced decrease 
of DA translocation by generating points mutations Tyr470F (Y470F-hDAT), Tyr470A-
hDAT (Y470A-hDAT), Tyr88Phe (Y88F-hDAT), Lys92Met (K92M-hDAT) and assessing 
their variability in function, surface expression, interaction with ligands and underlying 
mechanism for these alterations.  
3.2 MATERIALS AND METHODS  
3.2.1 PREDICTING THE SITE FOR hDAT BINDING WITH TAT  
The binding structure of hDAT with HIV-1 clade B type Tat was modeled and simulated 
based on the nuclear magnetic resonance (NMR) structures of Tat (Peloponese et al., 2000) 
and the constructed structure of hDAT-DA complex.  According to D-Y470 site-directed 
mutation experimental data as reported previously (Midde et al., 2013), Y470 of hDAT is a 
functional recognition residue for Tat-induced inhibition of DAT transport cycle. Therefore, 
Y470 of hDAT is expected to interact with Tat directly. The protein docking program 
ZDOCK (Pierce et al., 2011) was applied for obtaining the initial binding structure of the 
hDAT-Tat complex, with the constraint of contact between D-Y470 and Tat. Total 535 
potential conformations were generated based on 11 NMR structures of Tat, then all of these 
conformations were evaluated and ranked by ZRANK (Pierce and Weng, 2007). Top 107 
conformations (top 20%) were selected for further investigation by MD simulation. Then 
initial binding structure of the hDAT-Tat was identified from these simulations, with the best 
geometric matching quality and rational interaction between D-Y470 and Tat. With further 
relaxing and equilibrating the system, final MD-simulated hDAT-Tat binding structure was 
energy-minimized and analyzed.  
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3.2.2 CONSTRUCTION OF PLASMIDS  
All point mutations of Tyr88, Lys92, and Tyr470 in hDAT were selected based on the 
predictions of the 3D-computational modeling and simulations. Mutations in hDAT at Tyr88 
and Tyr470 (tyrosine to phenylalanine, Y88F-hDAT and Y470F-hDAT) are expected to 
destroy the hydrogen bond only. Since methionine is nearly isosteric with lysine, substitution 
at Lys92 (lysine to methionine, K92M-hDAT) should abolish hydrogen bond with minimal 
perturbations to the native structure of the transporter. Substitution of tyrosine at 470 with 
alanine or tryptophan (Y470A-hDAT and Y470W-hDAT) is expected to eliminate both 
hydrogen bond and cation-π interactions that is similar to Y470H-hDAT, but with different 
spatial effects on structural organization of the transporter. All mutations in hDAT were 
generated based on wild type human DAT (WT hDAT) sequence (NCBI, cDNA clone 
MGC: 164608 IMAGE: 40146999) by site-directed mutagenesis. Synthetic cDNA encoding 
hDAT subcloned into pcDNA3.1+ (provided by Dr. Haley E Melikian, University of 
Massachusetts) was used as a template to generate mutants using QuikChange™ site-
directed mutagenesis Kit (Agilent Tech, Santa Clara CA). The sequence of the mutant 
construct was confirmed by DNA sequencing at University of South Carolina EnGenCore 
facility. Plasmid DNA were propagated and purified using plasmid isolation kit (Qiagen, 
Valencia, CA, USA) 
3.2.3 CELL CULTURE AND DNA TRANSFECTION 
Chinese hamster ovary (CHO, ATCC #CCL-61) cells were maintained in F12 medium 
supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 U/ml penicillin and 
100 µg/mL streptomycin). Pheochromocytoma (PC12, ATCC #CRL-1721) cells were 
maintained in Dulbecco’s modified eagle medium supplemented with 15 % horse serum, 2.5 
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% bovine calf serum, 2 mM glutamine and antibiotics (100 U/ml penicillin and 100 µg/mL 
streptomycin). Both cells were cultured at 37°C in a 5% CO2 incubator. For hDAT 
transfection, cells were seeded into 24 well plates at a density of 1×105 cells/cm2. After 24h, 
cells were transfected with WT or mutant DAT plasmids using Lipofectamine 2000 (Life 
Tech, Carlsbad, CA). Cells were used for the experiments after 24 h of transfection.  
3.2.4 [3H]DA UPTAKE ASSAY 
Twenty four hours after transfection, [3H]DA uptake in PC12 cells transfected with WT 
hDAT and mutants was performed as reported previously (Midde et al., 2013). To determine 
whether mutated hDAT alters the maximal velocity (Vmax) or Michaelis-Menten constant 
(Km) of [3H]DA uptake, kinetic analyses were conducted in WT hDAT and mutants. To 
generate saturation isotherms, [3H]DA uptake was measured in Krebs-Ringer-HEPES (KRH) 
buffer (final concentration in mM: 125 NaCl, 5 KCl, 1.5 MgSO4, 1.25 CaCl2, 1.5 KH2PO4, 
10 D-glucose, 25 HEPES, 0.1 EDTA, 0.1 pargyline, and 0.1 L-ascorbic acid; pH 7.4) 
containing one of six concentrations of unlabeled DA (final DA concentrations, 1.0 nM–5 
µM) and a fixed concentration of [3H]DA (500,000 dpm/well, specific activity, 21.2 
Ci/mmol; PerkinElmer Life and Analytical Sciences, Boston, MA). In parallel, nonspecific 
uptake of each concentration of [3H]DA (in the presence of 10 µM nomifensine, final 
concentration) was subtracted from total uptake to calculate DAT-mediated uptake. The 
reaction was conducted at room temperature for 8 min and terminated by washing twice with 
ice cold uptake buffer. Cells were lysed in 500 μl of 1% SDS for an hour and radioactivity 
was measured using a liquid scintillation counter (model Tri-Carb 2900TR; PerkinElmer 
Life and Analytical Sciences, Waltham, MA). Kinetic parameters (Vmax and Km) were 
determined using Prism 5.0 (GraphPad Software Inc., San Diego, CA). To determine the 
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inhibitory effects of Tat on [3H]DA uptake, cells transfected with WT hDAT or mutants 
were preincubated with Tat1-86 or Tat Cys22 (500 nM, final concentration) for 20 min.  Tat 
Cyc22 was used as a negative control because our previous study shows that Tat Cyc22 has 
no effect on DA uptake (Zhu et al., 2009).  
The competitive inhibition DA uptake experiments were performed in duplicate in a 
final volume of 500 µl. Cells in each well were incubated in 450 µl KRH buffer containing 
50 µl one of final concentrations of unlabeled DA (1 nM-1 mM), GBR12909 (1 nM-10 µM), 
cocaine (1 nM-1 mM), WIN 35,428 (1 nM-1 mM) or ZnCI2 (10 µM) at room temperature for 
10 min and [3H]DA uptake was determined by addition of 50 µl of [3H]DA (0.1 µM, final 
concentration) for an additional 8 min.   
3.2.5 [3H]WIN 35,428 BINDING ASSAY 
Binding assays were conducted to determine whether mutated hDAT alters the 
kinetic parameters (Bmax or Kd) of [3H]WIN 35,428 binding in PC12 cells transfected with 
WT hDAT and mutants. Twenty four hours after transfection, PC12 cells were dissociated 
with trypsin/EDTA (0.25%/0.1%, 1 mL for 100 mm dish) and resuspended in growth 
medium. After 10 min incubation at room temperature, the dissociated cells were harvested 
by centrifugation at 3000 rpm for 5 min and washed once with phosphate-buffered saline 
(PBS). The resulted cell pellets were resuspended in sucrose-phosphate buffer (final 
concentration in mM: 2.1 NaH2PO4, 7.3 Na2HPO47H2O, and 320 sucrose, pH 7.4) for 
binding assay.   
To generate saturation isotherms, aliquots of cell suspensions (100 µl) were incubated 
with one of the eight concentrations of [3H]WIN 35,428 (84 Ci/mmol, PerkinElmer, 0.5 – 30 
nM final concentrations) in a final volume of 250 μl on ice for 2 h. In parallel, nonspecific 
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binding at each concentration of [3H]WIN 35,428 (in the presence of 30 µM cocaine, final 
concentration) was subtracted from total binding to calculate the specific binding. For the 
competitive inhibition experiment, assays were performed in duplicate in a final volume of 
500 μl. Aliquots of the cell suspensions (50 μl) were added to the assay tubes containing 50 
μl of [3H]WIN 35,428 (final concentration, 5 nM) and one of seven concentrations of 
unlabeled substrate DA (1 nM – 100 μM), inhibitors cocaine (1 nM – 100 μM) or GBR12909 
(0.01 nM – 1 μM) and incubated on ice for 2 h. Assays were terminated by rapid filtration 
onto Whatman GF/B glass fiber filters, presoaked for 2 h with assay buffer containing 0.5% 
polyethylenimine, using a Brandel cell harvester. Filters were rinsed three times with 3 ml of 
ice-cold assay buffer. Radioactivity remaining on the filters was determined by liquid 
scintillation spectrometry (model Tri-Carb 2900TR; PerkinElmer Life and Analytical 
Sciences, Waltham). 
3.2.6 CELL SURFACE BIOTINYLATION  
To determine whether DAT mutations alter DAT surface expression, biotinylation 
assays were performed as described previously (Zhu et al., 2005). CHO cells transfected with 
hDAT and mutants were plated on 6 well plates at a density of 105 cells/well. Cells were 
incubated with 1 ml of 1.5 mg/ml sulfo-NHS-SS biotin (Pierce, Rockford, IL) in PBS/Ca/Mg 
buffer (In mM: 138 NaCl, 2.7 KCl, 1.5 KH2PO4, 9.6 Na2HPO4, 1 MgCl2, 0.1 CaCl2, pH 7.3). 
After incubation, cells were washed 3 times with 1 ml of ice-cold 100 mM glycine in 
PBS/Ca/Mg buffer and incubated for 30 min at 4°C in 100 mM glycine in PBS/Ca/Mg 
buffer. Cells were then washed 3 times with 1 ml of ice-cold PBS/Ca/Mg buffer and then 
lysed by addition of 500 ml of Triton X-100, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µM 
pepstatin, 250 µM phenylmethysulfonyl fluoride), followed by incubation and continual 
shaking for 20 min at 4 °C. Cells were transferred to 1.5 ml tubes and centrifuged at 20,000g 
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for 20 min. The resulting pellets were discarded, and 100 µl of the supernatants was stored at 
-20 °C for determination of immunoreactive total DAT. Remaining supernatants were 
incubated with continuous shaking in the presence of monomeric avidin beads in Triton X-
100 buffer (100 µl/tube) for 1 h at room temperature. Samples were centrifuged subsequently 
at 17,000g for 4 min at 4°C, and supernatants (containing the nonbiotinylated, intracellular 
protein fraction) were stored at -20°C. Resulting pellets containing the avidin-absorbed 
biotinylated proteins (cell-surface fraction) were resuspended in 1 ml of 1.0% Triton X-100 
buffer and centrifuged at 17,000g for 4 min at 4°C, and pellets were resuspended and 
centrifuged twice. Final pellets consisted of the biotinylated proteins adsorbed to monomeric 
avidin beads. Biotinylated proteins were eluted by incubating with 75 µl of Laemmli sample 
buffer for 20 min at room temperature. If further assay was not immediately conducted, 
samples were stored at -20 °C. 
3.2.7 BASAL EFFLUX ASSAY  
DAT-mediated basal substrate efflux was carried out, as described previously 
(Guptaroy et al., 2009). We have reported that Y470H-hDAT significantly increased DA 
efflux compared to WT hDAT (Midde et al., 2013). In this study, we compared the effects of 
two types of substrates, DA or MPP+ on basal efflux in WT hDAT and mutants. The MPP+ 
was chosen because MPP+ has less diffusive properties than DA in heterologous expression 
systems (Scholze et al., 2001). CHO cells were seeded into 24 well plates and transfected 
with WT hDAT and mutants. Twenty four hours after transfection cells at a density of 105 
cells/well were washed 3 times with KRH buffer and preloaded with [3H]DA (50 nM, final 
concentration) or 5 nM final concentrations of [3H]1-methyl-4-phenylpyridinium 
([3H]MPP+, 5 nM, final concentration, specific activity, 83.9 Ci/mmol; PerkinElmer Life and 
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Analytical Sciences, Boston, MA) at room temperature for 20 or 30 min, respectively. After 
incubation, cells were washed 3 times with KRH buffer.  To obtain an estimate of the total 
amount of [3H]DA or [3H]MPP+ in the cells at the zero time point, cells from a set of wells 
(four wells/sample) were lysed rapidly in 1% SDS. To determine the time course of the 
fractional basal efflux, fresh buffer (500 µl) was added into separate set of cell wells (four 
wells/sample) and transferred to scintillation vials after 1 min as initial fractional efflux at 1 
min, and another 500 µl buffer was added to the same wells (where the buffer was just 
removed for 1 min point) and collected to vials after 10 min. Additional fractional efflux at 
20, 30, 40 and 50 min, respectively, was repeated under the same procedure. After last time 
point (50 min), cells were lysed in 1% SDS and counted as total amount of [3H]DA 
remaining in the cells from each well. 
3.2.8 DATA ANALYSES  
Descriptive statistics and graphical analyses were used as appropriate. Results are 
presented as mean ± SEM, and n represents the number of independent experiments for each 
experiment group. Kinetic parameters (Vmax, Km, Bmax, and Kd) were determined from 
saturation curves by nonlinear regression analysis using a one-site model with variable slope. 
IC50 values for substrate and inhibitors inhibiting [3H]DA uptake or [3H]WIN 35,428 were 
determined from inhibition curves by nonlinear regression analysis using a one-site model 
with variable slope. For experiments involving comparisons between unpaired samples, 
unpaired Student’s t test was used to assess any difference in the kinetic parameters (Vmax, 
Km, Bmax, Kd or IC50) between WT and mutant; log-transformed values of IC50, Km or Kd 
were used for the statistical comparisons. Significant differences between samples were 
analyzed with separate ANOVAs followed by post-hoc tests, as indicated in the results 
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Section of each experiment. All statistical analyses were performed using IBM SPSS 
Statistics version 20, and differences were considered significant at p < 0.05. 
3.3 RESULTS 
3.3.1 STRUCTURAL INDICATIONS FROM MOLECULAR MODELING AND DYNAMICS SIMULATIONS 
The transporting process of dopamine by DAT involves the conformational changes of DAT, 
typically from outward-open DAT (Figure 3.1A) bound with ions (2Na+, and Cl-) to 
outward-occluded DAT bound with both ions and substrate dopamine, and then to the 
inward-open DAT bound with Cl- (Figure 3.1C). The mode of intra-molecular interactions 
guarantees the smooth conformational change of DAT during dopamine transporting. We 
could assume that the transporter is optimized via natural evolution and energy barrier of 
conformation change is relatively low for an efficient transporting process. Therefore any 
mutation of key residues that make the structure incline to certain state may decrease the 
efficiency of dopamine transporting process. Based on the results of molecular modeling and 
molecular dynamics simulations, we found that the Y470 is the key component of a 
hydrophobic core, which is critical to stabilize the compact structure of DAT and then reduce 
the barrier of conformation change between outward-open and outward-occlude state of 
DAT (Figure 3.1B). In addition, residues Y88, K92 and D313 also help to stabilize TM1b 
and TM6a through hydrophobic or electrostatic intra-molecular interactions, which make the 
outward-open and outward-occlude state of DAT keep compact and be ready for 
conformation changing. The hydroxyl group at the aromatic side chain of Y88 reduces the 
hydrophobicity and makes the hydrophobic core nearby Y88 less stable than Y88F mutation, 
as a result, the Y88F mutation is expected to make the TM1b and EL4 more compact and 
bring about positive effect on the transporting kinetics of dopamine, i.e. increasing the 
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Vmax. However, the compact conformation of TM1b also squeeze the vacant of dopamine 
binding site, which may bring about negative effect of binding affinity of dopamine, i.e., 
increasing the Kmax. Specifically, the positive charged side chain of K92 could interact with 
the negative charged side chain of residue D313 through electrostatic interaction, and 
hydrogen bonding which is mediated by surrounding water molecules. As observed in our 
simulation, TM1b and TM6a move together during the conformation change of transporting, 
therefore K92-D313 interaction could stabilize the connection between TM1b and TM6a and 
consequently decrease the energy barrier of conformation change. It can be expected that the 
K92M mutation would bring about negative effects on the transporting kinetics of dopamine, 
i.e. decreasing the Vmax.  Moreover, the carboxyl of D79 in TM1b and carbonyl in main 
chain of F320 in TM6a interact directly with dopamine, so the K92M would pull away 
TM1b and TM6a, and these associated hydrogen bonding groups, which brings about 
negative effect of binding affinity of dopamine, i.e., increasing the Kmax (Figure 3.1D). 
Besides, as shown in the binding structure of HIV-1 TAT-DAT complex (Figure 3.2), the D-
Y470 interacts with the positive charged N-terminal of T-M1 through cation- interaction. 
Hydroxyl of D-Y88 forms hydrogen bond with side chain of T-K19. Side chain of D-K92 of 
DAT forms hydrogen bond with carbonyl of main chain of T-P18. Based on the mode of 
interaction between DAT and HIV-1 TAT, it could be expected that the mutating of residues 
Y88 and K92 into residues without hydrogen-bonding capacity will weaken the interaction 
between DAT and TAT. This is why that the mutations of Y88F and K92M decrease the 





3.3.2 MUTATIONS OF TYR88 AND LYS92 ALTER DA UPTAKE KINETICS AND POTENCY OF 
SUBSTRATE AND INHIBITORS  
To examine the functional relevance of Tyr88 and Lys92 residues of hDAT in 
intermolecular interaction between Tat and DAT, mutations in Tyr88 and Lys92 residues of 
hDAT (tyrosine to phenylalanine, Y88F-hDAT and lysine to methionine, K92M-hDAT) 
were generated by site-directed mutagenesis. We first determined the pharmacological 
profiles of [3H]DA uptake in CHO cells transfected with WT hDAT or mutated hDAT.  As 
shown in Table 3.1 and Fig. 3.4A, compared to WT hDAT (15.7 ± 0.9 pmol/min/105 cells), 
the Y88F-hDAT did not alter the Vmax values, whereas the K92M-hDAT displayed a 
decrease in the Vmax values (4.5 ± 1.7 pmol/min/105 cells, t(3) = 3.7, p<0.05, unpaired 
Student’s t test); no difference in the Km values was observed.  WIN 35,428 binding site 
shares pharmacological identity with the DA uptake carrier and is part of the cocaine binding 
domain (Pristupa et al., 1994). We also determined the effects of these mutants on possible 
relationship between the binding site of Tat on DAT and the WIN 35,428 binding site.  As 
shown in Table 3.1, the Bmax values were not altered in Y88F-hDAT (5.8 ± 0.9 pmol/105 
cells, t(8) = 2.1, p=0.07, unpaired Student’s t test) but decreased in K92M-hDAT (2.4 ± 0.4 
pmol/105 cells, t(8) = 4.4, p<0.01, unpaired Student’s t test) compared with WT hDAT (9.7 ± 
1.6 pmol/105 cells). However, the Kd values were significantly decreased in both in Y88F-
hDAT (4.0 ± 0.6 nM, t(8) = 3.6, p<0.01, unpaired Student’s t test) and K92M-hDAT (3.5 ± 
1.1 nM, t(8) = 3.2, p<0.01, unpaired Student’s t test) compared with WT hDAT (8.6 ± 1.1 
nM).     
We tested the ability of substrate and DAT inhibitors to inhibit [3H]DA uptake in WT 
hDAT and its mutants (Table 3.2). The apparent affinity (IC50) for DA was not significantly 
different among the WT hDAT (1730 ± 82 nM), Y88F-hDAT (3010 ± 60 nM) and K92M-
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hDAT (2870 ± 48 nM). However, the potencies of cocaine and GBR12909 for inhibition of 
[3H]DA uptake were 1.4 ~4.0-fold greater in Y88F-hDAT (Cocaine: 160 ± 9 nM and 
GBR12909: 95 ± 7 nM) and K92M-hDAT (Cocaine: 69 ± 4 nM and GBR12909: 101 ± 12 
nM)  as compared with WT hDAT (Cocaine: 285 ± 49 nM and GBR12909: 224 ± 41 nM).  
The apparent affinity (IC50) for WIN 35,428 was not significantly different in Y88F-hDAT 
(20 ± 2 nM) but more potent in K92M-hDAT (10 ± 1.0 nM) compared to WT hDAT (39 ± 
10 nM). The ability of substrate and DAT inhibitors to inhibit [3H]WIN 35,428 binding in 
WT hDAT and its mutants was also examined (Table 3.2). The apparent affinity (IC50) for 
DA was significantly lower in Y88F-hDAT (2071 ± 340 nM) and K92M-hDAT (4211 ± 118 
nM) than the WT hDAT (827 ± 120 nM). In addition, the IC50 for cocaine was increased in 
Y88F-hDAT (85 ± 60 nM, t(8)=5.8, p<0.01) but not K92M-hDAT compared to WT hDAT 
(150 ± 8.6 nM).         
To validate the relationship between the Vmax values and surface DAT expression in 
these mutants, we determined DAT surface expression in CHO cells transfected with WT or 
Y88F-hDAT or K92M-hDAT using biotinylation assay. As shown in Fig. 3.4B, despite no 
difference in the ratio of surface DAT (biotinylated DAT) to total DAT between WT (1.0 ± 
0.05), Y88F-hDAT (1.13 ± 0.13; p >0.05, one-way ANOVA) and K92M-hDAT (1.09 ± 
0.09; p >0.05, one-way ANOVA). The biotinylated DAT was not altered but total DAT was 
significantly decreased in K92M-hDAT compared to WT hDAT (t(8) = 4.6, p<0.01, 
unpaired Student’s t test). Thus, the decreased DA uptake in K92M-hDAT is not due to 





3.3.3 MUTATIONS OF TYR88, LYS92 AND TYR470 DIFFERENTIALLY INFLUENCE TAT-INDUCED 
INHIBITORY EFFECTS ON DA TRANSPORT 
We have recently reported that mutation of either Tyr470 in hDAT or Cys22 in Tat 
attenuated Tat-induced decrease in DA uptake (Zhu et al., 2009; Midde et al., 2013). To 
determine whether other substitutions at Tyr470 residue show differential effects on Tat-
induced decrease in DA uptake, we generated two mutations in Tyr470 residue of hDAT 
(tyrosine to phenylalanine, Y470F-hDAT and tyrosine to alanine, Y470A-hDAT) based on 
the predictions from computational modeling. We examined the specific [3H]DA uptake in 
WT hDAT and mutants in the presence or absence of recombinant Tat1-86 (500 nM) or 
recombinant Tat Cys22 (500 nM).  
As shown in Fig. 3.5A, two-way ANOVA on the specific [3H]DA uptake in WT 
hDAT and Tyr470 mutants revealed a significant main effect of mutation (F(2, 36) = 88.1; p < 
0.001) and Tat treatment (F(2, 36) = 15.5; p < 0.05), as well as a significant mutation × Tat 
interaction (F(4, 36) = 5.2; p< 0.01). The DA uptake was gradually decreased as Y470F (42%) 
> Y470H (72%) > Y470A (92%) compared to WT hDAT in the absence of Tat. Exposure to 
Tat decreased [3H]DA uptake by 32% in WT hDAT (F(1, 8) = 23.6; p < 0.01) and Y470F-
hDAT (47%, F(1, 8) = 15.4; p < 0.01); however, no effect of Tat was observed in Y470H-
hDAT (p > 0.05) and Y470A-hDAT (p > 0.05), suggesting that the different substitutions at 
Tyr470 residue in hDAT differentially influence Tat-induced down regulation of DA uptake. 
We have demonstrated that mutation of Cys22 in Tat shows no inhibitory effect on [3H]DA 
uptake (Zhu et al., 2009). As illustrated in Figure 3.5A, Tat Cyc22 did not alter DA uptake in 
WT hDAT and three Tyr470 mutants compared to respective controls, suggesting that Cyc22 
residue in Tat plays a critical role in Tat-induced regulation DAT function.     
75 
 
As shown in Figure 3.5B, two-way ANOVA on the specific [3H]DA uptake in WT 
and mutants revealed a significant main effect of mutation (F(2, 54) = 124; p < 0.001) and Tat 
treatment (F(2, 54) = 4.7; p < 0.05), however, mutation × Tat interaction (F(4, 54) = 1.9; p > 
0.05) was not significant. In control group, a subsequent simple effect analysis revealed 
decreased [3H]DA uptake in Y88F-hDAT (40%, p<0.05) and K92M-hDAT (72%, p<0.05) 
compared to WT hDAT in the absence of Tat. Exposure to Tat decreased [3H]DA uptake by 
32% in WT hDAT (F(1, 12) = 8.0; p < 0.05; Fig. 3.5B); however, no effect of Tat was 
observed in Y88F-hDAT (F(1, 12) = 1.1; p > 0.05) and K92M-hDAT (F(1, 12) = 1.4; p > 0.05), 
suggesting that mutation of either Tyr88 or Lys92 in hDAT attenuates Tat-induced reduction 
of hDAT function. With regard to the effect of recombinant Tat Cys22 on DA uptake (Fig. 
3.5B), exposure to Tat Cyc22 did not alter DA uptake in Y88F-hDAT and K92M-hDAT 
compared to WT hDAT.  
3.3.4 EFFECTS OF TYR88, LYS92, AND TYR470 MUTANTS ON ZINC REGULATION OF DAT 
CONFORMATIONAL TRANSITIONS AND BASAL DA EFFLUX 
 In general, occupancy of the endogenous Zn2+ binding site in WT hDAT (His193, 
His375, and Glu396) stabilizes the transporter in an outward-facing conformation, which 
allows DA to bind but inhibits its translocation, thereby increasing [3H]WIN 35,428 binding 
(Norregaard et al., 1998; Moritz et al., 2013), but decreasing [3H]DA uptake (Loland et al., 
2003) . Addition of Zn2+ is able to partially reverse an inward-facing state to an outward-
facing state (Norregaard et al., 1998; Loland et al., 2003). On the basis of this principle, the 
addition of Zn2+ to WT hDAT would inhibit DA uptake, whereas in a functional mutation in 
DAT Zn2+ might diminish the preference for the inward-facing conformation and thus 
enhance DA uptake. We recently reported that Y470H-hDAT exhibit an attenuation of Zn2+-
mediated decreased [3H]DA uptake and increased [3H]WIN35,428 binding observed in WT 
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hDAT, which demonstrates a preference for the inward-facing conformation of the 
transporter (Midde et al., 2013).  
To investigate the role of additional substitutions at Tyr470 and Tyr88, Lys92 
residues in DAT conformational transitions, we examined the effects of respective mutations 
on Zn2+ modulation of [3H]DA uptake and [3H]WIN35,428 binding. As described in Fig. 
3.6A, two-way ANOVA on the specific [3H]DA uptake in WT and Y470F-hDAT and 
Y470A-hDAT revealed a significant main effect of mutation (F(2, 24) = 99; p < 0.001), zinc 
(F(1, 24) = 40; p < 0.001) and a significant mutation × zinc interaction (F(2, 24) = 8.9; p < 0.02). 
The addition of Zn2+ decreased [3H]DA uptake in WT and Y470F-hDAT and Y470A-hDAT 
by 47%, 49% and 72% respectively (Fig. 3.6A, p< 0.01 relative to control, unpaired 
Student’s t test). A two-way ANOVA on the specific [3H]WIN35,428 binding in WT and 
Y470F-hDAT and Y470A-hDAT revealed a significant main effect of mutation (F(2, 44) = 38; 
p < 0.01), zinc (F(1, 44) = 5; p < 0.04); however, no significant mutation × zinc interaction (F(2, 
44) = 2; p > 0.13) was observed. Moreover, as presented in Fig. 3.6B. compared to respective 
control (in the absence of Zn2+), Zn2+ caused a 48% increase in [3H]WIN 35,428 binding in 
WT but 17% and 7% in Y470F-hDAT and Y470A-hDAT, respectively (p< 0.05 relative to 
control, unpaired Student’s t test). Additionally, as shown in Fig. 3.7A, two-way ANOVA on 
the specific [3H]DA uptake in WT and Y88F-hDAT and K92M-hDAT revealed a significant 
main effect of mutation (F(1, 24) = 170; p < 0.001), zinc (F(1, 24) = 102; p < 0.001) and a 
significant mutation × zinc interaction (F(2, 24) = 8.3; p < 0.01). The addition of Zn2+ 
decreased [3H]DA uptake in WT and Y88F-hDAT and K92M-hDAT by 48%, 73% and 81%, 
respectively (Fig. 3.6A, p< 0.001 relative to control, unpaired Student’s t test). A two-way 
ANOVA on the specific [3H]WIN35,428 binding in WT and Y88F-hDAT and K92M-hDAT 
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revealed a significant main effect of mutation (F(1, 18) = 7.8; p < 0.01), zinc (F(1, 18) = 26; p < 
0.001); however, no significant mutation × zinc interaction (F(2, 18) = 0.9; p > 0.05) was 
observed.  As displayed in Fig. 3.7B. compared to respective control (in the absence of 
Zn2+), Zn2+ caused a 54% increase in [3H]WIN 35,428 binding in WT but 22% and 19% in 
Y88F-hDAT and K92M-hDAT respectively (p< 0.001 relative to control, unpaired Student’s 
t test). These results suggest that Y88F, K92M, Y470F and Y470A mutants attenuate zinc 
modulation of [3H]WIN 35,428 binding sites but not [3H]DA uptake.  
To further evaluate the effects of mutations on transporter conformational transitions, 
we examined the fractional efflux levels of [3H]DA and [3H]MPP+ in WT hDAT and these 
mutants.  As shown in Fig. 3.6C, after preloading with 0.05 µM [3H]DA for 20 min at room 
temperature, cells were washed and fractional DA efflux samples were collected at the 
indicated times. A two-way ANOVA revealed significant main effects of mutation (F(2, 9) = 
10; p<0.05), time (F(5, 45) = 175; p<0.001) and significant mutation × time interaction (F(10,45) 
= 13; p<0.001) for Y470F-hDAT and Y470A-hDAT compared to WT. Post-hoc analysis 
showed that compared to WT hDAT, DA efflux levels were elevated at 1 and 10 min in 
Y470A-hDAT only (Figure 3.6C; p < 0.05, Bonferroni t-test). Similarly, a two-way ANOVA 
revealed significant main effects of mutation (F(3, 13) = 45; p<0.001) and time (F(5, 65) = 75; 
p<0.001) for Y88F-hDAT and K92M-hDAT compared to WT. A significant mutation × time 
interaction (F(15, 65) = 24; p<0.001) was also found. Post-hoc analysis revealed that compared 
to WT hDAT, DA efflux levels were at 1 and 10 min in K92M-hDAT (Figure 3.7C; p < 
0.05, Bonferroni t-test) but not in Y88F-hDAT. With regarding to MPP+ efflux, a two-way 
ANOVA revealed significant main effects of mutation (F(2, 9) = 19; p<0.05), time (F(5, 45) = 
253; p<0.001) and significant mutation × time interaction (F(10, 45) = 10; p<0.001) for Y470F-
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hDAT and Y470A-hDAT compared to WT. Post-hoc analysis displayed that compared to 
WT hDAT, MPP efflux levels were elevated at 1, 10, 20, 30, 40 and 50 min in Y470A-
hDAT only (Figure 3.6D; p < 0.05, Bonferroni t-test). Taken together, this data suggest that 
Tyr470, Tyr88 and Lys92 residues differentially affect the basal efflux levels of either DA or 
MPP+.  
3.4 DISCUSSION 
 Recently, we have demonstrated that Tyr470 in hDAT is a key residue in the 
intermolecular interaction between Tat and hDAT (Midde et al., 2013). In the current study, 
we extended characterization of Tyr470 by additional substitution mutations. Further, we 
pursued to characterize other predicted amino acids Tyr88 and Lys92 in the interaction of 
Tat with DAT. Tyr470 mutants exhibited differential impact on DAT uptake capacity and 
Tat-induced inhibition of DAT function, indicating the importance of Tyr470 in DAT 
interaction with Tat protein through cation- interaction. Mutations at Tyr88 and Lys92 
exhibited increased potencies for inhibitors to inhibit [3H]DA uptake and [3H]WIN 35,428 
binding with less impact on potencies for DA substrate to inhibit [3H]DA uptake and 
[3H]WIN 35,428 binding, suggesting the influence of Tat interaction on inhibitors binding to 
DAT without interfering  the DA uptake site. Notably, Y470F, Y470A, Y88F and K92M 
mutants did not reverse the Zn2+-facilitated inhibition of DA uptake but decreased the zinc-
mediated potentiation of WIN35,428 binding. In addition, Y470A and K92M displayed 
significant elevation in DA basal efflux compared to WT, suggesting the involvement of 
these residues in maintenance of conformational states of the transporter. Overall, our 
experimental evidence shows that Tyr88, Lys92 and Tyr470 play an essential role in 
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imparting Tat-induced conformational alterations in DAT and thereby inhibiting DA 
translocation process.  
 The current results show that K92M decreases Vmax but not the Y88F, and both 
mutants failed to show appreciable change in Km values compared to WT, reflecting that 
K92M indirectly involve in DA transport but not the Y88F. The likely reasons for impaired 
translocation in K92M would be either loss of transporter density on the membrane or 
alteration of DA turnover rate. Because of surface biotinylation data revealed similar 
amounts of WT and K92M mutant in the plasma membrane (Fig 3.4B) and Km value for DA 
uptake was not changed, the turnover for DA is possibly decreased in this mutant. 
Furthermore, decreased binding capacity and increased affinity for [3H]WIN35,428 binding 
(Table 3.2) were noted in both mutants. These observations indicate that Tat binding sites, 
Y88 and K92 are localized close to WIN35,428 binding site. Remarkably, our previous work 
showed that Tat protein decreases Bmax for [3H]WIN35,428 binding in dose dependent 
manner (Zhu et al., 2009). In addition, IC50 values for DA inhibiting [3H]DA uptake were not 
significantly altered in both mutants supporting the view that Y88 and K92 residues do not 
manipulate the DA binding affinities for the transporter. In contrary, IC50 values for 
inhibitors cocaine, GBR12909 inhibiting [3H]DA uptake are considerably decreased in both 
mutants compared to WT (Table 3.1), suggesting that increased potency for inhibitors 
observed in these mutants is a consequence of influence of Y88 and 92 on inhibitors binding 
sites. Similarly, this interpretation was further supported by increased potencies for inhibitors 
to inhibit [3H]WIN35,428 binding in these mutants (Table 3.2). Cocaine and its analog 
WIN35,428, and atypical inhibitor GBR12909 represent different classes of DAT inhibitors. 
While cocaine-like compounds exhibit increased binding affinity, GBR12909 shows weaker 
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binding affinity for DAT mutants (W84L, D313N and Y335A) that influence the 
conformational states of the transporter (Chen et al., 2001; Loland et al., 2002; Chen et al., 
2004). Unlike these reported mutants, Y88F and K92M displayed enhanced potencies for 
both cocaine and GBR12909, revealing that Tat may increase the effectiveness of cocaine 
through interaction at Tat binding sites. Furthermore, cocaine-like compounds were shown to 
interact with TM1 and TM6 of DAT, in the vicinity of substrate binding site (Beuming et al., 
2008; Parnas et al., 2008). As our computational modeling data indicated Tat impacts TM1b 
and TM6a helices movement through interacting with Tyr 88, Lys 92 and Tyr 470 (Figure 
3.2), it is conceivable that Tat and cocaine may have synergistic or additive effects on DAT 
function. In support of this interpretation, a recent study demonstrated that Tat expression in 
brain potentiates cocaine behavioral effects in mice (Paris et al., 2013) . Thus, these results 
support the idea of interactive effects of Tat and cocaine on DAT function. 
We demonstrated that mutating Tyr470 to His attenuates the inhibitory effects of Tat 
on DA uptake by eliminating both hydrogen bond and cation- interactions with Tat (Midde 
et al., 2013). To further validate Tyr470 residue, substitution mutants Y470A, Y470W and 
Y470F were generated with the expectation that Y470A and Y470W show characteristics 
similar to Y470H but with different sizes. Y470F mutant abolishes only hydrogen but not the 
cation- interactions (Figure 3.3). We did not characterize Y470W mutant because our 
efforts failed to improve basal uptake in this mutant irrespective of increased DNA for 
transfections or protein concentration for assays. Y470A displayed mitigation of Tat 
inhibitory effects on DA translocation (Figure 3.5A), which is similar to our reported mutant 
Y470H (Midde et al., 2013). Interestingly, other mutant Y470F failed to diminish Tat-
mediated effects on DA transport, indicating the important role of aromatic ring of Y470 in 
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DAT and Tat interaction. Moreover, Y88F and K92M mutants clearly showed attenuation of 
Tat-induced inhibition of DA uptake (Figure 3.5B) which is in line with Y470H and Y470A. 
Importantly, Tat Cys22 protein inhibitory effect was evidently attenuated by the mutant 
transporters irrespective of substitution, signifying the importance of physical interaction of 
Tat with DAT on transporter function. However, other residues of Tat protein that are 
involved in this interaction are needed to be evaluated. Taken together, this data demonstrate 
that Tat exploits Y470, Y88 and K92 amino acids of DAT to induce inhibitory effects on 
transporter function.    
In our recent report we revealed that Y470H mutant transporter prefers inward-facing 
conformational state (Midde et al., 2013). Zinc, a DAT modulator that stabilizes the 
transporter in outward conformation by loosely binding to the transporter, is extensively used 
to study the conformational effects of mutants on transporter function (Loland et al., 2003). 
Accordingly, studies show that Zn2+ inhibits DA uptake and increases WIN35,428 binding in 
WT. In the present study, we showed that Y88F, K92M, Y470F and Y470A mutants do not 
attenuate Zn2+-mediated inhibition of [3H]DA transporter but decrease potentiation of 
[3H]WIN 35,428 binding compared to WT. Established evidence indicate that transporters 
that prefer inward facing state reverse Zn2+ inhibitory effects on DA uptake and decrease 
Zn2+ -mediated WIN35,428 binding (Loland et al., 2002; Loland et al., 2004; Guptaroy et al., 
2009; Liang et al., 2009; Midde et al., 2013). A possible explanation for Y88F, K92M, 
Y470F and Y470A mutants failing to reverse Zn2+ influence on DA uptake could be that 
these particular mutants induce an aberrant structure of the DAT that may not be suitable for 
Zn2+ inhibitory effects on DA translocation because Zn2+ binding require strict geometrical 
structural constraints (Alberts et al., 1998). However, our data strongly supports a modified 
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conformational change in the mutant transporters by attenuation of Zn2+ induced [3H]WIN 
35,428 binding (Figure 3.6B, 3.7B) and by showing increased inhibitor potency values  for 
inhibiting [3H]WIN 35,428 binding (Table 3.2). The effect of mutations on conformational 
states of DAT was further probed by measuring substrate basal efflux. We used both DA and 
MPP+ for efflux studies to produce more accurate outcomes as MPP+ has less diffusive 
properties than DA. In our recent study we showed that Y470H mutant robustly increases 
DA efflux compared to WT (Midde et al., 2013). In the present study, we found that Y470A 
exhibits increased efflux of both DA and MPP+ but not the Y470F mutant. The likely 
explanation for normal efflux in Y470F would be due to less impact of this substitution on 
the structural integrity of the transporter. Interestingly, K92M displayed increased DA efflux 
at two initial time points but failed to retain this ability when MPP+ efflux was measured. 
The possible reason for K92M not replicating elevated efflux levels in [3H]MPP+ efflux 
assay as in [3H]DA efflux may be due to assuming a putative conformation that is not 
favorable to MPP+ binding  (Liang et al., 2009). This conformation may favor slower 
transition between inward and outward facing states and less effective at inducing DAT-
mediated efflux at least for substrate MPP+. The alternative explanation would be quick loss 
of substrate DA but not MPP+ by diffusion after short period of accumulation.  Taken 
together these findings infer that Y470A and K92M disrupt the inter-molecular interaction 
required to maintain transporter outward facing conformation. Nevertheless, we proposed 
that Tat promotes alterations in transporter conformation through allosteric regulation (Zhu 
et al., 2009; Zhu et al., 2011). Intriguingly, this mechanism is similar to the exogenous full 
substrates like amphetamines action on DAT (Robertson et al., 2009; Rothman et al., 2009). 
Therefore, it is important that systemic identification and characterization of all Tat binding 
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sites in DAT are required in order to pin point the mode of action of Tat on rearrangements 
of DAT conformational cycle.  
In summary, we have evaluated different substitutions at 470 (Y470F and Y470A) 
and identified additional residues (Y88 and K92) in DAT that are predicted to be interact 
with Tat. All mutants attenuated the inhibitory action of Tat on DA translocation except 
Y470F and we reasoned that these alterations are the result of disruption of critical 
intramolecular interactions in DAT by Tat binding. As different substitutions at 470 
consistently favored against Tat-induced decrease in DA uptake it is apparent that Tyr 470 of 
DAT plays central role in Tat and DAT interaction, and Tyr 88 and Lys 92 may work as 
supporting residues along with other unidentified residues. Because Tat-driven allosteric 
mechanism down regulates DA uptake (Zhu et al., 2011) and mutations at predicted amino 
acids show alterations in conformational distribution of DAT, future investigations that 
identify and validate other recognition residues will certainly improve our understanding of 
functional relevance of Tat binding sites on DAT. This information would be useful to 






Table 3.1 Summary of kinetic properties and inhibitory activities in [3H]DA uptake in 

























224 ± 41 
 





14.8 ± 3.7 1.9 ± 0.3
2010 ± 
60 





4.5 ± 1.7* 1.9 ± 0.4
2870 ± 
48 
69 ± 4* 101 ± 12* 10 ± 1* 
 
Data are presented as mean ± S.E.M. values from 5-7 independent experiments performed in 
duplicate. * p < 0.05 compared with WT hDAT (unpaired Student’s t test).    
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Table 3.2 Summary of kinetic properties and inhibitory activities in [3H]WIN 35,428 


















9.7 ± 1.6 8.6 ± 1.1 827 ± 102 150 ± 8.6 
 









2.4 ± 0.4* 3.5 ± 1.1* 4211 ± 118* 106 ± 31.5 12.8 ± 14.3
 
Data are presented as mean ± S.E.M. of IC50 values from five independent experiments 






Figure 3.1 MD simulated structure of outward-open DAT (A and B) and structure of 
inward-open DAT (C and D). (A) Side view of outward-open state of DAT structure shown 
as cyan-colored ribbon. 2 Na+ ions and 1 Cl- ion are shown as spheres. (B) Local view of the 
residues around the mouth of the vestibule of outward-open state of DAT. These residues are 
R85, Y88, K92, D313, Y470 and D476 shown in stick-style. Hydrogen bond between K92 
and D313 are represented as dashed lines with labeled distances (between hydrogen bond 
donor and acceptor, unit in Å), which stabilized the TM1b and TM6a. (C) Side view of 
inward-open state of DAT structure shown as colored ribbon. 1 Cl- ion is shown as sphere. 
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(D) Local view of residues around the mouth of the vestibule of inward-open state of DAT. 
We also found that the salt bridge formed by the positive side chain of residue R85 and the 
negative side chain of D476 act as the gate for the entry of substrate dopamine into its biding 























Figure 3.2 MD simulated structure of HIV-1 Tat-DAT binding complex. (A) HIV-1 Tat protein is shown as ribbon and colored in golden, 
and DAT is represented as cyan ribbon. Residues T-M1, T-P18 and T-K19 of HIV-1 Tat are represented as sticks and colored by atom 





interactions between HIV-1 Tat and DAT as observed from the binding structure. Critical residues of inter-molecular interactions from 
HIV-1 Tat and DAT are shown in stick style and colored by atom types. Two dashed lines on the left represent inter-molecular hydrogen 
bonds with labeled distances. The orange ball indicates the center of aromatic ring, and the dashed line pointing to the orange ball 






Figure 3.3 Interaction between TAT-M1 and DAT-Y470 mutations. (A) Residues T-M1 and 
D-Y470 are represented as sticks and colored by atom types. The orange ball indicates the 
center of aromatic ring, and the dashed line pointing to the orange ball represents the cation-
π interaction with labeled distance. (B) Y470F mutation retains the cation-π interaction 
between T-M1 and D-Y470. It can be expected Y470F would bring little influence on the 
TAT effect, which is consist with experimental data. (C) Y470W would eliminate the cation-
π interaction because of the unfavorable van der Waals interaction, which is expected to 
exhibit attenuation on DAT-TAT binding affinity. (D) Y470A would eliminate the cation-π 
interaction between T-M1 and D-Y470, which is also expected to exhibit attenuation on 























Figure 3.4 [3H]DA uptake and DAT surface expression in WT hDAT and mutants. (A) 
Kinetic analysis of [3H]DA uptake in WT hDAT, Y88F-hDAT and K92M-hDAT. CHO cells 
transfected with WT hDAT, Y88F-hDAT or K92M-hDAT were incubated with one of six 
mixed concentrations of the [3H]DA as total rate of DA uptake. In parallel, nonspecific 
uptake of each concentration of [3H]DA (in the presence of 10 µM nomifensine, final 
concentration) was subtracted from total uptake to calculate DAT-mediated uptake. * p < 












































WT-hDAT    (15.7  0.9       1.2  0.1)
Y88F-hDAT (14.8  3.7       1.9  0.3)
Vmax Km





























expression of WT hDAT (WT), Y88F-hDAT (Y88F) and K92M-hDAT (K92M) was 
analyzed by biotinylation assay. Top panel: representative immunoblots in CHO cells 
expressing WT hDAT, Y88F-hDAT or K92M-hDAT. Bottom panel: DAT immunoreactivity 
is expressed as mean ± S.E.M. densitometry units from three independent experiments (n = 














Figure 3.5 Effects of Tat or Tat Cys22 on [3H]DA uptake in WT hDAT and mutants. (A) 
PC12 cells transfected with WT, Y470F-hDAT (Y470F), Y470H-hDAT (Y470H) or 
Y470A-hDAT (Y470A) were preincubated with or without recombinant Tat Cys22 or Tat1-86 
(rTat1-86) at 500 nM final concentration at room temperature for 20 min followed by the 
addition of 0.05 μM final concentration of the [3H]DA. Nonspecific uptake was determined 
in the presence of 10 µM final concentration of nomifensine. (B) [3H]DA uptake in cells 
transfected with WT hDAT (WT), Y88F-hDAT (Y88F) and K92M-hDAT (K92M) was 
determined in the presence or absence of Tat Cys22 or rTat1-86 (500 nM, final concentration). 
Data are expressed as means from seven independent experiments ± S.E.M. * p < 0.05 







































































































































































































































































Figure 3.6 Effects of Y470F, Y470A and Y470H mutants on transporter conformational 
transitions.  Mutations of Tyr470 affect zinc regulation of [3H]DA uptake (A) and [3H]WIN 
35,428 binding (B). CHO cells transfected with WT hDAT (WT), Y470F-hDAT (Y470F) 
and Y470A-hDAT (Y470A) were incubated with assay buffer alone (control) or ZnCl2 (10 
µM, final concentration) followed by [3H]DA uptake or [3H]WIN 35,428 binding (n = 6). 
The histogram shows [3H]DA uptake and [3H]WIN 35,428 binding expressed as mean ± 
S.E.M. of the respective controls set to 100% for the mutant. * p < 0.05 compared to control. 




was determined in WT hDAT and mutants. CHO cells transfected with WT hDAT or 
mutants were preincubated with [3H]DA (0.05 µM, final concentration) or [3H]MPP+ (5 nM, 
final concentration) at room temperature for 20 or 30 min, respectively. After incubation, 
cells were washed and incubated with fresh buffer as indicated time points. Subsequently, 
the buffer was separated from cells, and radioactivity in the buffer and remaining in the cells 
was counted. Each fractional efflux of [3H]DA or [3H]MPP+ in WT hDAT (WT), Y470F-
hDAT (Y470F), Y470A-hDAT (Y470A) or Y470H-hDAT was expressed as percentage of 
total [3H]DA or [3H]MPP+ in the cells at the start of the experiment. Fractional [3H]DA 
efflux at 1, 10, 20, 30, 40 and 50 min are expressed as the percentage of total [3H]DA with 
preloading with 0.05 µM (WT hDAT: 26837 ± 5089 dpm, Y470F-hDAT: 20908 ± 4209 
dpm, Y470A-hDAT: 1158 ± 123 dpm and Y470H-hDAT: 2488 ± 150 dpm) present in the 
cells at the start of the experiment (n = 3).  ×× p < 0.05 compared to WT hDAT (Bonferroni t-
test). Fractional [3H]MPP+ efflux at 1, 10, 20, 30, 40 and 50 min are expressed as the 
percentage of total [3H]MPP+ with preloading with 0.05 µM (WT hDAT: 12120 ± 397 dpm, 
Y470F-hDAT: 7399 ± 359 dpm, Y470A-hDAT:  460 ± 46 dpm and Y470H-hDAT:  602 ± 
28 dpm) present in the cells at the start of the experiment (n = 3).  ×× p < 0.05, compared to 

















Figure 3.7 Effects of Y88F and K92M mutants on transporter conformational transitions. 
Mutations of Tyr88 and Lys92 affect zinc regulation of [3H]DA uptake (A) and [3H]WIN 
35,428 binding (B). The histogram shows [3H]DA uptake and [3H]WIN 35,428 binding 
expressed as mean ± S.E.M. of the respective controls set to 100% for the mutant. * p < 0.05 
compared to control. # p < 0.05 compared to WT hDAT with ZnCl2.   Functional efflux of 















































































































































[3H]DA or [3H]MPP+ in WT hDAT (WT), Y88F-hDAT (Y88F) or K92M-hDAT (K92M) 
was expressed as percentage of total [3H]DA or [3H]MPP+ in the cells at the start of the 
experiment. Fractional [3H]DA efflux at 1, 10, 20, 30, 40 and 50 min are expressed as the 
percentage of total [3H]DA with preloading with 0.05 µM (WT hDAT: 70082 ± 8256 dpm, 
Y88F-hDAT: 41805 ± 6887 dpm and K92M-hDAT: 9655 ± 2160 dpm) present in the cells at 
the start of the experiment (n = 3).  ×× p < 0.05 compared to WT hDAT (Bonferroni t-test). 
Fractional [3H]MPP+ efflux at 1, 10, 20, 30, 40 and 50 min are expressed as the percentage 
of total [3H]MPP+ with preloading with 0.05 µM (WT hDAT: 15516 ± 920 dpm, Y88F-
hDAT: 5695 ± 450 dpm and K92M-hDAT:  967 ± 121 dpm) present in the cells at the start 







HIV-1 TAT PROTEIN DECREASES DOPAMINE TRANSPORTER CELL SURFACE 
EXPRESSION AND VESICULAR MONOAMINE TRANSPORTER-2 FUNCTION IN RAT 
STRIATAL SYNAPTOSOMES2 
 
ABSTRACT: The dopamine (DA) transporter (DAT) and vesicular monoamine transporter 
(VMAT2) proteins interact as a biochemical complex to regulate dopaminergic 
neurotransmission. We have reported that HIV-1 Tat1-86 decreases the specific [3H]DA 
uptake and [3H]WIN 35,428 binding sites without a change in total DAT immunoreactivity 
in rat striatum (Zhu et al., 2009b). The present study determined the effects of Tat on DAT 
phosphorylation and trafficking, and vesicular [3H]DA uptake. Pre-incubation of rat striatal 
synaptosomes with the protein kinase C (PKC) inhibitor bisindolylmaleimide I (1 µM) 
completely blocked Tat1-86 -induced reduction of  [3H]DA uptake, indicating that Tat 
regulates DAT function through a PKC-dependent mechanism. After exposure of 
synaptosomes to Tat1-86 (1 µM), DAT immunoreactivity was decreased in plasma membrane 
enriched fractions (P3) and increased in vesicle-enriched fractions (P4) relative to controls 
without change in total synaptosomal fractions (P2), suggesting that Tat-induced inhibition 
of DA uptake is attributable to DAT internalization. Although both DAT and VMAT2 
proteins are essential for the regulation of DA disposition in synapse and cytosol, Tat 
                                                            
2 Midde NM, Gomez AM, Zhu J (2012) HIV-1 Tat Protein Decreases Dopamine Transporter Cell 
Surface Expression and Vesicular Monoamine Transporter-2 Function in Rat Striatal Synaptosomes. 





inhibited the specific [3H]DA uptake into vesicles (P4) and synaptosomes (P2) by 35% and 
26%, respectively, inferring that the inhibitory effect of Tat was more profound in VMAT2 
protein than in DAT protein.  Taken together, the current study reveals that Tat inhibits DAT 
function through a PKC and trafficking-dependent mechanism and that Tat impacts the 
dopaminergic tone by regulating both DAT and VMAT2 proteins. These findings provide 
new insight into understanding the pharmacological mechanisms of HIV-1 viral protein-
induced dysfunction of DA neurotransmission in HIV-infected patients.  
4.1 INTRODUCTION 
The prevalence of HIV-1-associated neurocognitive disorders (HAND) in HIV-1 
positive individuals remains high (~50%), regardless of the success with treatments of anti-
retroviral agents effectively controlling viral replication and dramatically improving 
longevity (Robertson et al., 2007; Tozzi et al., 2007; Ernst et al., 2009).  Notably, the 
incidence and severity of HAND are greatly enhanced (~70%) due to concomitant use of 
drugs of abuse such as cocaine (Norman et al., 2009), which has been postulated as a co-
morbid factor in the susceptibility and progression of HAND (Larrat and Zierler, 1993; Fiala 
et al., 1998; Webber et al., 1999; Buch et al., 2011). While HIV-1 virus enters the brain and 
produces proviral DNA in the early stage of HIV-1 infection (Nath and Clements, 2011), 
anti-retroviral agents cannot prevent the production of HIV-1 viral proteins in infected brain 
cells (McArthur et al., 2010; Nath and Clements, 2011).  HIV-1 viral proteins, such as Tat, 
have been detected in brains of patients with HIV-1 infection (Del Valle et al., 2000; Hudson 
et al., 2000; Lamers et al., 2010), and have been implicated in the pathophysiology of HAND 
(Li et al., 2009).  Moreover, Tat protein has been found to synergize with psychostimulant 
drugs in producing profound neural and behavioral impairments in preclinical models (Ferris 
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et al., 2008), consistent with the findings in the human HIV-1 positive drug abusing 
population (Larrat and Zierler, 1993).  Unfortunately, there are no promising therapeutic 
approaches for such HIV-1-associated neurocognitive impairments. 
The development of neurocognitive dysfunction in HAND patients is associated with 
perturbations of the central dopamine (DA) neurotransmission (Kumar et al., 2011; Meade et 
al., 2011a).  The DA system is a clinically relevant HAND target as evidenced by recent 
human imaging (Chang et al., 2008; Meade et al., 2011a), neurocognitive (Kumar et al., 
2011; Meade et al., 2011b), and post-mortem examinations (Silvers et al., 2007; Kumar et 
al., 2009), that HAND is associated with vulnerability of the DA system. Limited studies 
have reported that DA levels are decreased in DA-rich brain area (Sardar et al., 1996; Kumar 
et al., 2009), but increased in the CSF (Scheller et al., 2010) of HAND patients. The DA 
transporter (DAT) is critical for DA homeostasis, which is critical for neurocognitive 
function (Chudasama and Robbins, 2006).  DAT is a target for HIV-1 viral proteins (Hu et 
al., 2009; Zhu et al., 2009b) and cocaine to impact the DA system (Zhu and Reith, 2008).  
We have demonstrated that Tat inhibits DA uptake in rat striatal synaptosomes and that 
influence of Tat on DAT ligand binding sites involves a protein-protein interaction (Zhu et 
al., 2009b). In particular, we have shown that Tat allosterically inhibits DAT function and 
modulates cocaine binding sites on DAT in rat striatal synaptosomes and heterologous cells 
expressing human DAT (Zhu et al., 2011).  
The dynamic regulation of DAT function and cell surface localization of DAT are 
under the control of complex processes involving phosphorylation, protein-protein 
interaction, substrate pretreatment, and interaction with presynaptic receptors (Zhu and 
Reith, 2008).  For example, activation of protein kinase C (PKC) results in reduced DA 
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transport activity, decreased transporter recycling and DAT cell surface expression, thereby 
causing reduced DA uptake (Daniels and Amara, 1999; Melikian, 2004; Zahniser and 
Sorkin, 2004).  On one hand, dynamic cell surface localization of DAT is regulated by 
cellular signaling pathways and endocytotic trafficking (Zhu and Reith, 2008). On the other 
hand, the DAT and vesicular monoamine transporter (VMAT2) proteins interact as a 
biochemical complex to regulate dopaminergic tone in response to motivationally relevant 
stimuli, including abused drugs (Vergo et al., 2007; Zhu and Reith, 2008; Egana et al., 2009).   
This study was aimed to understand the molecular mechanisms underlying Tat-
induced decrease in DAT reuptake activity. The primary hypothesis tested here was that Tat-
induced reduction of DA transport is attributable to acceleration of DAT endocytosis through 
the dynamic-trafficking and phosphorylation-dependent mechanisms and that both DAT and 
VMAT-2 function contribute to Tat-induced impairment of DA neurotransmission.  
4.2 MATERIAL AND METHODS 
4.2.1 ANIMALS  
Adult male Sprague – Dawley rats (225-250g body weight) were obtained from 
Harlan Laboratories, Inc. (Indianapolis, IN). Rats were housed in standard polyurethane 
cages and provided normal rodent food (ProLab Rat/Mouse/Hamster Chow 3000) and water 
ad libitum. The colony was maintained at 21±2 °C, 50±10% relative humidity and a 12L: 
12D cycle with lights on at 0700 h (EST).The animals were maintained according to the 
National Institute of Health (NIH) guidelines in AAALAC accredited facilities. The 
experimental protocol was approved by the Institutional Animal Care and Use Committee 




4.2.2 DRUGS AND CHEMICALS 
[3H]DA (3,4-ethyl-2[N-3H]dihydroxyphenylethylamine; specific activity, 31 
Ci/mmol) and [3H]WIN 35,428 (specific activity, 85 Ci/mmol) were purchased from 
PerkinElmer Life and Analytical Sciences (Boston, MA). Recombinant HIV-1 transactivator 
of transcription (Tat1–86, Clade B, REP0002a) protein and its mutant protein Tat Cys22 
(cysteine 22 was substituted to glycine, REP0032) were purchased from Diatheva (Fano, 
Italy). D-amphetamine, cocaine and Bisindolylmaleimide-I (BIM-I) were purchased from 
Tocris Biosciences (Ellisville, MO).  Tetrabenazine (TBZ) was provided by NIMH Chemical 
Synthesis and Drug Supply Program (Bethesda, MD).  Antibodies recognizing rat DAT (C-
20; goat polyclonal antibody) and actin (C-2; mouse monoclonal antibody) were purchased 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-goat IgG horseradish 
peroxidase was purchased from Jackson ImmunoResearch Laboratories Inc. (West Grove, 
PA). Goat anti-mouse IgG-horseradish peroxidase was purchased from Santa Cruz 
Biotechnology, Inc. D-Glucose, L-ascorbic acid, WIN35,428, L-leucine, L-lysine, bovine 
serum albumin, pyrocatechol, EDC, HEPES, isopropanol, nomifensine maleate, pargyline 
hydrochloride, polyethylene glycol, sucrose, and Tween 20 were purchased from Sigma-
Aldrich (St. Louis, MO).  
4.2.3 PREPARATION OF SYNAPTOSOMES, SUBFRACTIONS AND SYNAPTIC VESICLES  
Striata from individual rats were homogenized in 20 ml of ice-cold 0.32 M sucrose 
containing 5 mM NaHCO3, pH 7.4, with 16 up-and-down strokes using a Teflon pestle 
homogenizer (clearance, approximately 0.003 in.).  Crude synaptosomal preparation was 
centrifuged at 2000g for 10 min at 4°C, and the resulting supernatants were then centrifuged 
at 20,000g for 15 min at 4°C. The resulting pellets (P2 fractions) were resuspended in 5 ml 
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of ice-cold Krebs-Ringer-HEPES assay buffer (final concentration in mM: 125 NaCl, 5 KCl, 
1.5 MgSO4, 1.25 CaCl2, 1.5 KH2PO4, 10 D-glucose, 25 HEPES, 0.1 EDTA, 0.1pargyline, 
and 0.1 L-ascorbic acid, saturated with 95% O2, 5% CO2; pH 7.4) for the synaptosomal 
[3H]DA uptake.  To determine the distribution of DATs in subcellular fractions after 
exposure to Tat, striata from every two rats were pooled to achieve sufficient vesicles and the 
subcellular fractions were prepared using a previously published method with minor 
modifications (Middleton et al., 2007).  Striata were homogenized in ice-cold 0.32 M sucrose 
buffer using a Teflon pestle homogenizer and then centrifuged at 800g for 12 min, 4°C.  The 
resulting supernatant (S1) was centrifuged at 22,000g for 15 min at 4°C to yield a crude 
synaptosomal pellet (P2). The P2 pellet was then resuspended in DA uptake assay to obtain 
synaptosomes. In order to determine whether Tat (1 µM)-induced decreases of [3H]DA 
uptake, as observed in our previous report (Zhu et al., 2009b), was associated with a 
reduction of DAT expression in plasma membrane, half of the synaptosomes were 
preincubated with Tat1–86 (1 µM), and the other half were preincubated without Tat1–86 as 
control at 34°C for 15 min.  This concentration of Tat1–86 was chosen based on our previous 
report showing that the inhibitory effect of Tat (1 µM) on DA uptake was reversible (Zhu et 
al., 2009b). Subsequently, the synaptosomal samples were centrifuged at 22,000g for 15 min 
at 4°C and synaptosomes in the pellets (P2) were then lysed in ice-cold 25 mM HEPES, pH 
7.5, and 100 mM potassium tartrate (pH 7.4) plus phosphatase inhibitor cocktails I (P2850, 
Sigma-Aldrich, St. Louis, MO) and protease inhibitor cocktail (P8340, Sigma-Aldrich, St. 
Louis, MO).  After thorough mixing of all contents, the resulting mixture was centrifuged at 
20,000g for 15 min at 4°C to get the plasma membrane enriched (P3) and vesicle-enriched 
supernatant (S3). The S3 was then centrifuged at 100,000g for 45 min at 4°C to yield the 
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cytoplasmic vesicles pellet (P4).  The three fractions (P2, P3, and P4) were used for Western 
blot assay.  Protein concentrations were determined by the Bradford protein assay (Bradford, 
1976) using bovine serum albumin as the standard (Bio-Rad Laboratories, Hercules, CA). 
4.2.4 SYNAPTOSOMAL [3H]DA UPTAKE  
[3H]DA uptake was determined using previously described methods (Zhu et al., 
2009b). Assays were performed in triplicate with a final volume of 1 mL.  Aliquots of striatal 
synaptosomes were preincubated in assay buffer containing BIM-I (100 µM, final 
concentration) at 34 °C for 5 min in an oxygenated metabolic shaker, and then incubated 
with amphetamine (20 µM, final concentration) or Tat (0.7 µM) for an additional 15 min. 
The concentration of BIM-I was chosen based on the previous report showing that BIM-I 
(100 µM) alone did not show inhibitory effect on [3H]DA into rat striatal synaptosomes 
(Richards and Zahniser, 2009).  A low concentration of Tat (0.7 µM) was chosen because 
our previously published study (Zhu et al., 2009b) has demonstrated that Tat at both 0.7 and 
1.0 µM concentrations significantly decreases [3H]DA uptake by 21% and 26%, respectively. 
The purpose of the experiment was to determine whether Tat-induced decrease in DAT 
function is PKC-dependent. We selected the low concentration because it was sufficient to 
elicit a significant decrease in DA uptake for the PKC experiment.  Subsequently, the 
synaptosomes were centrifuged at 20,000g for 15 min and the resulting pellets were 
resuspended with ice cold assay buffer. Aliquots of the well-washed synaptosomes were 
incubated with 5 nM [3H]DA (final concentration) at 34 °C for 10 min. The reactions were 
terminated by the addition of 3 ml of ice-cold assay buffer. Nonspecific uptake was 
determined in duplicate at each [3H]DA concentration by including 10 µM nomifensine in 
the assay buffer. Samples were filtered through Whatman GF/B glass fiber filters (Whatman, 
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Maidstone, UK), presoaked with assay buffer containing 1 mM pyrocatechol. Filters were 
washed three times with 3 ml of ice-cold assay buffer containing 1 mM pyrocatechol using a 
Brandel cell harvester (model M-48; Biochemical Research and Development Laboratories 
Inc., Gaithersburg, MD). Pyrocatechol (catechol) is a catechol-O-methyltransferase inhibitor. 
In the current study, pyrocatechol (1 mM) was included in the DA uptake assay buffer to 
prevent the degradation of [3H]DA during the processes of washes and harvesting (Zhu et al., 
2004). Radioactivity was determined using liquid scintillation spectrometry (model Tri-Carb 
2900TR; PerkinElmer Life and Analytical Sciences). 
4.2.5 VESICULAR [3H]DA UPTAKE  
To determine inhibitory effects of Tat on VMAT-2 function, vesicular [3H]DA 
uptake was measured using previously described methods (Volz et al., 2007).  In brief, 
assays were performed in duplicate with a final volume of 250 µl. For the competitive 
inhibition experiment, aliquots of P4 suspensions were preincubated in VMAT-2 assay 
buffer (final concentration in mM: 25 HEPES, 100 potassium tartrate, 0.05 EGTA, and 0.1 
EDTA, 1.7 ascorbic acid, and 2 ATP-Mg2+, pH 7.5) containing Tat, Tat Cys22 or TBZ (final 
concentration, 0.1 nM-10 µM) at 34 ºC for 15 min in an oxygenated metabolic shaker and 
subsequently incubated with a fixed concentration of [3H]DA (1 µM, final concentration) at 
34 ºC for additional 8 min. To determine if Tat differentially inhibits DAT and VMAT-2 
function, in a separate experiment, synaptosomes were preincubated with 1 µM Tat at 34 ºC 
for 15 min. Subsequently the synaptosomes were washed with fresh ice-cold assay buffer, 
and P2 and P4 fractions were then separated as described above.  Aliquots of P4 fractions 
were incubated in the assay buffer with 1 to 8 concentrations of [3H]DA (0.03-5 µM) at 34 
ºC for 8 min. Nonspecific uptake was determined in the presence of 10 µM TBZ. Reactions 
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were terminated by addition of 1 ml of cold wash buffer (assay buffer containing 2 mM 
MgSO4 substituted for the ATP-Mg2+, pH 7.5) and rapid filtration through Whatman GF/B 
filters soaked previously in 0.5% polyethylenimine. Filters were washed 3 times with the 
VMAT-2 assay buffer and radioactivity was measured using a liquid scintillation counter. 
4.2.6 WESTERN BLOTS 
Proteins were extracted from each fraction (P2, P3 and P4) as described above with 
the Laemmli sample buffer (Sigma-Aldrich, St. Louis, MO) containing  phosphatase 
inhibitor cocktail 1 (P2850, Sigma-Aldrich, St. Louis, MO) and protease inhibitors (P8340, 
Sigma-Aldrich, St. Louis, MO) and boiled for 5 min. To detect the immunoreactive DAT 
protein in these fractions, samples were subjected to gel electrophoresis and Western 
blotting. Proteins were separated by 10% SDS-polyacrylamide gel electrophoresis for 90 min 
at 150 V and transferred to Immobilon-P transfer membranes (Millipore, Billerica, MA) in 
transfer buffer (50 mM Tris, 250 mM glycine, and 3.5 mM SDS) using a Mini Trans-Blot 
Electrophoretic Transfer Cell (Bio-Rad Laboratories) for 110 min at 72 V. Transfer 
membranes were incubated with blocking buffer (5% dry milk powder in phosphate-buffered 
saline containing 0.5% Tween 20) for 1 h at room temperature, followed by incubation with 
goat polyclonal DAT antibody (1 µg/ml in blocking buffer) overnight at 4°C. Transfer 
membranes were washed five times with wash buffer (phosphate-buffered saline containing 
0.5% Tween 20) at room temperature and then incubated with rabbit anti-goat DAT antibody 
(1:2500 dilution in blocking buffer) for 1 h at 22°C. Blots on transfer membranes were 
detected using enhanced chemiluminescence and developed on Hyperfilm ECL-Plus (GE 
Healthcare, Chalfont St. Giles, Buckinghamshire, UK). After detection and quantification of 
the DAT protein, each blot was stripped in 10% Re-blot plus mild antibody stripping 
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solution (Millipore Bioscience Research Reagents, Temecula, CA) for 20 min at room 
temperature and reprobed for detection of actin. Actin was used as an intracellular control 
protein to monitor protein loading between samples and determined using a mouse 
monoclonal antibody (1:1000 dilution in blocking buffer). Multiple autoradiographs were 
obtained using different exposure time, and immunoreactive bands within the linear range of 
detection were quantified with densitometric scanning (Scion Image software; Scion 
Corporation, Frederick, MD). Band density measurements, expressed as relative optical 
density, were used to determine levels of the DAT immunoreactivity in synaptosomes. 
4.2.7 [3H]WIN 35,428 BINDING ASSAY  
To determine whether Tat-induced inhibition of [3H]DA uptake was the result of 
alterations in the maximal number of binding sites (Bmax) or affinity (Kd) for [3H]WIN 
35,428 binding in P3 fraction, kinetic analysis of [3H]WIN 35,428 binding was determined 
using a previously described method (Zhu et al., 2009b). After exposure of synaptosomes to 
Tat (1 µM) or vehicle (control) as described above, the P3 pellets were resuspended in ice-
cold sodium-phosphate buffer (2.1 mM NaH2PO4, 7.3 mM Na2HPO47H2O, and 320 mM 
sucrose, pH 7.4). Aliquots of P3 fractions were incubated with one of the eight 
concentrations of [3H]WIN 35,428 (final concentration, 0.5–30 nM) on ice for 2 h. In 
parallel, nonspecific binding at each concentration of [3H]WIN 35,428 (in the presence of 30 
µM cocaine, final concentration) was subtracted from total binding to calculate the specific 
binding. Assays were terminated by rapid filtration onto Whatman GF/B glass fiber filters, 
presoaked for 2 h with the assay buffer containing 0.5% polyethylenimine, using a Brandel 
cell harvester. Filters were rinsed three times with 3 ml of ice-cold assay buffer. 
Radioactivity remaining on the filters was determined by liquid scintillation spectrometry. 
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4.2.8 DATA ANALYSIS  
Data are presented as mean ± S.E.M., and n represents the number of independent 
experiments for each experiment.  The effect of BIM-I on Tat-induced changes in DA uptake 
was analyzed by one-way ANOVA. Student-Newman-Keuls comparisons were made for 
post hoc analyses. Separate paired Student’s t test was conducted on DAT immunoreactivity 
for comparisons between control and Tat treated samples. Kinetic parameters (Bmax and Kd) 
of [3H]WIN 35,428 binding were determined from saturation curves by nonlinear regression 
analysis using a one-site model with variable slope. For experiments involving comparisons 
between two paired samples, paired Student’s t test was used to determine the ability of Tat 
to alter the kinetic parameters [Km and Vmax for [3H]DA uptake; Kd and Bmax for [3H]WIN 
35,428 compared with control (the absence of Tat)]; log-transformed values of Km or Kd 
were used for these statistical comparisons. IC50 values for Tat-induced inhibition in specific 
vesicular [3H]DA uptake were determined from inhibition curves by nonlinear regression 
analysis using a one-site model with variable slope.  All statistical analyses were performed 
using SPSS, standard version 19.0 (SPSS Inc., Chicago, IL), and differences were considered 
significant at p < 0.05. 
4.3 RESULTS 
4.3.1 INVOLVEMENT OF PKC IN TAT-INDUCED DOWN-REGULATION OF DAT FUNCTION IN RAT 
STRIATAL SYNAPTOSOMES 
To determine whether the Tat-induced down-regulation of DAT function was 
mediated by activation of PKC, synaptosomes were preincubated with the PKC inhibitor 
BIM-I (1 µM) for 5 min prior to preincubation with Tat (0.7 µM) or amphetamine (20 µM) 
for additional 15 min. Amphetamine was used as a positive control, because the previous 
report has shown that amphetamine-induced down-regulation of DAT activity was blocked 
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by preincubation of BIM-I (Richards and Zahniser, 2009). As shown in Figure 4.1, 
amphetamine (F(3, 15) = 8.83, p < 0.01) or Tat (F(3, 15) = 8.28, p < 0.05) alone significantly 
reduced [3H]DA uptake, and preincubation of BIM-I completely blocked both amphetamine- 
and Tat-induced reductions.  
4.3.2 TAT PROTEIN DECREASED CELL SURFACE DAT EXPRESSION IN RAT STRIATAL 
SYNAPTOSOMES  
To determine if the Tat-induced decrease in [3H]DA uptake  of DAT function was 
attributed to a reduction in the plasma membrane of the DATs, DAT expression in 
subfractions was examined.  As shown in Figure 4.2, after exposure of synaptosomes to Tat 
(1 µM), DAT immunoreactivity was decreased by 46% in P3 fractions (t(3) = 3.22, p<0.05) 
and increased by 49% in P4 fractions (t(3) = 5.64, p<0.05) without changes in P2 fractions. 
To verify the Tat-induced decreases in P3 fractions, the Bmax of [3H]WIN 35,428 in P3 
fractions was determined. Figure 4.3 shows that 15 min preincubation of synaptosomes with 
Tat (1 µM) led to a significant decrease of the Bmax value by 64% (3.99 ± 0.6 pmol/mg 
protein) compared with the control [11.2 ± 1.3 pmol/mg protein; t(3) = 5.6, p<0.05, paired 
Student’s t test]. There was no change in the Kd value between Tat-treated and control 
samples (38.9 ± 8.7 and 33.9 ± 11.4 nM).     
4.3.3 INHIBITORY EFFECTS OF TAT ON VMAT-2 AND DAT FUNCTION 
To determine whether Tat differentially inhibited DAT and VMAT-2 function, the 
ability of Tat protein to inhibit vesicular [3H]DA uptake or synaptosomal [3H]DA uptake was 
measured.  As shown in Figure 4.4, 15 min preincubation of synaptosomes with Tat (1 µM) 
caused a 35 ± 1.8 and 26 ± 1.5% reduction in [3H]DA uptake into vesicles and 
synaptosomes, respectively.    
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To determine the concentration-dependent inhibitory effect of Tat on specific [3H]DA 
uptake into striatal vesicles, vesicular [3H]DA uptake was examined in the presence of 
various concentrations of Tat. Specific [3H]DA uptake was substantially inhibited by Tat 
(IC50 = 210 ± 19 nM; Figure 4.5). TBZ was used as a positive control for the [3H]DA uptake 
assay and had a IC50 value of 9.8 ± 0.7 nM.  Tat Cys22 was a negative control for the assay, 
which showed no inhibitory effect on vesicular [3H]DA uptake across the concentration 
range from 0.1 nM to 10 µM.   
4.4 DISCUSSION 
We have reported previously that Tat protein induced decrease of [3H]DA uptake in 
rat striatal synaptosomes (Zhu et al., 2009b). The current study investigated the mechanism 
of this Tat-induced impairment of DAT activity.  This study also determined the effect of Tat 
on VMAT-2 function. The results provide evidence that the Tat-induced decrease in DA 
uptake is ascribed to a DAT trafficking- and phosphorylation-dependent mechanism. Further, 
we demonstrated that Tat inhibited not only DAT activity but also VMAT-2 function. These 
findings provide new insight into understanding the molecular mechanisms of HIV-1 viral 
protein-induced dysfunction of DA neurotransmission in HIV-1 infected patients. 
The present results are in agreement with previous work showing that in vitro 
exposure of rat striatal synaptosomes to Tat protein leads to a decrease in DAT uptake 
function (Wallace et al., 2006; Zhu et al., 2009b).  In this study, while a PKC inhibitor, BIM-
I, alone had no effect on DA uptake, Tat (0.7 µM)-induced decrease (21%) in specific 
[3H]DA uptake was ablated by BIM-I. Similarly, preincubation of the synaptosomes with 
BIM-I completely blocked amphetamine-induced decrease (31%) in [3H]DA uptake, which 
is consistent with a previous report (Richards and Zahniser, 2009). Therefore, compared to 
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amphetamine, Tat produces a similar regulatory effect on DAT uptake function through a 
PKC-dependent mechanism. It has been well documented that exposure to amphetamine 
results in DAT internalization or reduced DA uptake in cell lines expressing DAT and 
synaptosomes (Chen et al., 2010).  Also, DAT shows a time-dependent, biphasic trafficking 
pattern in vitro and in vivo upon short- and long-exposure to amphetamine (Chen et al., 
2010). For example, rapid treatment (less than 1 min) of rat striatal synaptosomes with 
amphetamine increased DAT surface expression (Furman et al., 2009), whereas a prolonged 
stimulation (30-60 min) led to reductions of surface DAT (Gulley et al., 2002; Johnson et al., 
2005; Thwar et al., 2007), indicating that rapid amphetamine-induced DAT surface 
expression may contribute to amphetamine-induced DA efflux.  While the current results and 
previous studies (Cervinski et al., 2005; Gorentla and Vaughan, 2005; Richards and 
Zahniser, 2009) have demonstrated that amphetamine-induced reduction of DA uptake can 
be blocked by pretreatment of BIM-I, it was reported that amphetamine-induced reduction in 
surface DAT in human DAT-PC12 cells was not inhibited by BIM-I (Boudanova et al., 
2008), suggesting that amphetamine regulates DAT activity through a PKC-independent 
pathway. In contrast, this study shows that Tat decreased DA uptake via activation of PKC 
pathway. Importantly, we have demonstrated that the influence of Tat on DAT function 
involves a protein-protein interaction between Tat and DAT (Zhu et al., 2009b) and that Tat 
acts as an allosteric modulator of DAT rather than as either a reuptake inhibitor (e.g. cocaine) 
or a substrate releaser (e.g. amphetamine) (Zhu et al., 2011).  Allosterism has been shown to 
be responsible for the conformational transitions via substrate- and ligand-binding sites on 
the DAT (Shan et al., 2011).  Tat-induced inhibition of DA transporting may involve a 
change in the DAT conformation that requires DAT phosphorylation. Previous studies 
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suggest that Tat protein and amphetamine synergistically impair DAT function in vitro (Cass 
et al., 2003; Theodore et al., 2006) and in vivo (Kass et al., 2010); however, underlying 
mechanism(s) are unclear.  To investigate the synergistic effects of Tat and amphetamine on 
DAT function and trafficking will be an essential task in our future study.  
In the current study, exposure to Tat (0.7 µM) for 15 min decreased [3H]DA uptake 
activity in rat synaptosomes.  In general, Tat-induced decrease of DA transport could be 
accomplished in several manners: increased DAT protein degradation, decreased turnover 
rates of DAT, or changes in DAT trafficking on the cell surface expression without changes 
in total DAT immunoreactivity. To validate these potential mechanisms, first, we have 
demonstrated that a 15-min exposure to Tat1-86 induced a rapid and reversible decrease in 
Vmax of [3H]DA uptake without changes in total DAT levels (Zhu et al., 2009b), suggesting 
that Tat-induced reduction in Vmax of DA uptake is not caused by DAT degradation. Second, 
transporter turnover rate, which reflects the number of DA molecules transported per second 
per site (Lin et al., 2000), was determined and shown that 15-min exposure of synaptosomes 
to 1 µM Tat did not alter the ratio of Vmax for [3H]DA uptake/Bmax for [3H]WIN 35,428 
binding. This result provides evidence that Tat does not decrease the turnover rates of DAT 
(Zhu et al., 2009b).  The current results display that the levels of DAT immunoreactivity 
were increased by 49% in vesicle-enriched fractions (P4) and decreased by 46% in plasma 
membrane enriched fractions (P3) without changes in total synaptosomal fractions (P2) in 
Tat-exposed samples compared to the respective controls. These data indicate that exposure 
to Tat results in a redistribution of DAT from the cell surface to intracellular compartments 
(i.e. internalization) and that loss of DAT from the plasma membrane is responsible for the 
decrease in Vmax observed after Tat exposure.  
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The efficiency of DA transport depends on the number of DAT molecules expressed 
on the plasma membrane, which is regulated by a dynamic-trafficking mechanism (Zhu and 
Reith, 2008). This has been consistently reported  in a number of studies using cells 
expressing DAT (Saunders et al., 2000; Chi and Reith, 2003) and rat striatal synaptosomes 
(Chi and Reith, 2003; Zhu et al., 2005; Zhu et al., 2009a).  Changes in DAT dynamics in 
plasma membranes can be detected using either biotinylation assay (Zhu et al., 2005; Zhu et 
al., 2009a) or subfractionation method (Middleton et al., 2007). In the current study, a 49% 
decrease in DAT surface expression (P3) was not comparable to the magnitude (26%) of the 
decrease in Vmax for [3H]DA uptake in rat striatal synaptosomes demonstrated in our 
previous report (Zhu et al., 2009b). This result is also supported by [3H]WIN 35,428 binding 
experiment showing that the Bmax was decreased in P3 of Tat-treated samples compared to 
controls.  As reported in our previous studies, levels of the changes in DAT cell surface 
expression were less than (Zhu et al., 2009a) or similar (Zhu et al., 2005) to the magnitude of 
the changes in Vmax for [3H]DA uptake.  Trafficking of plasma membrane transporters is 
associated with changes in posttranslational modifications of the DAT protein, including 
phosphorylation states and protein-protein interactions (Sager and Torres, 2011).  Therefore, 
the current results infer that Tat-induced great decrease of DAT expression in plasma 
membranes could be regulated by both phosphorylation (i.e. PKC-dependent mechanism) 
and protein-protein interactions (e.g. allosteric modulation).  In contradiction with our 
results, 30-min exposure of PC12 cells expressing human DAT to 120 nM Tat1-86 increased 
(24%) DA uptake using measurement of the fluorescence ASP+, which was accompanied by 
a profound increase (177%) in plasma membranes and a minor decrease (14%) in 
cytoplasmic membranes compared to respective controls (Perry et al., 2010).  The 
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contrasting results might be due to differences in DAT expression models (rat synaptosomes 
versus a human DAT cell line), Tat concentration, exposure time and methodology.  Tat-
induced changes in DAT surface levels could arise from increased PKC-mediated 
endocytosis, decreased DAT recycling rates, or both.  Rat synaptosomes express DAT 
endogenously and have less surface DAT expression compared to DAT expressed in 
heterologous cells such as PC12 cells (Johnson et al., 2005; Boudanova et al., 2008). In 
addition, synaptosomes exhibit fast DAT recycling rates for basal DAT levels in plasma 
membranes, whereas the PC12 cells overexpressing DAT have slow DAT recycling rates 
(Johnson et al., 2005; Boudanova et al., 2008).  These differences may, at least in part, 
contribute to the contrasting results between the current study and the previous report (Perry 
et al., 2010).  Nevertheless, the results from Perry et al’s study demonstrate that increased 
membrane DAT may be a compensatory response to decreased transporting efficiency of 
individual DAT (Perry et al., 2010).         
Another important finding from this study is that Tat inhibited not only DAT function 
and trafficking but also VMAT-2 function. Although both DAT and VMAT-2 proteins are 
essential for the regulation of DA disposition in the synapse and cytosol, our data show that 
the inhibitory effects of Tat are more profound in VMAT2 protein than in DAT protein. 
Moreover, the potency of Tat for inhibiting synaptosomal [3H]DA uptake (IC50 = 3.1 µM) 
(Zhu et al., 2009b) is 15-fold higher than that for inhibiting vesicular [3H]DA uptake (IC50 = 
0.21 µM). Thus, VMAT-2 protein may play a more critical role in Tat-induced alterations of 
extracellular DA concentrations.  In the current study, the affinity of TBZ, a highly selective 
compound for VMAT-2 (Erickson et al., 1996) was about 20-fold greater than that of Tat 
protein. Interestingly, our recent study shows that the influence of Tat on DAT ligand 
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binding sites involves a protein-protein interaction and that a mutation of Tat (Cys22Gly) 
significantly attenuates Tat-induced inhibitory effects on DA transport (Zhu et al., 2009b).  
In addition to influencing DAT function, the current study demonstrates that this mutant of 
Tat (Cys22Gly) also attenuates Tat-induced decrease in VMAT-2 function. Together, these 
findings suggest that the residue (Cys22) of Tat may share a favorable inter-molecular 
interaction between Tat protein and human DAT (or VMAT-2). Furthermore, this result also 
suggests that Tat protein may cause synergistic effects on impairing DA neurotransmission 
by inhibition of both DAT and VMAT-2 proteins. At the functional level, plasma membrane 
DAT translocates substrates through a sodium- and chloride-dependent mechanism (Rudnick 
and Clark, 1993; Gu et al., 1994), whereas vesicular transporters use the proton 
electrochemical gradient across the vesicular membrane to transport monoamines (Johnson, 
1988).  Many DAT inhibitors have an ability to rapidly regulate VMAT-2 localization and 
function (Fleckenstein et al., 2009). For example, methamphetamine leads to releases of DA 
from synaptic vesicles into the cytosol via an interaction with the VMAT2 and by disruption 
of the vesicular proton gradient (Sulzer et al., 1995; Fleckenstein et al., 2007). Subsequently, 
available cytosolic DA is reversely transported by the DAT into the extracellular space 
(Sulzer et al., 1995).  Co-exposure to Tat and methamphetamine produces synergistic effects 
on impairing DA terminals (Theodore et al., 2006) and methamphetamine-mediated behavior 
(Kass et al., 2010). Thus, the current results provide a mechanistic basis to interpret the 
synergistic effects of Tat and methamphetamine.   
  HIV-1 associated dementia and neurocognitive disorder progress gradually over 
months or years. Such long time intervals are not practical or feasible for in vitro 
determination of long-term alteration of DAT function.  Hence, we investigated acute effects 
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of Tat exposure on DAT dynamics. Using this in vitro model, we have found that 15-min 
exposure of synaptosomes to Tat (1 µM) caused a reversible reduction of DA uptake, 
whereas 60-min Tat exposure greatly inhibited DA uptake that was not reversible (Zhu et al., 
2009b). It is possible that reduction of DA uptake and plasma membrane DAT in response to 
a short-term Tat exposure is a protective mechanism against the build-up of toxic levels of 
DA, whereas a long-term Tat exposure accelerates DAT degradation.  Excessive levels of 
cytosolic DA and its oxidative products can be toxic to dopaminergic neurons and are 
postulated to contribute to the development of HIV-associated dementia and neurocognitive 
disorders (Mosharov et al., 2009).  HIV-1 infection causes the hallmark decrease in CD4+ T 
cells, which results from programmed cell death, apoptosis (McCune, 2001). Tat protein 
released from infected cells can induce apoptosis in uninfected bystander T cells (Ma and 
Nath, 1997) or neurons (New et al., 1997) and these cells subsequently become toxic cells 
and can destroy other bystander cells (Campbell and Loret, 2009).  While the present study 
has provided evidence that in vitro exposure of rat synaptosomes to Tat functionally 
regulates DAT function and trafficking, it also indicates potential roles of Tat in dynamic 
regulation of DAT in vivo. Given that Tat can be absorbed by non-infected neurons, our 
results infer that Tat-induced decrease in DAT function and cell surface expression in this in 
vitro model may continue to produce long-term impairments of dopaminergic terminals in in 
vivo models.  Several studies have reported that continued presence of HIV-1 viral proteins 
may be not required for Tat-induced long-term process of neurotoxicity. For example, an 
exposure to Tat for a few minutes was sufficient for sustained releases of cytokines for 
several hours (Nath et al., 1999); following a single intraventricular injection of Tat in rats, 
progressive glial activation and macrophage infiltration could maintain for several days, 
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whereas Tat was undetectable in the brain a few hours after the injection (Jones et al., 1998).  
Further, an exposure of Tat for only milliseconds is adequate to induce prolonged 
depolarization in neurons (Magnuson et al., 1995). Therefore, it is possible that a transient 
exposure to Tat in dopaminergic target proteins, such as DAT, may share a similar “hit and 
run” phenomenon to initiate a cascade of events, leading to progressive neuropathogenesis, 
such as HIV-1 associated dementia (Wang et al., 2004).  
In conclusion, Tat protein exposure led to changes of DAT and VMAT2 function and 
expression in rat striatal synaptosomes. The Tat-induced reduction of DAT uptake function 
is mediated by DAT trafficking- and PKC-dependent mechanisms.  These findings may have 
important implication for preclinical studies of the role of DAT and VMAT-2 in drugs of 
abuse in HIV-1 infected individuals. Future studies will be necessary to investigate how 
DAT interacts with VMAT-2 to promote Tat-induced dysfunction of DA neurotransmission 
















































































Figure 4.1 PKC inhibition attenuated Tat- and d-amphetamine (AMPH)-induced reduction 
of [3H]DA uptake in rat striatal synaptosomes.  After pre-incubation of synaptosomes with 1 
µM BIM-I for 5 min, Tat (0.7 µM, A) or AMPH (20 µM, B) were added for another 15 min 
and subsequently all reagents were washed off, specific uptake of 5 nM [3H]DA uptake was 








































Figure 4.2 Tat protein decreased DAT cell surface expression. Rat striatal synaptosomes 
were incubated with or without Tat (1 µM). Subsequently, total synaptosomal fractions (P2), 
plasma membrane enriched fractions (P3), and vesicle-enriched fractions (P4) were prepared 
for western blot analysis. The same portion of P3 fraction were used in [3H]WIN 35,428 
binding assay (see Figure 4.3).  The levels of DAT immunoreactivity are increased in P4 and 
decreased in P3 without changes in P2 in Tat-exposed samples compared to the respective 








































































Figure 4.3 Tat protein decreased the specific [3H]WIN35,428 binding in plasma membrane 
enriched fraction. Rat striatal synaptosomes were incubated with or without Tat (1 µM), and 
then total synaptosomal fractions (P2), plasma membrane enriched fractions (P3) and 
vesicle-enriched fractions (P4) were prepared and used for the specific [3H]WIN35,428 























































































Figure 4.4 Inhibitory effects of Tat on synaptosomal [3H]DA uptake and vesicular [3H]DA 
uptake in rat striatum. Rat striatal synaptosomes were preincubated with or without Tat (1 
µM) for 15 min. Drug was then washed off, and specific synaptosomal and vesicular uptake 
of 0.1 µM [3H]DA uptake were measured. Tat inhibited the specific [3H]DA uptake into 
vesicles (A; via VMAT2) and synaptosomes (B; via DAT) by 35% and 26%, respectively, 
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Figure 4.5 Pharmacological profiles of vesicular [3H]DA uptake in rat striatum in the 
presence of Tat1–86, Tat Cys22, or tetrabenazine (TBZ, a VMAT2 inhibitor).  Striatal 
synaptosomes were preincubated with various concentrations of Tat1–86, Tat Cys22, or TBZ 
(0.1 nM–10 µM) at 34°C for 15 min followed by the addition of [3H]DA (final 
concentration, 0.1 µM) for 8 min. Tat Cys22 and TBZ were used as negative and positive 
controls, respectively.  Data are expressed as mean ± S.E.M. as percentage of control (CON) 
values (28,205 ± 1965 dpm) from five independent experiments performed in duplicate. 
Nonspecific [3H]DA uptake was determined in the presence of 10 µM nomifensine. All 









GENETICALLY EXPRESSED HIV-1 VIRAL PROTEINS ATTENUATE NICOTINE-
INDUCED BEHAVIORAL SENSITIZATION AND ALTER MESOCORTICOLIMBIC ERK 
AND CREB SIGNALING IN RATS3 
 
Abstract: The prevalence of tobacco smoking in HIV-1 positive individuals is 3-fold greater 
than that in the HIV-1 negative population; however, whether HIV-1 viral proteins and 
nicotine together produce molecular changes in mesolimbic structures that mediate 
psychomotor behavior has not been studied.  This study determined whether HIV-1 viral 
proteins changed nicotine-induced behavioral sensitization in HIV-1 transgenic (HIV-1Tg) 
rats. Further, we examined cAMP response element binding protein (CREB) and 
extracellular regulated kinase (ERK1/2) signaling in the prefrontal cortex (PFC), nucleus 
accumbens (NAc) and ventral tegmental area (VTA).  HIV-1Tg rats exhibited a transient 
decrease of activity during habituation, but showed attenuated nicotine (0.35 mg/kg, s.c.)-
induced behavioral sensitization compared to Fisher 344 (F344) rats. The basal levels of 
phosphorylated CREB and ERK2 were lower in the PFC of HIV-1Tg rats, but not in the 
NAc and VTA, relative to the controls. In the nicotine-treated groups, the levels of 
phosphorylated CREB and ERK2 in the PFC were increased in HIV-1Tg rats, but decreased 
in F344 animals. Moreover, repeated nicotine administration reduced phosphorylated ERK2 
in VTA of HIV-1Tg rats and in the NAc of F344 rats, but had no effect on phosphorylated
                                                            
3 Midde NM, Gomez AM, Harrod SB, Zhu J (2011) Genetically expressed HIV-1 viral proteins 
attenuate nicotine-induced behavioral sensitization and alter mesocorticolimbic ERK and CREB 
signaling in rats. Pharmacology, Biochemistry, and Behavior 98:587-597. PMCID: PMC3091851 
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CREB, indicating a region-specific change of intracellular signaling.  These results 
demonstrate that HIV-1 viral proteins produce differences in basal and nicotine-induced 
alterations in CREB and ERK signaling that may contribute to the alteration in psychomotor 
sensitization.  Thus, HIV-1 positive smokers are possibly more vulnerable to alterations in 
CREB and ERK signaling and this has implications for motivated behavior, including 
tobacco smoking, in HIV-1 individuals who self-administer nicotine.   
5.1 INTRODUCTION  
Tobacco smoking prevalence among HIV-1 positive population is 3-fold greater than 
that in HIV-1 negative population, according to Centers for Disease Control and Prevention 
(2007).  HIV-1 infected patients are more likely to become dependent on nicotine, and less 
likely to quit than HIV-1 negative individuals (Hershberger et al., 2004; Fuster et al., 2009; 
Nahvi and Cooperman, 2009).  There is an increasing body of clinical and experimental 
evidence that tobacco smoking is associated with a more rapid progression to AIDS (Nieman 
et al., 1993; Crothers et al., 2005; Furber et al., 2007; Zhao et al., 2010) and HIV-1 
associated dementia (Burns et al., 1996; Manda et al., 2010).  Considering that the HIV-1 
positive population exhibits a greater risk for tobacco-associated morbidity and mortality 
(Palella et al., 2006; Triant et al., 2007), there is a critical need to define the molecular 
mechanisms underlying the enhanced susceptibility to nicotine dependence in this 
population.    
HIV-1 infection is associated with a variety of neurological impairments that result, 
in part, from the presence of HIV-1 viral proteins, such as Tat and gp120.  Some of the 
neurological deficits caused by these viral proteins reflect an apparent dysfunction of the 
mesocorticolimbic dopamine (DA) system (Nath et al., 1987; Berger and Arendt, 2000; 
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Koutsilieri et al., 2002), the motivation pathway of the brain (Wise and Bozarth, 1987; 
Everitt and Robbins, 2005; Berridge, 2007).  Indeed, long-term viral protein exposure can 
accelerate damage in this DA system (Del Valle et al., 2000; Ferris et al., 2008; Hudson et 
al., 2010; Nath, 2010).  For example, a significant reduction in DA transporter (DAT) 
density in striatum was observed in HIV-1 positive patients (Wang et al., 2004; Chang et al., 
2008), and in vitro Tat and gp120 in vitro decreased the specific [3H]DA uptake in rat 
striatum (Wallace et al., 2006; Zhu et al., 2009).  Importantly, the use of addictive drugs by 
HIV-1 positive individuals results in greater neurological impairments relative to individuals 
who are infected with HIV-1 but do not abuse drugs (Del Valle et al., 2000; Ferris et al., 
2008; Hudson et al., 2010; Nath, 2010).  Furthermore, the mesocorticolimbic DA pathway is 
compromised in HIV-1 positive individuals that exhibit co-morbid drug abuse (Kumar et al., 
2009; Norman et al., 2009; Obermann et al., 2009).  The extent to which HIV-1 related viral 
proteins and drugs of abuse alter motivation in humans is not well understood.    
Our laboratory uses a rodent model to investigate the neurobehavioral and 
neurochemical changes induced by the combination of HIV-1 viral proteins and abused 
drugs.  Several approaches are utilized to study these viral proteins because experimental 
rodents cannot be infected with HIV-1: 1) in vitro exposure to Tat (Zhu et al., 2009), 2) 
direct microinjection of Tat into rat brain (Fitting et al., 2008; Harrod et al., 2008), 3) 
transgenic mice that express Tat protein (Kim et al., 2003; Duncan et al., 2008), and 4) HIV-
1 transgenic (HIV-1Tg) rats, which express HIV-1 viral proteins (Reid et al., 2001).  These 
models mimic different aspects of viral protein-induced neurotoxicity, although none of 
these models fully represent the spectrum of HIV-1 viral protein insult in humans (Nath, 
2010).  We are using the HIV-1Tg model in combination with basic behaviors that are 
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mediated by the mesocorticolimbic system.  This pathway organizes motivated behaviors 
that range various levels of complexity.  For example, psychomotor behavior, such as 
locomotor/exploratory activity, represents the integration of sensory and motor information 
(Wise and Bozarth, 1987; Berridge, 2007), whereas drug maintained responding is a 
combination of Pavlovian and operant conditioning processes (Rescorla, 1991; Robinson and 
Berridge, 2003; Everitt and Robbins, 2005), and is a relatively more complex form of 
motivated behavior.  Insult to this pathway produces significant changes in both types of 
responding (Kelly and Iversen, 1976; Roberts et al., 1977; Fink and Smith, 1980; Joyce and 
Koob, 1981; Koob et al., 1981; Kubos et al., 1987; Corrigall et al., 1992).   
Nicotine activates nicotinic acetylcholine receptors (nAChRs) located throughout the 
mesocorticolimbic DA system, specifically in the prefrontal cortex (PFC), nucleus 
accumbens (NAc) and ventral tegmental area (VTA) (Kita et al., 1992; Panagis and Spyraki, 
1996; Mansvelder et al., 2002; Laviolette and van der Kooy, 2004).  Nicotine increases DA 
levels in the NAc (Nisell et al., 1994b, a), and repeated nicotine treatment induces a 
progressive increase in psychomotor behavior, which represents the initiation of behavioral 
sensitization (Post, 1980; Clarke and Kumar, 1983b, a; Kalivas, 1995).  Accordingly, the 
locomotor stimulant properties of nicotine are blocked by lesion of mesolimbic DA neurons 
(Louis and Clarke, 1998) or by nicotinic receptor antagonists (Clarke and Kumar, 1983b; 
Corrigall et al., 1994).  The behavioral sensitization procedure is sensitive to behavioral 
changes produced by the psychostimulant effects of abused drugs, however, it is not a 
measure of drug reward (Wise and Bozarth, 1987; Robinson and Berridge, 1993; Berridge 
and Robinson, 1998).  This procedure was used in the present experiment to determine 
whether HIV-1 Tg rats exhibited deficits in locomotor sensitization to nicotine.  
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Furthermore,  HIV-1 viral proteins alter dopaminergic pathways that medaite behavioral 
sensitization.  For example, intra-accumbal or striatal Tat rats show decreased DAT activity 
in striatum (Maragos et al., 2002), decreased DA levels (Cass et al., 2003), and attenuated 
behavioral sensitization to cocaine (Harrod et al., 2008).  Moreover, HIV-1Tg rats show 
enhanced behavioral sensitization to methamphetamine (Liu et al., 2009; Kass et al., 2010).  
However, whether the combination of nicotine and HIV-1 viral proteins alters psychomotor 
behavior has not been investigated.        
The extracellular regulated protein kinase (ERK) and its downstream transcriptional 
signaling protein, the cyclic AMP response element-binding protein (CREB), appear critical 
for long-term adaptations in individuals who exhibit drug abuse (Berhow et al., 1996; 
Carlezon et al., 1998; Nestler, 2001; Girault et al., 2007).  ERK is one of the mitogen-
activated protein kinases involved in numerous cellular processes, including long-term 
neuronal plasticity and survival (Hetman and Gozdz, 2004; Subramaniam and Unsicker, 
2010).  Abundant evidence suggests that ERK is an essential component of the signaling 
pathways involved in synaptic plasticity and the long-term effects of drugs of abuse (Berhow 
et al., 1996; Valjent et al., 2006; Girault et al., 2007; Lu et al., 2009).  Two major isoforms of 
ERK, ERK1 and ERK2, are very similar in sequence (Yoon and Seger, 2006), but have 
distinct functions (Lloyd, 2006; Lu et al., 2009).  It has implicated that ERK2 is more 
strikingly changed than ERK1 in the long-term effects of drugs of abuse (Valjent et al., 
2005; Girault et al., 2007; Iniguez et al., 2010).  Moreover, acute nicotine treatment increases 
CREB phosphorylation in the NAc, striatum and VTA (Walters et al., 2005; Jackson et al., 
2009).  Chronic nicotine exposure in mice decreases CREB phosphorylation in the NAc, 
whereas nicotine withdrawal increases CREB phosphorylation in the VTA (Brunzell et al., 
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2003).  In addition, the levels of CREB and phosphorylated CREB are decreased in the 
cortex and amygdala after withdrawal from repeated nicotine administration (Pandey et al., 
2001).  Thus, long-term nicotine exposure leads to neural adaptations in intracellular 
signaling through the changes of ERK and CREB signaling (Brunzell et al., 2003; Brunzell 
et al., 2009; Mineur et al., 2009).  To date, the effects of HIV-1 viral proteins on ERK and 
CREB signaling are unknown. 
It was hypothesized that the combination of HIV-1 viral proteins and nicotine would 
alter nicotine-induced behavioral sensitization, and would also produce changes in the 
expression of intracellular signaling proteins.  To test these hypotheses, HIV-1Tg rats and 
Fischer 344/NHsd (F344) non-transgenic, wild-type control rats were used to determine if 
genetically expressed HIV-1 viral proteins produce altered nicotine-induced behavioral 
sensitization.  To investigate a potential mechanism, the modulation of ERK and CREB 
signaling following repeated nicotine exposure was determined in the PFC, NAc and VTA 
regions of the mesocorticolimbic DA system.  
5.2 MATERIALS AND METHODS  
5.2.1 SUBJECTS 
Male HIV-1Tg Fisher 344/NHsd rats and age-matched male nontransgenic Fisher 
344/NHsd rats were obtained from Harlan Laboratories, Inc. (Indianapolis, IN).  The HIV-
1Tg rat model carries a gag-pol-deleted HIV-1 provirus regulated by the viral promoter 
expressing seven of the nine HIV-1 viral proteins (Reid et al., 2001).  Since the HIV-1Tg rat 
model is developed from F344 strain, F344 rats were used as the control animals.  Rats at 
age of 7-9 weeks arrived in the animal care facilities and were pair housed throughout the 
experiment.  Rodent food (Pro-Lab Rat, Mouse Hamster Chow #3000) and water were 
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provided ad libitum.  The colony was maintained at 21 ± 2 °C, 50 ± 10% relative humidity 
and a 12L:12D cycle with lights on at 0700 h (EST).  The animals were weighed daily.  The 
animals were maintained according to the National Institute of Health (NIH) guidelines in 
AAALAC accredited facilities.  The experimental protocol was approved by the Institutional 
Animal Care and Use Committee (IACUC) at the University of South Carolina. 
5.2.2 DRUGS 
Nicotine hydrogen tartrate salt was purchased from Sigma-Aldrich (St. Louis, MO, 
USA) and dissolved in sterile saline (0.9% sodium chloride).  Nicotine was prepared 
immediately prior to injection.  The nicotine solution was neutralized to pH 7.0 with 
NaHCO3.  Nicotine (0.35 mg/kg, freebase) was administered subcutaneously (s.c.) in a 
volume of 1 ml/kg once daily for 20 days.   
5.2.3 LOCOMOTOR ACTIVITY PROCEDURE 
5.2.3.1 BEHAVIORAL APPARATUS  
The activity monitors were square (40 × 40 cm) locomotor activity chambers 
(Hamilton-Kinder Inc., Poway, CA) that detect free movement of animals by infrared 
photocell interruptions.  This equipment uses an infrared photocell grid (32 emitter/ detector 
pairs) to measure locomotor activity.  The chambers were converted into round (~ 40 cm in 
diameter) compartments by adding clear Plexiglas inserts; photocell emitter/detector pairs 
were tuned by the manufacturer to handle the extra perspex width.  Total horizontal activity 
represents all beam breaks in the horizontal plane.  All activity monitors were located in an 
isolated room.   
5.2.3.2 HABITUATION 
Rats in the HIV-1Tg-Saline (HIV1Tg-Sal; n = 8/group), HIV-1Tg-Nicotine (HIV-
1Tg-Nic; n = 8/group), F344-Saline (F344-Sal; n = 8/group) and the F344-Nicotine (F344-
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Nic; n = 8/group) groups were habituated to the locomotor activity chambers for two 60-min 
sessions, once/day.  No injections were administered on the habituation days.  Twenty four 
hours after the second habituation session, all rats were habituated to the chambers for 30 
min prior to injection, and then injected (s.c.) with saline and placed into the activity 
chambers for 60-min to measure baseline activity. 
5.2.3.3 PRE-INJECTION HABITUATION AND NICOTINE-INDUCED BEHAVIORAL SENSITIZATION  
The behavioral sensitization procedure began 24 hours after the saline baseline 
measurement.  First, all rats received a 30-minute habituation period in the testing chamber 
prior to nicotine (0.35 mg/kg) or saline injection as previously reported (Addy et al., 2007).  
This was done so that the onset of nicotine’s effects did not overlap with the period that rats 
showed the most exploratory behavior in the chamber, which was during the first 15 min.  
Previous research indicates that control rats exhibit asymptotic levels of within-session 
habituation by 20 to 30 min, according to similar procedures and use of the same automated 
chambers (Harrod et al., 2008; Harrod and Van Horn, 2009).  Rats were administered 
nicotine or saline subcutaneously every day for a total of 20 days.  Locomotor activity was 
assessed every other day, i.e., on days 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19, for 60 min.  On 
alternate days, nicotine and saline administered in the home cage.   
5.2.4 WESTERN BLOT ANALYSIS 
Following completion of the behavioral study, brains were removed by rapid 
decapitation 4 hours after the last injection on day 20.  Brains were placed in ice-cold PBS 
and dissected in a chilled matrix.  PFC, NAc and VTA were dissected and immediately 
sonicated on ice in a homogenization buffer containing 20 mM HEPES, 0.5 mM EDTA, 0.1 
mM EGTA, 0.4 M NaCI, 5 mM MgCI2, 20% glycerol, 1 mM PMSF, phosphatase inhibitor 
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cocktails I (Sigma, P2850) and protease inhibitors (Sigma, P8340).  Samples were 
centrifuged at 12000 g for 15 min.  The supernatant was stored at -80°C.   Protein 
concentrations were determined in duplicate using Bio-Rad DC protein detection reagent.  
Proteins (30, 10 or 15 µg per sample in the PFC, NAc or VTA) were loaded for ERK, 
phosphorylated ERK (pERK), CREB, phosphorylated CREB (pCREB) and Tyrosine 
Hydroxylase (TH) immunoreactivity. 
Proteins were separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) for 90 min at 150 V, and subsequently transferred to Immobilon-P transfer 
membranes (Cat # IPVH00010, 0.45 µm pore size; Millipore Co., Bedford, MA) in transfer 
buffer (50 mM Tris, 250 mM glycine, 3.5 mM SDS) using a Mini Trans-Blot Electrophoretic 
Transfer Cell (Bio-Rad, Hercules, CA) for 110 min at 72 V.  Transfer membranes were 
incubated with blocking buffer (5% dry milk powder in PBS containing 0.5% Tween 20) for 
1 h at room temperature followed by incubation with primary antibodies diluted in blocking 
buffer overnight at 4 ºC.  Antisera against ERK½ (V114A, Promega, Madison, WI) and 
pERK½  (SC-16982R, Santa cruz biotechnology, inc, Santa Cruz, CA) were used at a 
dilution of 1:2000 and 1:1000, respectively.  Anti-CREB (9104, Cell signaling, Danvers, 
MA) and anti-pCREB (9196, Cell signaling, Danvers, MA) antibodies were used at a 
dilution of 1:1000 and 1:500, respectively.  Anti-TH (2792) was diluted 1:2000 (Cell 
signaling, Danvers, MA).  Blots were washed 5 min × 5 times with wash buffer (PBS 
containing 0.5% Tween 20) at room temperature, and then incubated for 1 h in affinity-
purified, peroxidase-labeled, anti-rabbit IgG (1:10000 for  ERK½, 1:5000 for pERK½, 
1:20000 for TH, Jackson ImmunoResearch, West Grove, PA) and 1:2000 anti-mouse IgG 
(7076, Bio-Rad, Hercules, CA) in blocking buffer for 1 h at room temperature.  Blots on the 
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transfer membranes were detected using enhanced chemiluminescence and developed on 
Hyperfilm (ECL-plus; Amersham Biosciences UK Ltd., Little Chalfont Buckinghamshire 
UK).  After detection and quantification of these proteins, each blot was stripped in 10% of 
Re-blot plus mild antibody stripping solution (CHEMICON, Temecula, CA) for 20 min at 
room temperature and reprobed for detection of β-tubulin (sc-9104, Santa cruz 
biotechnology, inc, Santa Cruz, CA).  β-tubulin was used to monitor protein loading among 
samples.  Multiple autoradiographs were obtained using different exposure times, and 
immunoreactive bands within the linear range of detection were quantified by densitometric 
scanning using Scion image software (Scion Corp., Frederick, MD).      
5.2.5 DATA ANALYSES 
 The data are presented as mean values ± standard error of the mean (S.E.M.).  In 
order to analyze the effects of nicotine exposure on body weight gain, the body weights of 
the rats were expressed as a percentage of the body weights on the day prior to nicotine 
injection.  The effect of nicotine administration on body weight gain was analyzed with a (2 
× 2 × 20) mixed factorial analysis of variance (ANOVA), with genotype (HIV1-Tg or F344) 
and treatment (nicotine or saline) as the between-subjects factors, and day as the within-
subjects factor.  A genotype × day × time (2 × 2 × 12) mixed factorial ANOVA was used to 
analyze data from the 2 habituation days, and a genotype x time (2 × 12) factorial ANOVA 
was conducted on the saline baseline day.  The pre-injection habituation part of the 
experiment was analyzed using a genotype × treatment × day × time (2 × 2 × 10 × 12) 
ANOVA.  The effect of repeated nicotine injection on total horizontal activity was analyzed 
using a genotype × treatment × day × time (2 × 2 × 10 × 12) factorial ANOVA, with 
genotype and treatment as between-subjects factors, and day and time as within-subjects 
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factors.  To determine the effects of repeated nicotine administration on the activity of 
signaling proteins (ERK, CREB and TH), separate genotype x treatment (2 × 2) factorial 
ANOVAs were performed on the data from the PFC, NAc, and VTA.  Simple effect 
comparisons were made for post hoc analyses.  All statistical analyses were performed using 
SPSS (standard version 18.0, Chicago, IL) and differences were considered significant at p < 
0.05.  
5.3 RESULTS 
5.3.1 EFFECT OF NICOTINE ON BODY WEIGHT 
Daily body weights were analyzed using a genotype × treatment × day ANOVA.  
There were significant main effects of genotype (F(1,28) = 25.71; p < 0.001) and day 
(F(19,532) = 384.28; p < 0.001), indicating that HIV-1Tg rats weighed less than F344 
controls, and that all animals gained weight over days.  Body weight gain across days was 
not different between HIV-1Tg rats and F344 rats (F(19,532) = 1.24; p = 0.22): these groups 
showed 11 and 12% increase in weight gain from day 1 to day 20, respectively (Figure 5.1).     
5.3.2 HABITUATION, PRE-INJECTION HABITUATION, AND NICOTINE-INDUCED LOCOMOTOR 
ACTIVITY IN HIV-1TG AND F344 RATS  
Habituation and Saline Baseline 
Animals were habituated to the chambers for two days, 60 min per day.  The total 
horizontal activity that occurred during the two habituation days is shown on Figures 5.2A 
and 2B.  A genotype × day × time ANOVA (2 × 2 × 12) revealed main effects of day (F(1, 
30) = 55.95, p < 0.001) and time (F(11, 330) = 147.6, p < 0.001), and a significant genotype 
× day × time interaction (F(11, 330) = 2.14, p < 0.05).  Both genotypes showed the most 
activity at the beginning of the habituation session, and the activity decreased over the 30-
min period, and both groups of rats were at asymptote for the remaining 30 min of the 
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session.  HIV-1Tg rats exhibited less locomotor activity than did F344 rats in the first 30 min 
of the first habituation session (p < 0.01 Bonferroni t-test), and this is observed as a 
downward, and leftward shift in the habituation curve (Figure 5.2B).  No significant 
differences in total horizontal activity during second habituation session were detected (Fig. 
5.2B).  On the third day, total horizontal activity was recorded for all groups after a saline 
injection to determine baseline activity prior to the induction of sensitization phase of the 
experiment.  The genotype × time ANOVA revealed a main effect of time (F(11, 330) = 
41.77, p < 0.001), and a genotype × time interaction (F(11, 330) = 2.41, p < 0.05).  No main 
effect of genotype was found.  In general, both genotypes showed lower activity during the 
first 5 min of the saline baseline day, acquired asymptotic levels of activity more quickly, 
and showed a lower asymptote compared to that of the habituation sessions (Fig. 5.2C).  
Within the first 30 min period, the F344 habituation curve crosses and slightly goes below 
that of the HIV-1Tg curve.  The habituation curve crosses again at minute 30, and this was 
observed again at the end of the session within the last 30 min (data not shown).  None of the 
comparisons indicated differences between the HIV-1Tg and F344 rats (all p >.05). 
Pre-injection habituation 
 Animals were placed into locomotor chambers for 30 min prior to the activity 
measurement to produce within-session habituation of activity prior to nicotine or saline 
injection.  Total horizontal activity during the 30 min habituation period across the 19-day 
treatment was recorded and is shown in Figure 5.3A.  A mixed-factor genotype × treatment × 
day × time ANOVA (2 × 2 × 10 × 12) revealed main effects of treatment (F(1, 28) = 4.76, p 
< 0.05), day (F(9, 252) = 9.15, p < 0.05), time (F(5, 140) = 705.56, p < 0.05) and a 
significant day × treatment interaction (F(9, 252) = 2.74, p < 0.01).  There was no main 
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effect of genotype and there were no significant interactions containing this factor.  The 
treatment × day interaction indicates that, regardless of genotype, animals treated with 
nicotine show increased activity during the pre-injection habituation measures as the number 
of habituation/injection days increased.  To test this, activity from the first and last pre-
injection habituation days were compared using a within-subjects comparison of the saline 
(HIV-1Tg Sal and F344 Sal) and nicotine (HIV-1Tg Nic and F344 Nic) treated groups.  The 
saline treated rats showed activity counts of 652.6 (± 39.3) and 586.4 (± 20.3) on days 1 and 
19, respectively; no change in pre-injection habituation activity was observed (F(1, 15) = 
2.6, p > 0.05).  The nicotine treated animals exhibited 640.3 (± 29.9) and 764.6 (± 35.5) 
activity counts on days 1 and 19, respectively, and this increase in locomotor activity during 
pre-injection habituation sessions was significant (F(1, 15) = 25.0, p < 0.001).  These data 
indicate that animals injected with nicotine, but not saline, exhibit a significant increase in 
activity during the pre-injection observation.   
Nicotine-induced behavioral sensitization 
To determine the effect of HIV-1 viral proteins on nicotine-mediated locomotor 
sensitization, we measured horizontal activity following administration of nicotine (0.35 
mg/kg, s.c.) or saline in HIV-1Tg and F344 rats (Fig. 5.3B).  A genotype × treatment × day × 
time ANOVA revealed significant main effects of genotype (F(1, 27) = 4.37, p < 0.05), 
treatment (F(1, 27) = 965.71, p < 0.001), day (F(9, 243) = 23.52, p < 0.001) and time (F(11, 
297) = 536.04, p < 0.001).  A significant treatment × day interaction (F(9, 243) = 37.40, p < 
0.05) was found, indicating that repeated nicotine injection produced behavioral 
sensitization.  Rats treated with saline exhibited decreased activity across treatment days, 
from a mean (±S.E.M.) of 357 (±27) activity counts on day 1, to 245 (±32) on day 19.  
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Nicotine treated rats exhibited 763 (±28) activity counts on day 1, but showed increased 
locomotor counts of 1287 (±33) on day 19.  The genotype × treatment (F(1, 27) = 4.40, p < 
0.05) and genotype × day (F(9, 243) = 2.76, p < 0.05) interactions indicate that genotype 
significantly interacted with the effects of repeated nicotine administration.  The pattern of 
nicotine-induced sensitization was similar for the HIV-1Tg and F344 rats following the first 
ten nicotine injections; however, the nicotine-induced behavioral sensitization was attenuated 
in HIV-1Tg rats compared to F344 rats during treatment days 11-19.  The HIV-1Tg rats 
showed decreased nicotine-induced activity on four of the remaining five nicotine behavioral 
assessments, thus suggesting that transgenic animals do not acquire the same magnitude of 
nicotine-induced behavioral sensitization. 
  A genotype × treatment × day ANOVA was conducted on the first and final 
injection days to determine if HIV-1Tg rats exhibited attenuated nicotine-induced behavioral 
sensitization (Figures. 5.4A and 4B).  There were significant main effects of genotype 
(F(1,28) = 6.27; p < 0.05), treatment (F(1,28) = 192.05; p < 0.001) and day (F(1,28) = 14.97; 
p < 0.01).  A significant genotype × day interaction (F(1,28) = 5.29; p < 0.05) and a 
significant treatment × day interaction (F(1,28) = 40.96; p < 0.001) were found.  On day 1, 
the HIV-1Tg and F344 rats in nicotine-treated groups exhibited more activity than their 
saline controls (p < 0.001; p < 0.001, Bonferroni t-test, respectively).  No differences 
between the HIV-1Tg-Nic and F344-Nic groups were observed (p > 0.05).  Similarly, there 
were no differences between HIV-1Tg-Sal and F344-Sal groups on day 1 (p > 0.05).  On day 
19, HIV-1Tg and F344 rats injected with nicotine displayed greater activity compared to 
their saline controls (p < 0.001), however, both groups showed enhanced activity following 
repeated nicotine injection relative to day 1 (F(1,6) = 136.5;  p< 0.001), and day 19 (F(1,7) = 
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98.8; p < 0.001, respectively).  The HIV-1Tg-Nic group, however, exhibited less locomotor 
activity relative to the F344-Nic group (p < 0.01), suggesting that the HIV-1Tg rats exhibited 
attenuated psychomotor sensitization relative to the F344 rats.   
The time course data from Day 1 and Day 19 are illustrated in Figures 5.4C and 4D.  
Figure 5.4C shows that rats treated with nicotine and saline had the same amount of activity 
in the first five min of the session, and that nicotine injected rats showed more activity than 
did the rats administered saline.  Figure 5.4D, which represents day 19, clearly shows that 
animals treated with nicotine exhibited higher activity counts in the first 5 min relative to the 
saline groups, and although both groups showed within-session habitua-tion, animals in the 
nicotine conditions exhibited higher activity counts throughout the remainder of the hour.  
Furthermore, HIV-1Tg rats treated with nicotine showed less activity than the F344 rats 
treated with nicotine throughout the remainder of the hour measurement.   
5.3.3 LEVELS AND ACTIVITY OF ERK AND CREB SIGNALING PROTEINS IN HIV-1TG AND 
F344 RATS 
To determine whether the nicotine-induced behavioral change is associated with 
mesocorticolimbic DA signaling, we examined the effects of repeated nicotine 
administration on the levels and the phosphorylation state of CREB and ERK in the PFC, 
NAc and VTA from the HIV-1Tg and F344 rats used in the behavioral experiment.   
Prefrontal Cortex (PFC) 
Separate two-way ANOVAs were performed to determine the effect of nicotine on 
the levels and phosphorylation state of the signaling proteins.  As shown in Figure 5.5, no 
significant differences in total CREB, ERK1, ERK2 and TH were found in the PFC among 
the groups.  With respect to the ratio of pCREB /β-tubulin, a main effect of genotype (F(1, 
27) = 4.34, p < 0.05) and a significant genotype × treatment interaction (F(1, 27) = 9.47, p < 
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0.05) were found.  Post hoc analysis revealed that the ratio of pCREB /β-tubulin was lower 
in the HIV-1Tg rats than that in the F344 rats in saline-control groups (F(1, 13) = 5.64, p < 
0.05).  The level of pCREB was greater in the nicotine-treated HIV-1Tg group than that in 
the saline-treated HIV-1Tg group (F(1, 13) = 4.69, p < 0.05).  In contrast, pCREB levels 
were decreased in the nicotine-treated F344 group compared to the saline-treated F344 group 
(F(1, 13) = 4.31, p < 0.05).   
With respect to the ratio of pERK2/β-tubulin in the PFC, a main effect of genotype 
(F(1, 27) = 4.32, p < 0.05) and a significant genotype × treatment interaction were found 
(F(1, 27) = 8.81, p < 0.05).  Post hoc analysis revealed that the ratio of pERK2/β-tubulin in 
the PFC was lower in HIV-1Tg rats than that in F344 rats in saline-treated group (F(1, 13) = 
13.2, p < 0.05).  Nicotine increased the ratio in HIV-1Tg rats compared to the saline-treated 
group (F(1, 13) = 6.64, p < 0.05).  There was a trend toward a decrease in the ratio of 
pERK2/β-tubulin in F344 rats after repeated nicotine injection (F(1,13) = 3.31; p = 0.07).  
The ratio of pERK2/β-tubulin was greater in HIV-1Tg-Nic group than that in F344-Nic 
group (p < 0.05).   
Nucleus Accumbens (NAc) 
There were no changes in total and phosphorylated CREB, in total ERK and pERK1, 
or in the levels of TH observed in NAc of HIV-1Tg and F344 rats following nicotine or 
saline injection.  With respect to ratio of pERK2/β-tubulin, the two-way ANOVA revealed a 
significant main effect of treatment (F(1, 27) = 5.31, p < 0.05), but neither the main effect of 
genotype nor the genotype × treatment interaction was significant (Fig. 5.6).  Repeated 
nicotine administration decreased the ratio of pERK2/β-tubulin in F344 rats (F(1, 14) = 7.05, 
p < 0.05), but not in the HIV-1Tg rats (F(1.14) = 0.51, p > 0.05). 
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Ventral Tegmental Area (VTA)  
There was no change in total and phosphorylated ERK and CREB, or in the levels of TH 
observed in the VTA following nicotine administration.  Regarding the ratio of pERK2/β-
tubulin, two-way ANOVA revealed a significant main effect of treatment (F(1, 27) = 4.45, p 
< 0.05), but neither the main effect of genotype nor the genotype × treatment interaction was 
not significant (Fig. 5.7).  Repeated nicotine administration produced a decreased ratio of 
pERK2/β-tubulin in HIV-1Tg rats (F(1, 14) = 6.74, p < 0.05), but not in the F344 rats 
(F(1.14) = 0.34, p > 0.05).   
5.4 DISCUSSION 
The present findings demonstrate that genetically expressed HIV-1 viral proteins alter 
the sensitivity of the locomotor effects of repeated nicotine administration.  HIV-1Tg rats 
exhibited diminished locomotor activity during habituation to a novel context and showed an 
attenuation of nicotine-induced behavioral sensitization.  Importantly, the basal levels of 
pCREB and pERK2 in the PFC were lower in the HIV-1Tg saline group compared to F344 
saline controls.  Following repeated nicotine administration, the levels of pCREB and 
pERK2 in PFC were decreased in F344 rats, but increased in HIV-1Tg rats, suggesting 
opposite effects of nicotine on these phosphorylated signaling proteins.  In addition, repeated 
nicotine administration decreased pERK2 levels in the NAc of F344 rats and this effect was 
also observed in the VTA of HIV-1Tg rats.  Thus, HIV-1 viral protein-induced alterations in 
the CREB and ERK signaling pathway in the mesocorticolimbic DA system appear to have 
played a role in the locomotor effects of repeated nicotine in HIV-1Tg rats.     
Regarding the behavioral portion of the experiment, we observed that HIV-1Tg rats 
exhibited alterations in locomotor activity during both the habituation and behavioral 
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sensitization phases of the experiment.  First, the transgenic rats showed less activity during 
day 1 of habituation compared to F344 rats, indicating that the novelty of the initial context 
exposure produced less activity in the transgenics relative to control rats.  This difference in 
habituation between the HIV-1Tg and F344 rats was transient, as the transgenic rats did not 
continue to exhibit the blunted locomotor response, relative to F344 controls, on either day 2 
of habituation or on the saline baseline measure.  A recent study reported HIV-1Tg rats 
exhibited less rearing and head movement activity compared to F344 rats following repeated 
saline injections (Liu et al., 2009), but these differences did not reach significance in another 
report (Kass et al., 2010).  The lower baseline activity exhibited by HIV-1Tg rats in the 
present study and reported by Liu et al. (2009) appear to be the result of manipulation of 
dopaminergic system by genetically expressed viral proteins (Fink and Smith, 1980).  
Indeed, HIV-1Tg rats exhibited increased expression of D1 receptors in the PFC (Liu et al., 
2009) and a decrease in DAT mRNA (Webb et al., 2010).  These studies are consistent with 
clinical studies showing a significant reduction of DAT density in the putamen and ventral 
striatum in HIV-1 infected patients (Wang et al., 2004; Chang et al., 2008).  In addition, D1 
expression has been reported to be negatively correlated with baseline locomotor activity 
observed in D1 receptor-deficient mice (El-Ghundi et al., 2010).  Thus, our behavioral data 
indicate that the attenuated habituation curve in HIV-1Tg rats is related to neural adaptations 
produced by HIV-1 viral proteins, and that this transient effect represents an attenuation of 
activity in response to the novelty of the locomotor activity chambers.  
The induction of nicotine-induced behavioral sensitization was altered in transgenic 
rats as well.  In this study, enhanced locomotor activity was observed in both genotypes 
across days following repeated nicotine administration.  Although no difference in acute 
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nicotine-induced activity between the two genotypes was observed on day 1, the HIV-1Tg 
group displayed reduced nicotine-induced locomotor activity during the later days, i.e., 13-
19, relative to the nicotine-treated F344 group.  Thus, although transgenic rats showed a 
blunted response to repeated nicotine exposure during the induction of sensitization, those 
animals did not exhibit a deficit in developing behavioral sensitization.  Rather, HIV-1Tg 
rats exhibited less sensitivity to the repeated effects of nicotine, and this deficit may 
contribute to an alteration in nAChR-mediated dopamine neurotransmission.  In accord with 
these behavioral data, we recently found that HIV-1Tg rats had lower IC50 values for 
[3H]nicotine binding with 5-fold rightward shift of the nicotine concentration curve, 
compared to F344 controls (unpublished data).  Similarly, previous research showed that 
intra-accumbal Tat infusion attenuated cocaine-induced behavioral sensitization in rats 
(Harrod et al., 2008), suggesting that the viral protein Tat is involved in the altered 
behavioral response to psychostimulant drugs.  Together, the results indicate that the HIV-
1Tg rats are a pertinent model to investigate how chronic exposure to viral proteins and 
nicotine alter dopaminergic pathways that mediate motivated behavior.   
Notably, although behavioral sensitization is a sensitive measure for the influence of 
psychostimulants on the mesocorticolimbic system (Berridge, 2007), it does not measure 
drug reward.  Thus, predictions regarding cigarette smoking in HIV-1 positive individuals 
are limited.  Given that two behavioral models of viral protein exposure produced diminished 
psychostimulant-induced behavioral sensitization (Harrod et al., 2008), it is suggested that 
cigarette smoking by HIV-1 positive individuals will produce alterations in motivated 
behavior due to the interplay of nicotine exposure and HIV viral proteins within the 
mesocorticolimbic DA system.   
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Previous research suggests the possibility that the sensitization of one type of 
behavior, like rearing, could result in the decrease of another behavior, such as horizontal 
activity (Iwamoto, 1984; Jerome and Sanberg, 1987; Ksir, 1994; Reid et al., 1998).  That the 
attenuation of total horizontal activity exhibited by the HIV-1Tg rats was diminished in 
response to the emergence of a competing behavior like rearing or stereotypy, however, is 
not likely.  First, our automated activity chambers measure rearing as all beam breaks in the 
vertical plane.  In the present experiment, there were no effects or interactions with the factor 
of genotype so the data are not shown; however, animals progressively exhibited 
sensitization and both genotypes showed asymptotic levels by day 7.  Thus, rearing did not 
emerge on days 11-19, which corresponds to the treatment days that transgenic rats exhibited 
less nicotine-induced total horizontal activity.  Although nicotine-induced sensitization of 
stereotypy has been reported (Reid et al., 1998), it is not a consistent finding (Jerome and 
Sanberg, 1987; Ksir, 1994; Harrod et al., 2004; Harrod et al., 2008).  We did not use 
observational procedures in the present experiment, so the levels of nicotine-induced 
stereotypy were not determined.  Our previous studies, which used a combination of 
automated and observational procedures, show that repeated nicotine or cocaine injection 
induced sensitization of horizontal activity and rearing incidence, but not of stereotypy 
(Harrod et al., 2004; Harrod et al., 2008).  It is unlikely that the attenuation of total horizontal 
activity observed for the HIV-1Tg rats is attributable to an emergence of stereotypic 
behavior. 
The present results show that animals injected with nicotine, regardless of genotype, 
exhibited increased locomotor activity during pre-injection habituation, which was 
particularly evident on days 13-15.  Rats in the saline control groups showed steady activity 
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across the 19 day period.  The increase in activity in the nicotine treated groups likely 
represents drug-induced conditioned hyperactivity, which is well documented to be mediated 
by Pavlovian conditioning processes (Anagnostaras and Robinson, 1996; Bevins and 
Palmatier, 2003).  Repeated psychostimulant injection within the same context allows for 
contextual cues to function as a conditional stimulus, and the drug effect, e.g., hyperactivity, 
to act as an unconditional stimulus (Anagnostaras and Robinson, 1996).  In the present 
experiment, repeated context-nicotine pairings support the standard associative model 
described above, and exposure to the chamber prior to daily drug injection represents 
presentation of the conditional stimulus, or the context alone, without the influence of the 
unconditional stimulus.  Our results indicate that after being placed in the context, 
hyperactivity, which is similar to the unconditional stimulus effects of repeated nicotine, was 
observed and there were no effects of genotype on this effect.   
The second part of the experiment determined levels of transcriptional factors 
throughout the mesocorticolimbic DA system in nicotine sensitized HIV-1 rats relative to 
F344 controls.  First, HIV-1Tg-saline rats exhibited lower basal levels of pCREB and 
pERK2 in the PFC, but not in the VTA or NAc, compared to F344-saline controls.  These 
findings suggest that viral proteins produced a neurobiological adaptation in ERK and CREB 
signaling in the PFC.  The observed changes in signaling have implications for the 
functionality of the mesocorticolimbic DA system.  For example, neuronal firing elicits ERK 
activity in the brain of rats (Davis et al., 2000; Thiels et al., 2002; Ying et al., 2002), whereas 
blocking ERK activity decreases the firing rate of DA neurons (Iniguez et al., 2010).  
Increased tonic release of DA enhances ERK activity, which is attenuated in DA D1 receptor 
mutant mice (Chen and Xu, 2010).  Further, deletion of DA D1 receptors in mice produces 
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higher pCREB levels in the striatum (El-Ghundi et al., 2010), suggesting that CREB 
phosphorylation is stimulated by DA D1 receptor activation.  ERK activation is coupled to 
activation of CREB (Nakayama et al., 2001; Ying et al., 2002) and, in turn, supports adaptive 
processes such as long-term potentiation and psychostimulant-induced sensitization (Ying et 
al., 2002; DiRocco et al., 2009).  It has been reported that Tat, gp120 and other viral proteins 
have higher expression in the PFC compared to other brain regions of HIV-1Tg rats (Peng et 
al., 2010).  Thus, the lower basal levels of pERK2 and pCREB could contribute to the 
differences in DA D1 receptor expression that was previously reported between HIV-1Tg 
rats and the F344 controls (Liu et al., 2009).  Moreover, although the regional high 
expression of these viral proteins may contribute to the PFC-specific changes of pERK2 and 
pCREB, it is also possible that these signaling proteins in PFC are more sensitive to HIV-1 
viral protein insult.  Together, the molecular data show that the basal levels of particular 
transcriptional factors, which are implicated in the regulation of mesocorticolimbic function, 
are altered in HIV-1Tg animals.    
  Repeated nicotine administration significantly decreased pCREB in the PFC of 
F344-nicoitne rats compared to F344-saline group.  Although delivering chronic nicotine 
through drinking water increased the ratio of pCREB/CREB in the PFC in C57BI/6J mice 
(Brunzell et al., 2003),  another report showed that the levels of CREB and pCREB were 
decreased in the cortex of rats 18 h after withdrawal from repeated administration of 2 mg/kg 
of nicotine (Pandey et al., 2001).  Thus, nicotine-mediated regulation of CREB activity is 
largely dependent on the species, dosage, route of administration, and the time needed to 
harvest brains (Pandey et al., 2001; Brunzell et al., 2003).  The current results show that 
repeated nicotine increased pCREB in cortical tissue of HIV-1Tg rats, with no change in 
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CREB.  This finding is interesting for two reasons.  First, F344 rats exhibited decreased 
pCREB following repeated nicotine administration, and second, the nicotine-induced 
increase in pCREB occurred despite lower basal levels of this transcription factor in HIV-
1Tg rats relative to F344 controls.  This suggests that the processes that mediate the lower 
basal levels of pCREB in the transgenic rats do not prevent repeated nicotine from regulating 
CREB signaling.  Rather, the current results suggest that nicotine and HIV-1 viral proteins 
act synergistically to alter CREB signaling in the PFC.  Decreased CREB activity is 
associated with an increase in drug reward and food preference (Carlezon et al., 1998).  In 
general, this suggests that an aberrant decrease in CREB activity, as is shown in the present 
experiment, may negatively impact normal function of the mesocorticolimbic DA system.  
Determining if PFC CREB activity is also implicated in the reduced rate of nicotine-induced 
reward in HIV-1Tg rats is of future interest.   
  Regarding the ERK experiments, we observed significant alterations in pERK2 
levels in the PFC, NAc, and VTA with no change in ERK1, ERK2, or pERK1 in either HIV-
1Tg or F344 rats.  Notably, the overall levels of pERK2 in the PFC were similar to those 
changes observed with pCREB in the PFC.  Basal levels of pERK2 from the HIV-1Tg-Saline 
rats were lower than that of the F344-Saline rats, which indicates that the presence of viral 
proteins reduces pERK2 in the PFC.  Following repeated nicotine injection, F344 animals 
exhibited a trend for decreased pERK2 relative to F344-Saline rats, whereas HIV-1Tg 
showed increased pERK2 relative to their saline controls.  Regarding the VTA, basal pERK2 
levels did not differ by genotype in the saline control group, but repeated nicotine decreased 
this transcriptional factor in HIV-1Tg rats relative to the saline controls.  In the NAc, 
however, there were no differences between levels of pERK2 in the HIV-1Tg-Nic and HIV-
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1Tg-Saline rats, but the nicotine sensitized F344 rats exhibited decreased pERK2 relative to 
controls.  This is consistent with the diminished pCREB levels observed in the PFC of HIV-
1Tg rats, and this result indicates that viral proteins manipulate ERK signaling in a region 
specific manner.    
Our results suggest that viral protein-induced changes in ERK phosphorylation may 
exacerbate the plasticity related to the magnitude of the attenuated nicotine-induced 
sensitization observed in the behavioral part of our experiment.  This conclusion is supported 
by recent reports (Valjent et al., 2005; Valjent et al., 2006; Girault et al., 2007; Iniguez et al., 
2010).  For example, blocking ERK1/2 activity by SL327, a selective inhibitor of mitogen-
activated protein kinase, prevented the induction of locomotion sensitization by repeated 
injection of cocaine or amphetamine (Valjent et al., 2005; Valjent et al., 2006).  Further, 
discrete manipulation of ERK2 within the VTA, using viral-mediated dominant negative 
mutant of ERK2, blunted the expression of cocaine-induced behavioral sensitization (Iniguez 
et al., 2010).  The current findings suggest that low levels of prefrontal pERK2 may 
contribute to the blunted nicotine-induced locomotor activity observed in transgenic rats.  
Thus, the present study provides evidence that HIV-1 viral proteins impair ERK signaling, 
thereby contributing to the long-term behavioral changes induced by repeated nicotine.  
Additional research is needed to elucidate the role of HIV-1 viral proteins on ERK and 
CREB signaling in the PFC on nicotine reward.  As mentioned above, whether the combined 
effects of nicotine and HIV-1 viral proteins alter the rewarding effects of nicotine cannot be 
inferred from the present experiment.  Nonetheless, these findings further indicate that HIV-
1 positive individuals who smoke cigarettes may experience a synergistic effect of viral 
proteins and nicotine on transcriptional factors that regulate mesocorticolimbic function.  
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   The current study found no differences in basal TH levels regardless of region or 
genotype, which is consistent with the findings of a recent report showing no change in 
protein levels of TH in the striatum of naive HIV-1Tg rats (Webb et al., 2010).  Notably, 
regardless of the nicotine-induced changes in pCREB and pERK in the PFC, repeated 
nicotine injection did not alter the level of TH in any region.  This is in contrast to the 
findings of Brunzell et al. who reported that chronic nicotine exposure in drinking water 
increased TH levels in the PFC in mice 1.5 h after the last nicotine injection; an increase that 
returned to normal levels 24 h after withdrawal (Brunzell et al., 2003).  The discrepant 
findings between the current and previous experiments may be related to differences in 
species and in the route of nicotine administration.  However, a recent report showed that in 
vitro exposure to nicotine only increased TH mRNA levels of mouse midbrain slices within 
1 hour, but did not change TH protein for different periods of time up to 48 hours (Radcliffe 
et al., 2009).  Hence, it is possible that nicotine stimulation transiently changes 
transcriptional TH levels, without changing the protein levels of TH. 
In conclusion, the current results suggest that genetically expressed HIV-1 viral 
proteins in rats diminish basal expression levels of pERK2 and pCREB in the PFC, which 
may explain, at least in part, the low baseline locomotor activity of HIV-1Tg rats.  The 
opposite effects of nicotine on pERK2 and pCREB in the PFC between HIV-1Tg rats and 
F344 rats may play a role in the blunted locomotor response to repeated administration of 
nicotine noted in HIV-1Tg rats.  Determining how HIV-1 viral proteins and nicotine 
influence ERK and CREB signaling in the mesocorticolimbic system will be important to 
understand why HIV-1 positive individuals exhibit increased vulnerability for nicotine 
addiction.   
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Figure 5.1 Body weights of HIV-1Tg and F344 rats during the nicotine or saline treatment 
period.  Beginning at 12 weeks of age, rats were injected subcutaneously with nicotine or 

























































Figure 5.2 The time-course data during the habituation and the saline baseline sessions.  Panels A and B show the total horizontal activity 
(mean ± S.E.M.) during the first 30 min of the habituation period.  Panel C shows the total horizontal activity (mean ± S.E.M.) across the 
first 30 min of the session following saline injection.  * p < 0.05, difference between HIV-1Tg and F344 rats at the corresponding time 






































































Figure 5.3 The time-course data during the behavioral sensitization phase. HIV-1Tg and F344 rats were administered nicotine (Nic; 0.35 
mg/kg; s.c.) or saline (Sal) on Days 1-19.  Panel A shows the total horizontal activity (mean ± S.E.M.) during the 30 min pre-injection 
habituation period.  Panel B shows the total horizontal activity (mean ± S.E.M.) during 60 min following nicotine or saline injection.  n=8 






























































































































Figure 5.4 The time-course data for total horizontal activity during day 1 and day 19 of the 
behavioral sensitization phase.  Panels A and B show the total horizontal activity (mean ± 
S.E.M.) across the 60-min session.  Panels C and D show the time course of the total 
horizontal activity (mean ± S.E.M.) during each 5-min time interval.  * p < 0.05 difference 
between HIV-1Tg and F344 rats.  # p < 0.05 difference between nicotine- and saline-
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Figure 5.5 Levels of ERK, CREB and TH proteins in the PFC in HIV-1Tg and F344 rats. 
(A) Representative western blots showing the protein density of CREB, pCREB, ERK1/2, 
pERK1/2, TH and β-tubulin in nicotine or saline treated HIV-1Tg (HIV-1Tg-Nic, HIV-1Tg-
Sal) and F344 rats (F344-Nic, F344-Sal). (B) Total and phosphorylated protein levels of 




Ratios are presented as the mean percentage of β-tubulin ± S.E.M.  * p < 0.05 difference 
between HIV-1Tg and F344 rats.  # p < 0.05 difference between the nicotine- and saline-
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Figure 5.6 Levels of ERK, CREB and TH proteins in the NAc in HIV-1Tg and F344 rats. 
(A) Representative western blots showing the protein density of CREB, pCREB, ERK1/2, 
pERK1/2, TH and β-tubulin in the nicotine or saline treated HIV-1Tg (HIV-1Tg-Nic, HIV-
1Tg-Sal) and F344 rats (F344-Nic, F344-Sal). (B) Total and phosphorylated protein levels of 




Ratios are presented as the mean percentage of β-tubulin ± S.E.M.  # p < 0.05 difference 
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Figure 5.7 Levels of ERK, CREB and TH proteins in the VTA in HIV-1Tg and F344 rats. 
(A) Representative western blots showing the protein density of CREB, pCREB, ERK1/2, 
pERK1/2, TH and β-tubulin in the nicotine or saline treated HIV-1Tg (HIV-1Tg-Nic, HIV-




ERK1, ERK2 and CREB along with levels of TH after chronic nicotine or saline injection.  
Ratios are expressed as the mean percentage of β-tubulin ± S.E.M.  # p < 0.05 difference 









CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 SUMMARY AND CONCLUSIONS 
Increasing evidence suggest that the alarming rise in HIV-1 associated 
neurocognitive disorder is, at least in part, associated with HIV-1 viral proteins shed from 
infected macrophages/microglia, including the nonstructural viral protein Tat, despite the 
success of anti-retroviral therapies. Tat enhances extra synaptic DA levels by inhibiting 
DAT, and the concerted effects of Tat and cocaine escalate the severity and amelioration of 
the HAND. In order to develop adjunctive therapies that can stabilize the altered DA system 
in the HIV-1 positive brains, it is crucial to understand the underlying mechanism for Tat 
inhibitory effects on DAT function. The research described in this dissertation focused on 
addressing the central hypothesis- ‘HIV-1 Tat protein via allosteric modulation of DAT 
induces inhibition of DA transport, leading to dysfunction of the DA system’. This chapter 
summarizes the findings that were presented in earlier chapters with the following 
subheadings: (1) protein-protein interactions between Tat and DAT, (2) molecular dynamics 
simulated structure of HIV-1 Tat and DAT binding complex, (3) mutational analysis of DAT 
residues involved in HIV-1 Tat-DAT binding complex, (4) effect of HIV-1 Tat protein on 
trafficking dependent regulation of DAT, (5) effect of HIV-1 Tat protein on VMAT2 
function, and (6) released Tat is more potent than synthetic Tat. Finally, the chapter 
concludes with the proposed model for HIV-1 Tat protein effects on DAT and VMAT2 
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functions, and future directions for this work. 
PROTEIN-PROTEIN INTERACTIONS BETWEEN TAT AND DAT 
The preliminary evidence for protein-protein interaction between Tat and DAT 
comes from Zhu et al. (2009), using a biophysical technique, surface plasmon resonance. 
This real time measurement using immobilized membranes that overexpress hDAT-GFP 
revealed that the transporter interacts with Tat protein but not with Tat Cys22. This proposed 
biomolecular interaction was further strengthened by the lack of inhibitory effects of Tat 
mutant proteins Tat∆31-61 and Tat Cys 22 on DA transport. However, there is lack of evidence 
for this protein-protein interaction from a biochemical perspective. In the current dissertation 
work, I addressed this gap by performing Co-IP and GST-pull down assays to confirm the 
direct interaction between Tat and DAT proteins (Chapter 2) (Midde et al., 2013). In Chapter 
2, it was shown that recombinant Tat protein can immuneprecipitate DAT from the rat 
striatal synaptosomes and Glutathione S-transferases (GST)-tagged Tat protein was able to 
pull-down DAT (Figure 2.1B and C). Taken together, these results strongly support that Tat-
mediated inhibitory effect on DAT function is triggered by a protein-protein interaction 
between these two proteins.    
MOLECULAR DYNAMICS SIMULATED STRUCTURE OF HIV-1 TAT AND DAT BINDING COMPLEX 
The above described experimental evidence provides a strong base to further evaluate 
the mechanism of Tat binding and to predict molecular determinants for DAT and Tat 
interaction. Binding structure of DAT-Tat-DA-Cocaine was constructed  based on the 
crystallized structure of the leucine transporter (Yamashita et al., 2005) – the bacterial 
homolog of NSS family proteins, modeling studies of DA substrate and inhibitor cocaine 
binding to DAT (Huang and Zhan, 2007; Beuming et al., 2008; Huang et al., 2009), and 
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nuclear magnetic resonance structure of Tat (Peloponese et al., 2000). As displayed in Figure 
2.1C (Chapter 2) and Figure 6.1, the proposed binding of Tat protein at the substrate entry 
tunnel region through electrostatic inter-molecular interactions does not directly interfere 
with DA binding sites. However, the cocaine binding site is located inside the substrate 
transport path in the vicinity of DA binding site, and cocaine binding has a direct impact on 
affinity and transport kinetics of substrate.  
According to the most embraced model, the alternating access model of Jardetzky 
(1966), the substrate binding site is only available to either side of membrane surface at a 
given time during the DA translocation process. This model proposes that the transporter 
exists primarily in an outward facing conformation and stabilization of this conformation 
require a network of intra-molecular interactions. Binding of substrate, two Na+ and one Cl- 
ions trigger allosteric rearrangements of the transporter to the inward facing conformation 
followed by initiation of substrate release into the intracellular milieu. A schematic showing 
the outward open state structure of DAT is depicted in Figure 3.3A and B (Chapter 3). 
According to this model and Singh et al. (2008), residues located in TM1b (TM, 
transmembrane) and TM6a helices are highly required for conformational transitions during 
functional DA translocation. These two helices move as group to the inner side of transporter 
during conversion from outward-open to inward-open state of DAT. TM1b and TM6a 
involve in a direct interaction with TM11 and EL4 (EL, extracellular) helices. As part of 
extracellular gating creation Arg85 and Asp476 form a salt-bridge (joint hydrogen and ionic 
interactions), which drives EL6 to stabilize the TM10 by hydrophobic interaction with 
Tyr470. Tyr470 is critical to overcome the impermeable barrier of conformational alterations 
between outward-open and outward-occluded state. Furthermore, this salt-bridging enhances 
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the flexibility of TM1b for easy movement than TM6a. As a result salt-bridge between 
Lys92 and Asp313 play an essential role for synchronizing motion of TM1b and TM6a. 
Thus, residues Tyr88, Lys92 and Asp313 support to stabilize TM1b and TM6a through 
hydrophobic or electrostatic intra-molecular interactions, and Tyr470 is the key residue in 
the hydrophobic core of the central cavity of the plasma membrane. 
Molecular modeling and molecular dynamics simulations predict the plausible 
interaction of Tat protein with DAT as presented in Figure 3.2 (Chapter 3). According to this 
model, the aromatic ring of Tyr470 of DAT interacts with the amino terminal of Met1 of Tat 
through cation-π interaction. Hydroxyl group of Tyr88 of DAT participates in hydrogen 
bond attractions with ε-amino group of Tat Lys19. Besides, the side chain of Lys92 of DAT 
forms hydrogen bond with carbonyl group of main chain of Pro18 of Tat protein. This initial 
binding structure of Tat and DAT binding complex demonstrates that Tat molecule is 
associated with DAT through inter molecular electrostatic attractions and complementary 
hydrophobic interactions.  
MUTATIONAL ANALYSIS OF DAT RESIDUES INVOLVED IN HIV-1 TAT-DAT BINDING COMPLEX 
As described above, DAT residues that are involved in favorable inter-molecular 
interaction with Tat are part of the conformational stabilizing network that is critical for 
smooth conformational transitions during DA transport cycle. Consequently, mutation of 
these residues may cause alterations in the conformation of the transporter that will 
manipulate affinity and kinetics of DA transporting process. The research shown in this 
dissertation uses a systemic mutagenesis approach to define the predicted binding sites in 
DAT for Tat binding. As a proof of concept, initially Y470H mutant was generated in DAT 
with the expectation that Y470H disrupts critical cation-π interaction required for Tat 
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binding (Chapter 2) (Midde et al., 2013). In Y470H mutant, the effect of recombinant Tat1-86 
on DA uptake was attenuated compared to 38% decrease in WT-hDAT transfected cells that 
are exposed to Tat1-86, suggesting the antagonistic nature of Tat to inhibit transporter function 
through direct interaction with Tyr470 of hDAT (Figure 2.4). As our hypothesis regarding 
role of Tyr470 in Tat interaction with DAT was verified to be correct, additional 
substitutions at 470 – Y470F, Y470A and mutation of other predicted residues such as Tyr88 
and Lys92 of DAT would be expected to show similar attenuation in response to Tat 
treatment (Chapter 3). Indeed, all other mutants exhibited similar diminution in Tat-induced 
inhibition of DA uptake except Y470F (Figure 3.5) emphasizing the importance of aromatic 
ring of Tyr470 in Tat binding with DAT, and the involvement of Y88 and K92 in Tat and 
DAT interaction. Thus, these observations further confirm our prediction that Tyr470, Tyr88 
and Lys92 are part of the critical network that is required for DA transport and Tat reduces 
the transporter efficiency by altering the conformation of the transporter by interacting with 
these residues.  
Pharmacological characterization revealed that Y470H and K92M mutations were 
not only accompanied by decreased Vmax with no noticeable change in Km for DA uptake, 
but also by significant increase in apparent affinities (IC50) for inhibitors (Chapter 2 and 3). 
Whereas the apparent affinity for substrate DA was not significantly different from WT, the 
apparent affinities for cocaine and GBR12909 inhibitors were significantly increased to 
inhibit [3H]DA uptake (Table 2.1 and 3.1). These results indicate that Tat binding sites do 
not overlap with the binding sites of substrate DA and do not influence the affinity for DA 
uptake. However, increased apparent inhibitor affinities suggest the direct involvement of 
Tat binding sites with cocaine binding. This close proximity of Tat and cocaine binding sites 
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was further supported by Tat-induced decrease in Bmax for [3H]WIN35,428 binding (Chapter 
3, Table 3.2 and (Zhu et al., 2009)).  These observations are in line with previous report 
demonstrating that Tat protein allosterically interacts with the transporter and modulates 
cocaine binding sites (Zhu et al., 2011). In addition, Y88F and K92M mutants displayed 
decreased IC50 values for cocaine and GBR12909 to inhibit [3H]WIN35,428 binding, a 
structural derivative of cocaine. Cocaine and GBR12909 belong to different DAT inhibitor 
classes that are structurally distinct and label different binding sites on the transporter. 
Furthermore, substantial evidence indicate that inhibitor binding require a specific 
conformational state of the DAT and cocaine –like compounds prefer the outward facing 
conformation (Reith et al., 2001; Schmitt et al., 2013). It is interesting to note that mutants 
increased both cocaine and GBR12909 apparent affinities similarly but with varying degrees 
of impact. One possible explanation for this variability is that Tat-mediated allosteric effects 
cause subtle conformational alterations in the transporter which consequently enhances DA 
uptake potencies for cocaine. An alternative possibility is that GBR12909 can bind to several 
conformations or is less dependent on conformation of the DAT (Schmitt and Reith, 2011). 
Nevertheless, these inferences underscore the importance of extensive characterization of 
predicted Tat recognition residues before concluding the influence of Tat binding on 
inhibitors affinities. Taken together, it is evident that Tat through allosteric modulation of 
transporter function escalates the inhibitory action of cocaine on DA translocation.   
To explore the molecular basis for mutants altered pharmacological properties and 
thereby to substantiate our hypothesis that Tat down regulates DAT function through 
allosteric regulation, this research employed DA uptake and WIN35,428 binding studies in 
the presence of zinc, a noncompetitive DAT inhibitor  that blocks the DA uptake but 
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potentiates WIN35,428 binding by stabilizing the transporter in the outward facing state 
(Norregaard et al., 1998; Loland et al., 2003). Ample evidence indicates that specific 
conformational effects in DAT that differ in response to bound ligand or mutations can be 
investigated by Zn2+. In the presence of zinc, the uptake ability in Y470H was increased but 
not in all other four mutants (Chapter 2 and 3). Interestingly, zinc-induced increase in 
WIN35,428 binding was attenuated not only in Y470H but in all tested mutants with 
different proportions. It was reasoned that Y470H mutation may cause the transporter to stay 
principally in an extreme inward facing conformation that is highly suitable to reverse Zn2+-
mediated effects on DA uptake and WIN35,428 binding (Guptaroy et al., 2009; Liang et al., 
2009). In the case of Y88F, K92M, Y470F and Y470A mutations induce an inward 
conformation that is able to abolish the binding preference for WIN35,428 without  
interfering with zinc stimulated down regulation in DA uptake. These conformational 
preferences of the mutants were further screened by measuring basal efflux (DAT-mediated 
release of preloaded substrate). Y470H and Y470A displayed significant increase in both DA 
and MPP+ efflux but not the Y470F and Y88F (Chapter 3). The most likely reason for the 
low retention of substrate is that elevation of efflux without improving the uptake capacity 
i.e. forward transport. Curiously, the K92M mutant exhibited considerable increase in the 
DA basal efflux but not MPP+ efflux. It was interpreted that this may be due to K92M 
inclination for a conformation that is not suitable for MPP+ binding (Liang et al., 2009). 
Alternatively, the observed DA efflux in K92M is merely a quick leakage of substrate by 
non-specific diffusion as MPP+ was showed to exhibit less diffusive properties compared to 
DA in heterologous expression systems (Scholze et al., 2001). However, provided that the 
effect of mutants on kinetic differences, increased inhibitor apparent affinities and the 
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attenuation of zinc-mediated increase in WIN35,428 binding, it was deduced that the 
reported mutants adopt similar molecular mechanisms that are ranging  from closed-to-out 
(occluded) to open-to-in (inward) conformational states. While these results strongly support 
the allosteric mode of regulation by Tat protein to inhibit DAT function, further strategies 
are required to confirm specific conformational states that are attributed to the identified 
residues in transporter. For example substituted-cysteine accessibility method (Javitch, 1998; 
Norregaard et al., 2003; Loland et al., 2008) and amphetamine-induced substrate efflux 
(Khoshbouei et al., 2004; Guptaroy et al., 2011) can be used to further support the above 
stated inferences for Tat induced effects on DAT structure and function.  
EFFECT OF HIV-1 TAT PROTEIN ON TRAFFICKING DEPENDENT REGULATION OF DAT 
A recent NMR spectroscopy study has shown Tat as a “natively unfolded” protein 
with no distinctive three-dimensional structure but with fast dynamics (Shojania and O'Neil, 
2006). Moreover, the unique genetic arrangement of Tat sequence and post-translational 
modifications (Hetzer et al., 2005) enhances the likelihood of Tat protein interaction with 
multiple cellular proteins. As described earlier, due to the complex nature of the DAT 
regulation it is possible that Tat may impact other regulatory partners of DAT because of its 
flexible and versatile nature, which ultimately leads to the reduction in DA uptake. As 
previous studies (Aksenova et al., 2006; Zhu et al., 2009) indicated exposure to Tat reduces 
Vmax of [3H]DA uptake  with no change in the total DAT immunoreactivity levels. It clearly 
suggests that there is no degradation of DAT protein due to Tat treatment at least in the acute 
treatment time periods. However, it remains uncertain whether Tat causes any alterations in 
the surface expression levels of the transporter. Ample experimental evidence has 
demonstrated that redistribution of DAT proteins to and away from the presynaptic 
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membrane is a predominant mechanism of DAT regulation (Chen et al., 2010). In an attempt 
to understand the effects of Tat on DAT surface localization, rat striatal synaptosomes were 
exposed to Tat protein for 15 min and it was found that  DAT immunoreactivity levels were 
decreased by 46% in the plasma membrane enriched fractions (P3) with no changes in the 
total synaptosomal fractions (P2) (Chapter 4) (Midde et al., 2012). It was reasoned that Tat 
could promote the redistribution of surface DAT to intracellular compartments possibly 
through manipulating trafficking events, results in the reduction of DAT density at the 
surface, which causes the observed decrease in Vmax of DA uptake. This hypothesis was 
further supported by the decrease in Bmax of [3H]WIN 35,428 binding in P3 of Tat-treated 
samples.  
 These findings raise vital questions, what is underlying mechanism for Tat-induced 
shift in the surface DAT? Is it due to acceleration of endocytosis or diminution of recycling 
to the membrane, or a combination of both? Numerous studies have demonstrated that DAT 
undergo both constitutive and regulated endocytic trafficking. Following internalization, 
DAT can be recycled back to the plasma membrane via the endocytic recycling pathways, or 
targeted to lysosomal degradation pathways (Sorkina et al., 2009). Since PKC has been 
shown as a key mediator for regulating recycling to the plasmalemma and internalization of 
DAT to the early/late endosomes (Loder and Melikian, 2003; Chen et al., 2010), we exposed 
rat striatal synaptosomes to the Tat protein that were pre-treated with PKC inhibitor, 
bisindoylmaleimide-I (BIM-I) and observed the attenuation of Tat inhibitory effects on DA 
uptake (Chapter 4). This outcome indicates that Tat exploits PKC-dependent signaling 
pathway to modulate the functional regulation of the DAT. However, it is worth noting that 
residues 587-596 at carboxyl-terminal of the DAT are required for the PKC-mediated 
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internalization of the transporter (Holton et al., 2005). Furthermore, studies suggest that 
mutating classical PKC consensus serine and threonine sites (Chang et al., 2001) and 
truncation of amino-terminal of DAT (Granas et al., 2003) prevent direct phosphorylation of 
the transporter but not the internalization. Collectively, these findings suggest that Tat may 
manipulate the structural determinants that lead to rapid PKC-stimulated internalization of 
DAT. Alternatively, Tat potentially interferes with functions of other downstream kinases 
and/or scaffolding proteins in the PKC signaling cascade (Yang et al., 2010). Future studies 
are necessary to address whether Tat-mediated influences on DAT endocytic trafficking is 
phosphorylation dependent or independent.  
EFFECT OF HIV-1 TAT PROTEIN ON VMAT2 FUNCTION 
In the central nervous system, vesicular monoamine transporter 2 (VMAT2, Slc18a2) 
is the only transporter that sequesters cytoplasmic monoamines, in particular DA, into 
synaptic vesicles for storage and subsequent release (Zheng et al., 2006; Vergo et al., 2007). 
This packaging process is highly regulated and dysfunction plays a role in a variety of 
disorders including Parkinson’s disease (Caudle et al., 2008; Taylor et al., 2009; Rilstone et 
al., 2013), Huntington’s disease (Ondo et al., 2002; Paleacu et al., 2004; Morrow, 2008), and 
neuropsychiatric disorders (Zubieta et al., 2001; Zucker et al., 2001; Eiden and Weihe, 
2011). Moreover, VMAT2 is one of the principal targets for amphetamine-derived 
psychoactive drugs (Sulzer et al., 2005; Fleckenstein et al., 2007; Fleckenstein et al., 2009). 
Having proven evidence for Tat induced effects on dopaminergic neurons especially on DAT 




  To test this hypothesis, synaptic vesicular uptake in the presence of 1 µM Tat was 
performed and demonstrated that inhibitory effects of Tat are more profound in VMAT2 
(35%) than DAT (25%) protein. Importantly, current data show that Tat potency for 
inhibiting vesicular DA uptake (IC50 =0.21 µM) (Chapter 4) is 15-fold higher than that for 
inhibiting synaptosomal DA uptake (IC50 = 3.1 µM) (Zhu et al., 2009). These results visibly 
imply the essential role played by Tat protein in the impairment of VMAT2 that results in the 
reduction of the loading and storage of DA into the synaptic vesicles. Moreover, mutant Tat 
Cys22 (Cys22Glys) protein attenuates Tat-induced decrease in VMAT2 function, which is 
similar to reported attenuation of Tat effects on DAT function (Zhu et al., 2009). Along these 
lines, Theodore et al. (2012) using in vivo microdialysis reported that striatal synaptic 
vesicles incubated with Tat show ~35% decrease in DA uptake and ~30%  reduction in K+ -
evoked total DA overflow in rats injected with Tat. Taken together, these findings tempting 
to speculate that Tat may directly influence VMAT2 structure through protein-protein 
interactions. However, future investigations are necessary to delineate this possible 
mechanism. Furthermore, recent studies proposed a physical and functional coupling 
between DAT and VMAT2 to regulate dopaminergic tone in response to normal and drug-
induced stimuli (Zhu and Reith, 2008; Egaña et al., 2009; Sager and Torres, 2011), 
suggesting that Tat protein may increase the neurodegeneration of dopaminergic terminal by 
simultaneously targeting both DAT and VMAT2. In addition, it was reported that 
simultaneous exposure of Tat protein and amphetamine synergistically impairs DAT 
function in vitro (Cass et al., 2003; Theodore et al., 2006) and in vivo (Kass et al., 2010). 
Having established evidence for VMAT2 as a target for amphetamine class of drugs (Sulzer 
et al., 2005; Sulzer, 2011), it is conceivable that co-exposure of Tat protein and abused drugs 
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by complementing each other may further deteriorate neuronal terminal loss that eventually 
contribute to HAND (Purohit et al., 2011; Purohit et al., 2013).  
RELEASED TAT IS MORE POTENT THAN SYNTHETIC TAT 
Unconventional secretion of Tat (Pugliese et al., 2005; Rayne et al., 2010; Bachani et 
al., 2013) by infected cells without cell lysis causes neurotoxicity to the neighboring 
uninfected cells including neurons (Li et al., 2009). This extracellularly released Tat is 
biologically active and can interact with DAT (Zhu et al., 2009; Midde et al., 2013) 
suggesting that Tat protein is very flexible and can assume a unique conformation to bind 
with the target molecule. It was demonstrated that a point mutation in Tat that substitutes 
cysteine with alanine at 22 (Tat Cys22) attenuates Tat-mediated inhibition of DA uptake 
(Zhu et al., 2009). In addition, this study also showed that deletion of residues 31-61 (Tat∆31-
61) abolishes inhibitory effects of Tat on DAT function indicating that specific recognition 
residues of Tat are responsible for Tat and DAT interaction. However, one caveat here is that 
synthetic Tat used for these experiments is substantially less potent than Tat released from 
Tat-expressing astrocytes (Li et al., 2008). Degradation of Tat during purification process, 
high susceptibility of Tat to freeze/thaw cycles, and ability to get oxidized easily are the most 
likely reasons for less Tat activity (Nath et al., 2000). As a part of this dissertation work, Tat-
conditioned medium which was obtained from the cells that were transiently transfected with 
Tat plasmid DNA was evaluated to confirm whether it can be substituted for commercially 
available recombinant Tat in the proposed experiments (Chapter 2) (Midde et al., 2013). This 
approach was chosen because extracellularly released Tat exhibits more relevant 
constitutively produced Tat effects than recombinant protein (Nath et al., 2000). As shown in 
Figure 2.5B secreted Tat1-72, Tat1-86 or Tat1-101 variants exhibited a similar inhibitory pattern 
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which decreased DA uptake in heterologous cells that were expressing hDAT, and this 
diminished effect was attenuated when released Tat was immunodepleted with anti-Tat 
antibodies (Figure 2.5C). Furthermore, released Tat displayed ~4000 times more potent 
inhibitory effects on DA uptake than recombinant Tat (Chapter 2). Therefore, these results 
indicate that secreted Tat is more neurotoxic and Tat-conditioned media can be used as a 
source of extracellular Tat (by producing different Tat mutant proteins) to characterize 
unique binding sites of Tat that are required for functional interaction with DAT.  
OVERALL CONCLUSIONS 
In summary, the Tat protein plays a significant role in the impairment of DA system 
by affecting regulatory pathways that control the functional attributes of DAT and VMAT2. 
A graphical representation of potential ways by which Tat protein exerts its actions are 
depicted in Figure 6.2 that include (1) direct protein-protein interaction with DAT, (2) 
stimulation of PKC-mediated endocytosis, (3) diminution of recycling of DAT to the plasma 
membrane, (4) alteration of direct phosphorylation state of the DAT, and (5) direct protein-
protein interaction with VMAT2 protein. Even though most of these regulatory components 
are interconnected, here they were shown separately for the sake of clarity. It is quite 
possible that Tat interaction or influence at one molecular component can trigger activation 
of other factors or cellular events that ultimately lead to dysregulation of the DA system. As 
described in this work, it appears that Tat will have a profound impact on DA translocation 
process principally by altering the conformational states of the DAT through direct protein-
protein interaction. We do not know whether this Tat-mediated impact on structure of DAT 
could also prompt increased endocytosis to early/recycling endosomes or diminished 
recycling to the surface. Curiously, recent findings suggest that modifications in the 
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conformational equilibrium of the DAT influence the endocytic trafficking of the transporter 
molecules (Sorkina et al., 2009).    
6.2 FUTURE DIRECTIONS 
Several studies with various approaches and models tried to explain the evolution of 
neuroAIDS. HAND begins as HIV-1 enters the brain and ARTs have little impact on viral 
reservoir in the CNS, insisting the need to develop adjunctive therapies to treat neurological 
complications associated with HIV-1 infection that can improve the HIV-1 positive 
individual’s capability to perform daily activities. With increasing evidence it is almost 
certain that HIV-1 viral proteins dysregulate the dopaminergic system and cause subsequent 
neurodegeneration (Purohit et al., 2011; Barreto et al., 2014). However, delineating the 
mechanism of action of Tat protein on target molecules, such as DAT, is a key step forward 
to combat the progression of neuronal damage in HIV-1 infected brains. As described above, 
the initial findings show that Tat recognition residues Tyr88, Lys92 and Tyr470 of DAT are 
part of the crucial framework of substrate permeation pathway in DAT. Nonetheless, this 
information is not sufficient to completely understand Tat and DAT interaction. Doubtlessly, 
identification and characterization of other recognition residues is necessary to construct a 
ligand-binding pocket for the functional interaction of Tat with DAT. Moreover, the 
fundamental role of these DAT domains involved in DAT-Tat interaction are subject of great 
debate, and shedding light on these regions will greatly improve our understanding of the 
basic functionality of DA transport process. As it is hypothesized that neurocognitive deficits 
and alterations in DA homeostasis are more severe in HIV-1 positive drug abusers (Nath, 
2010; Gaskill et al., 2013), understanding how concerted effects of Tat and cocaine 
manipulate the structural and functional attributes of the transporter is an important goal for 
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future research in this area. Finally, the major obstacle would be how to translate these 
computational and in vitro findings into a preclinical setting. This is very important because 
evaluating the molecular mechanisms in a relevant model system is a key step before 
exploiting them as clinically effective strategies. Hence, HIV-1 Tg rat model that was 
utilized to demonstrate that genetically expressed HIV-1 viral proteins modify the locomotor 
sensitization in response to nicotine administration (Chapter 5) (Midde et al., 2011) could be 
used to investigate perturbations of DA neurotransmission that are present in HIV-infected 
brains. Considering the alteration in dopaminergic biomarkers and behavioral evaluations 
(Persidsky and Fox, 2007; Vigorito et al., 2007; Lashomb et al., 2009; Webb et al., 2010; 
Rao et al., 2011), HIV-1 Tg rat model may be an appropriate model to evaluate the ligand-
binding pocket in DAT for Tat binding and to screen potential small molecules that can 










Figure 6.1 Structure of DAT-Tat-Dopamine-Cocaine complex. DAT, Tat, cocaine, and 
dopamine are colored in cyan, orange, red and blue respectively. Tat, cocaine and dopamine 







Figure 6.2 Proposed model of HIV-1 Tat protein effects on DAT and VMAT2 proteins. Tat 
protein may elicit its effects on DA system by influencing the structure, function and 
endocytic trafficking of the DAT. (1) physical interaction of Tat with DAT induces 
transporter down regulation and this physical coupling may encourage (2) PKC-stimulated 
endocytosis and/or, (3) reduced recycling to the surface. Tat may also play a role in 
alterations of (4) phosphorylation status of the DAT. (5) The direct interaction of Tat with 
VMAT2 is also an important mechanism to dysregulate DA synaptic vesicular loading 
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GENERAL STATISTICAL ANALYSES CONSIDERATIONS 
1. Replicates 
For all the experiments performed in this dissertation, I used a minimum of two or 
three technical replicates. These replicates were either cell culture wells or tubes carrying 
same amount cell suspension. The reason for such technical replicates was to establish the 
validity of the method (e.g. pipetting errors). Three to eight biological replicates (sample 
size) were used to differentiate the random effect from “true” biological difference that is 
triggered by the treatment. The major advantage with the replicates is that they provide the 
ability to run various statistics to evaluate the variability. Ability to detect smaller but 
important changes and the capacity to spot the outliers in a dataset are the other benefits 
that can be achieved from the replicates. Using both technical and biological replicates in 
the experimental design increases the confidence of conclusions drawn from these 
experiments. 
2. Power Analyses 
A priori type power analysis was conducted for behavioral experiments for HIV-1 
Tg and nicotine project using G*power software (Faul et al. 2007). This analysis indicated 
that a total sample of 32 animals would be needed to detect medium effects (0.40) with 
80% power using an analysis of variance with alpha set at 0.05. A detailed statistical design 
for behavioral assays was described in the data analysis section of chapter 5. For the in 
vitro assays a priori power analysis was not estimated, however 0.75 to 0.99 ‘observed
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power’ was noted after experimental data was analyzed. Nevertheless, this post-hoc power 
analyses doesn’t convey any new information as the significant p value (<0.05) indicates 
actually observed effect (Hoenig and Heisey, 2001; Levine and Ensom, 2001). Factorial 
design and statistical methods used for analysis of pharmacological data were elaborated 
in respective chapters in the dissertation.  
3. Outlier detection 
The outlier labeling rule (Hoaglin and Iglewicz, 1987) was used to identify the 
outliers in the data set. The formulae Upper limit = Q3 + (2.2 * (Q3 - Q1)); Lower limit = 
Q1 - (2.2 * (Q3 - Q1)) were used to detect extreme values from both ends. If an outlier was 
spotted, a root cause analysis was performed to determine the potential reason (e.g. 
measurement error). The data points were trimmed which accounts for only less than 5% 
of total data set for further analyses. 
4. Randomization 
To minimize the possibility of bias in the behavioral experiments, both HIV-1 Tg and 
F344 rats were randomly assigned to two treatment groups such as nicotine and saline. 
Sixteen HIV-1 Tg and 16 F344 animals were randomized into blocks of 8, 8 respectively. 
The randomization scheme was generated by using the Web site Randomization.com 
(http://www.randomization.com). Animal handling, drug treatment and placing the 
animals into locomotor chambers were performed by three technicians to further insure 
against human introduced bias into the procedure. Overall, randomization eliminates the 
selection bias and assures equality of treatments for accurate statistical analyses.  
